

0-7242-178

US ARMY INSTITUTE OF SURGICAL RESEARCH ANIMAL RESERVE

PROGRESS REPORT FOR FISCAL YEAR 1987(U) ARMY INST OF

SURGICAL RESEARCH FORT SAM HOUSTON TX B A PRUITT  
01 007 07


UNCLASSIFIED

01 OCT 87

F/G 6/5

NL

1



US ARMY INSTITUTE OF SURGICAL RESEARCH

AD-A212 178



ANNUAL RESEARCH PROGRESS REPORT

FOR FISCAL YEAR 1987

1 OCTOBER 1986 - 30 SEPTEMBER 1987

PREPARED BY: US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

PREPARED FOR: US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
FORT DETRICK  
FREDERICK, MARYLAND 21701-5012

DTIC  
ELECTE  
SEP 12 1989  
S E D

APPROVED FOR PUBLIC RELEASE. DISTRIBUTION UNLIMITED.

1 October 1987

89 9 11 084

APPROVED FOR PUBLIC RELEASE. DISTRIBUTION UNLIMITED.

DESTROY THIS REPORT WHEN IT IS NO LONGER NEEDED. DO NOT RETURN IT TO THE ORIGINATOR.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

Human subjects participated in these studies after giving their free and informed voluntary consent. Investigators adhered to Army Regulation 70-25 and US Army Medical Research and Development Command Regulation 70-25 on the use of volunteers in research.

In conducting the research described in this report, the investigators adhered to the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals and with the Guide for the Care and Use of Laboratory Animals, National Institutes of Health Publication 86-23.

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

This publication was compiled and edited by Christine C. Davis, Research Protocol Coordinator, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas 78234-5012.



UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE

## REPORT DOCUMENTATION PAGE

Form Approved  
OMB No 0704-0188  
Exp Date Jun 30 1986

1a REPORT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>			1b RESTRICTIVE MARKINGS		
2a SECURITY CLASSIFICATION AUTHORITY			3 DISTRIBUTION/AVAILABILITY OF REPORT <b>APPROVED FOR PUBLIC RELEASE. DISTRIBUTION UNLIMITED.</b>		
2b DECLASSIFICATION/DOWNGRADING SCHEDULE					
4 PERFORMING ORGANIZATION REPORT NUMBER(S)			5 MONITORING ORGANIZATION REPORT NUMBER(S)		
6a NAME OF PERFORMING ORGANIZATION <b>US Army Institute of Surgical Research</b>		6b OFFICE SYMBOL (if applicable) <b>SGRD-USM</b>	7a NAME OF MONITORING ORGANIZATION <b>US Army Medical Research and Development Command</b>		
6c ADDRESS (City, State, and ZIP Code) <b>Fort Sam Houston San Antonio, Texas 78234-5012</b>			7b ADDRESS (City, State, and ZIP Code) <b>Fort Detrick Frederick, Maryland 21701-5012</b>		
8a NAME OF FUNDING SPONSORING ORGANIZATION		8b OFFICE SYMBOL (if applicable)	9 PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		
8c ADDRESS (City, State, and ZIP Code)			10 SOURCE OF FUNDING NUMBERS		
			PROGRAM ELEMENT NO	PROJECT NO	TASK NO
			WORK UNIT ACCESSION NO		
			<b>SEE PAGES IX AND X OF THIS REPORT</b>		
11 TITLE (Include Security Classification) <b>US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1987 (U)</b>					
12 PERSONAL AUTHOR(S) <b>PRUITT, Basil A. Jr.</b>					
13a TYPE OF REPORT <b>Annual</b>		13b TIME COVERED <b>FROM 86/10/01 to 87/09/30</b>		14 DATE OF REPORT (Year, Month, Day) <b>1 October 1987</b>	
15 PAGE COUNT <b>307</b>					
16 SUPPLEMENTARY NOTATION					
17 COSATI CODES			18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP			
19 ABSTRACT (Continue on reverse if necessary and identify by block number)					
20 DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED UNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS			21 ABSTRACT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>		
22a NAME OF RESPONSIBLE INDIVIDUAL <b>COL Basil A. Pruitt, Jr., MD, FACS</b>			22b TELEPHONE (Include Area Code) <b>512-221-2720</b>		22c OFFICE SYMBOL <b>SGRD-USM</b>



DEPARTMENT OF THE ARMY  
US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON, TEXAS 78234-6200

SGRD-USZ

1 October 1987

MEMORANDUM: SEE DISTRIBUTION

SUBJECT: US Army Institute of Surgical Research Annual Research  
Progress Report for Fiscal Year 1987

The US Army Institute of Surgical Research Annual Research  
Progress Report for Fiscal Year 1987 is forwarded under the  
provisions of OTSG Regulation 70-31 dated 2 April 1969.

Enclosure  
as

*Basil A. Pruitt, Jr.*

BASIL A. PRUITT, JR., MD, FACS  
Colonel, MC  
Commander and Director

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input checked="" type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



## FOREWORD


Much of liability law and economic theory are based on the concept of the prudent man. The assumption that human actions will be governed by rational decisions based on available data is applicable to physician supply and career choice as well and explains, in large part, shortages of medical specialists in the military and the difficulty in recruiting and retaining physicians and scientists on the staff of the biomedical research institutes of the uniformed services in general and this Institute in particular (1). A principal negative influence on the prudent surgeon's career decision is the discrepancy in salary vis-a-vis civilian peers. One can predict the decision of a prudent surgeon freshly graduated from a residency program who will receive, as a Captain, total compensation of \$53,234 including bonuses, as contrasted to the near total compensation of \$85,700 received by entry level full-time assistant professors of surgery at US medical schools during the 1985-86 academic year and the even greater income of private practice surgeons (2,3). This discrepancy is accentuated by the fringe benefits of journal subscriptions, professional association dues, dependent tuition, and generous travel allowances available to the civilian analogue of a military surgeon.

The prudent surgeon contemplating initiation or continuation of a military career must also, on the basis of his personal interests and preferences, evaluate other aspects of the career of the military physician scientist. The limited duration of assignments will be compared to the relative, if not absolute, permanence of residence of a civilian peer, and the paucity of research opportunities at some of those assignments will be contrasted to continuity of research opportunity in the civilian sphere. The dissociation of scholarly productivity and advancement in the military will also have a chilling effect. A retention decision on the part of the prudent surgeon investigators has been further prejudiced by a unique and unusual preoccupation with body size and physical prowess. No other organization in the world gives any consideration to weight or running speed as employment criteria for physicians or scientists. One ordinarily selects a physician and/or scientist on the basis of intellectual capability and professional skills, not on the basis of physical endurance. It is generally believed that Walter Reed's accomplishments were not the result of outrunning mosquitos.

Fortunately, the economic and other disincentives have been, to a certain degree, counterbalanced in the decision process of the surgical investigators of this Institute by the availability of research support funds provided by the US Army Medical Research and Development Command. Those funds permit the young investigator to initiate his research career without involvement in the NIH grant application process. In that process, only slightly more than one in three applications are

approved and those, on the average, after three review iterations. The work reported in this volume has resulted from the efforts of these dedicated physicians and scientists for whom this Institute's clinical, teaching, and research opportunities have made possible their professional productivity and counterbalanced the economic and other negative factors noted above. The results of their research have increased our understanding of the multisystem organ response to injury and led to the improvements in clinical management that have reduced the morbidity and increased the survival of seriously injured soldiers.

Unfortunately, retention of such productive investigators and maintenance of research momentum and continuity are ever more tenuous. Since the noted disincentives are similar for mid-career surgical scientists with established research track records. A lieutenant colonel must compare his total compensation of \$79,217 to the mean compensation of \$109,700 for a full-time associate professor of surgery. The commonly observed resignation and migration to medical school faculty positions of such individuals is preordained. The unresponsiveness of retention to cosmetic pay increases in the past has led some to the opinion that increased remuneration doesn't influence retention, but the existing pay discrepancies indicate that salary comparability has never been attempted, let alone evaluated, and that there is no basis for that opinion. Appropriate remuneration and treatment of physicians as physicians give promise of arresting the medical department's brain drain and increasing clinical, educational, and research productivity by enhancing staff continuity (4). Those actions, whose time has come, will maintain the vitality of this Institute.

  
BASIL A. PRUITT, JR., MD, FACS  
Colonel, MC  
Commander and Director

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

#### REFERENCES

1. Despite Recruiting Activities, Navy Finding Fewer Physicians Want Military Careers. American Medical News, 2 Sep 87, pp 25.
2. Smith WC Jr: Report on Medical School Faculty Salaries, 1985-1986. Washington, DC: Association of American Medical Colleges, c1986.

3. Socioeconomic Characteristics of Medical Practice, 1986.  
Chicago: American Medical Association, 1986.
4. NEWS: Koop's corps of biomedical workers cured with  
kindness Nature 328:368, 1987.

# TABLE OF CONTENTS

	<u>Page Number</u>
<u>PROJECT NUMBER 3S162787A874-00, APPLIED RESEARCH</u>	
CLINICAL OPERATION, CENTER FOR TREATMENT OF BURNED SOLDIERS.....	1
<p>COL William F. McManus, MD; LTC Khan Z. Shirani, MD; LTC George M. Vaughan, MD; LTC Donna W. Kyzar; MAJ Thomas B. Dougherty, MD, PhD; MAJ James C. McKay, MD; MAJ Anne E. Missavage, MD; MAJ Steven I. Schmidt, MD; MAJ Anthony A. Smith, MD; MAJ William G. Cioffi, Jr., MD; CPT Gary R. Culbertson, MD; CPT Theresa A. Graves, MD; CPT Mark R. Jackson, MD; CPT Judson C. Lively, MD; CPT David W. Mazingo, MD; CPT L. Willis Roberts, MD; CPT Frank M. Robertson, MD; MAJ Patricia S. Latona, RN; CPT Rosendo T. Gutierrez; CPT Stephen H. Luster; CPT Kathleen F. McCoy; CPT Susan W. Wilson, and COL Basil A. Pruitt, Jr., MD</p>	
Anesthesiology.....	26
<p>MAJ Thomas B. Dougherty, MD, PhD; MAJ Steven I. Schmidt, MD; CPT Charles P. Kingsley, MD; COL William F. McManus, MD; and COL Basil A. Pruitt, Jr., MD</p>	
EVALUATION OF BURN WOUND CARE IN TROOPS WITH BURN INJURY.....	36
E-Z Derm <sup>TM</sup> and Biobrane <sup>R</sup> - A Comparative Study..	37
<p>Stephen M. Pratt, MD; CPT L. Willis Roberts, MD; COL William F. McManus, MD; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD</p>	
A Study to Evaluate the Effectiveness and Safety of Artificial Skin in the Treatment of Third Degree Flame or Scald Injuries.....	46
<p>Stephen M. Pratt, MD; CPT Bryan S. Jordan, RN; COL William F. McManus, MD; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD</p>	

	<u>Page Number</u>
<b>PROJECT NUMBER 3S162787A874-00, APPLIED RESEARCH</b>	
5% Aqueous Sulfamylon <sup>R</sup> Soaks Used in Topical Treatment of Burned Soldiers.....	66
COL William F. McManus, MD, and COL Basil A. Pruitt, Jr., MD	
STUDIES OF THE NEUROENDOCRINE ABNORMALITIES IN BURN INJURY.....	69
Alterations of Temperature, Sleepiness, Mood, and Performance in a Nontrauma, Nonillness Stress Model Are Not Associated with Changes in Sulfatoxymelatonin Excretion.....	70
LTC George M. Vaughan, MD; Katherine A. Sharp, PhD; David J. Kennaway, PhD; and COL Basil A. Pruitt, Jr., MD	
HIGH FREQUENCY VENTILATION IN PATIENTS WITH INHALATION INJURY.....	90
QUANTIFICATION OF DYNAMIC SPLINT FORCES ON METACARPOPHALANGEAL FUNCTION RECOVERY.....	91

**PROJECT NUMBER 3M161102BS14-00, BASIC RESEARCH**

STUDIES OF INFECTION AND MICROBIOLOGIC SURVEILLANCE OF TROOPS WITH THERMAL INJURY.....	93
<p>Albert T. McManus, PhD; Jack R. Henderson, PhD; SSG Timothy E. Lawson; SGT Charles E. Guymon; SSG Aldo H. Reyes, SSG Kenneth Hawthorne; SGT Anne Lasko; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD</p>	
A Clinical Study of the Efficacy of Ceftazidime in the Parenteral Therapy of Infections in Hospitalized Burn Patients.....	143
<p>CPT Leslie B. Scorza, MD; Albert T. McManus, PhD; COL William F. McManus, MD; and COL Basil A. Pruitt, Jr., MD</p>	
THE STUDY OF METABOLISM AND NUTRITIONAL EFFECTS OF BURN INJURY IN SOLDIERS.....	148
Thiamine Levels in the Acutely Burned Patient...	149
<p>Debra Ann Reilly, MD; CPT Ronald L. Shippee, PhD; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD</p>	
ALTERATION OF HOST RESISTANCE IN BURNED SOLDIERS..	154
<p>Albert T. McManus, PhD; Virginia C. English, MS; Camille L. Denton, MA; SGT Charles H. Guymon, MS; SSG Aldo H. Reyes; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD</p>	
Characterization of Biochemical Indicators of Infection in the Thermally Injured.....	166
<p>LTC David G. Burleson, PhD; Avery A. Johnson, BS; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD</p>	
Studies on the Role that Outer Membrane Proteins Play in the Susceptibility of <u>Pseudomonas aeruginosa</u> (PA) to Imipenem.....	173
<p>Robert G. Eagon, PhD; Albert T. McManus, PhD; and COL Basil A. Pruitt, Jr., MD</p>	



PROJECT NUMBER 3M161102BS14-00, BASIC RESEARCH

Therapy with IgG and T <sub>4</sub> in Burn Patients.....	188
MAJ Anne E. Missavage, MD; LTC George M. Vaughan, MD; Albert T. McManus, PhD; LTC David G. Burleson, PhD; COL William F. McManus, MD; COL Basil A. Pruitt, Jr., MD; and Arthur D. Mason, Jr., MD	
ROLE OF THYROID HORMONES IN BURN PATHOPHYSIOLOGY..	200
Control of Thyrotropin (TSH) After Burn Injury..	202
LTC George M. Vaughan, MD; LTC Khan Z. Shirani, MD; Mary K. Vaughan, PhD; Sandy H. Coggins; COL David E. Scott, PhD, and COL Basil A. Pruitt, Jr., MD	
INEQUALITY OF VA/Q RATIOS FOLLOWING SMOKE INHALATION INJURY AND THE EFFECT OF ANGIOTENSIN ANALOGUES.....	212
Takeshi Shimazu, MD; Hisashi Ikeuchi, MD; LTC Gene B. Hubbard, D.M., MS; Avery A. Johnson, BS; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD	
PRELIMINARY STUDIES ON ZINC HOMEOSTATIC CONTROL AND IMMUNOCOMPETENCE IN A BURNED ANIMAL MODEL.....	232
EVALUATION OF SERUM VISCERAL PROTEIN LEVELS AS INDICATORS OF NITROGEN BALANCE IN THERMALLY INJURED PAIENTS.....	234

PROJECT NUMBER 3A1611-1A91C-00, IN-HOUSE LABORATORY INDEPENDENT RESEARCH

Effect of Growth Factors on the Healing of Partial-Thickness Scald Wounds in the Guinea Pig..	235
Cellular Host Defense Function After Thermal Injury: Assessment by Flow Cytometry of Peripheral Blood Cells.....	237
LTC David G. Burleson, PhD; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD	
A Study of Biochemical Changes in the Cellular Environment of Tissue of the <u>in vivo</u> Partial-Thickness Rat Burn Wound.....	255
Wanda L. Brown, MS; Arthur D. Mason, Jr., MD; and COL Basil A. Pruitt, Jr., MD	
The Effect of Interleukin-2 Administration on Mortality to Rats with Pseudomonas Burn Wound Sepsis.....	264
Derivative Spectroscopy Chemiluminogenic Probing of Granulocyte Redox Function in Healthy Controls and Burn Patients.....	265
Evaluation of <u>in vitro</u> Cultivated Keratinocytes as Epithelial Autografts for the Closure of Burn Wounds.....	267
The Effect of High Frequency Ventilation on VA/Q in Sheep with Inhalation Injury.....	268
Effects of Replacement Therapy on Hemodynamic Parameters in an Ovine Model of Controlled Pure Plasma Loss.....	270

	<u>Page Number</u>
PRESENTATIONS.....	271
PUBLICATIONS.....	283
MOTION PICTURES.....	286
DISTRIBUTION LIST.....	287

<u>FISCAL YEAR 1987</u>		<u>FISCAL YEAR 1988</u>		<u>PAGE NUMBER</u>
<u>Project Number</u>	<u>Unit Number</u> Work	<u>Project Number</u>	<u>Unit Number</u> Work	
3S162787A874				APPLIED RESEARCH
3S162772A874	164	3S162787A874	164	Clinical Operation, Center for Treatment of Burned Soldiers 1
3S162772A874	162	3S162787A874	162	Evaluation of Burn Wound Care in Troops with Burn Injury 36
3S162772A874	163	3S162787A874	163	Studies of the Neuroendocrine Abnormalities of Burned Soldiers 69
3S162772A874	166	3S162787A874	166	High Frequency Ventilation in Patients with Inhalation Injury 90
		3S162787A874	167	Quantification of Dynamic Spinal Forces on Metacarpophalangeal Function Recovery 91

<u>FISCAL YEAR 1987</u>		<u>FISCAL YEAR 1988</u>		<u>PAGE NUMBER</u>
<u>Project Number</u>	<u>Unit Number</u>	<u>Project Number</u>	<u>Unit Number</u>	
3M161102BS10	301	3M161102BS14	301	93
3M161102BS10	302			148
3M161102BS10	303	3M161102BS14	303	154
3M161102BS10	304	3M161102BS14	304	200
3M161102BS10	305	3M161102BS14	305	212
3M161102BS10	306	3M161102BS14	306	232
		3M161102BS14	307	234

BASIC RESEARCH

Studies of Infection and Microbiologic Surveillance of Troops with Thermal Injury

The Study of Metabolism and Nutritional Effects of Burn Injury in Soldiers

Alteration of Host Resistance in Burned Soldiers

Role of Thyroid Hormones in Burn Pathophysiology

Inequality of VA/Q Ratios Following Smoke Inhalation Injury and the Effect of Angiotensin Analogues

Preliminary Studies on Zinc Homeostatic Control and Immuno-competence in a Burned Animal Model

Evaluation of Serum Visceral Protein Levels as Indicators of Nitrogen Balance in Thermally Injured Patients

FISCAL YEAR 1967		FISCAL YEAR 1988		PAGE NUMBER
Project Number	Unit Number	Project Number	Unit Number	
3A161101A91C				IN-HOUSE LABORATORY INDEPENDENT RESEARCH
3A161101A91C	075	3A161101A91C	075	Effect of Growth Factors on the Healing of Partial-Thickness Scald Wounds in the Guinea Pig 235
3A161101A91C	076	3A161101A91C	076	Cellular Host Defense Function After Thermal Injury: Assessment by Flow Cytometry of Peripheral Blood Cells 237
3A161101A91C	077	3A161101A91C	077	A Study of Biochemical Changes in the Cellular Environment of Tissue of the <u>in vivo</u> Partial-Thickness Rat Burn Wound 255
		3A161101A91C	078	The Effect of Interleukin-2 Administration on Mortality to Rats with Pseudomonas Burn Wound Sepsis 264
3A161101A91C	079			Derivative Spectroscopy Chemiluminescent Probing of Granulocyte Function in Healthy Controls and Burn Patients 265
3A161101A91C	081	3A161101A91C	081	Evaluation of <u>in vitro</u> Cultured Keratinocytes as Epithelial Autografts for the Closure of Burn Wounds 267

FISCAL YEAR 1987		FISCAL YEAR 1988		PAGE NUMBER
Project Number	Unit Number	Project Number	Unit Number	
3A161101A91C				
				IN-HOUSE LABORATORY INDEPENDENT RESEARCH
3A161101A91C	083	3A161101A91C	083	The Effect of High Frequency Ventilation on VA/Q in Sheep with Inhalation Injury 268
3A161101A91C	085	3A161101A91C	085	Effects of Replacement Therapy Hemodynamic Parameters in an Ovine Model of Controlled Pure Plasma Loss 270

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION DAOG6380	2 DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR&H(A) 636	
3. DATE PREV SUMRY 86 10 01	4. KIND OF SUMMARY D	5. SUMMARY SCTY U	6. WORK SECURITY U	7. REGRADING	8. DISB'N INSTR'N CX	9. LEVEL OF SUM A WORK UNIT	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a. PRIMARY	62787A	3S162787A874	AD	164			
b. CONTRIBUTING							
c. CONTRIBUTING	DA LRRDAP, FY88-01						
11. TITLE (Precede with Security Classification Code) (U) Clinical Operation, Center for Treatment of Burned Soldiers							
12. SUBJECT AREAS 06 05 Medicine and Medical Research 06 13 Microbiology 06 15 Pharmacology							
13. START DATE 50 07	14. ESTIMATED COMPLETION DATE 99 09	15. FUNDING ORGANIZATION DA	16. PERFORMANCE METHOD C				
17. CONTRACT GRANT MILITARY RELEVANCY CERTIFIED				18. RESOURCES ESTIMATE			
a. DATE EFFECTIVE	b. EXPIRATION	c. FISCAL YEARS	d. PROFESSIONAL WORK YEARS	e. FUNDS (In thousands)			
b. CONTRACT GRANT NUMBER		87	53.0	2,115			
c. TYPE	d. AMOUNT	88	53.0	2,221			
a. KIND OF AWARD	f. CUM. TOTAL						
19. RESPONSIBLE DOD ORGANIZATION				20. PERFORMING ORGANIZATION			
a. NAME US Army Institute of Surgical Research				b. NAME US Army Institute of Surgical Research			
b. ADDRESS (include zip code) Fort Sam Houston San Antonio, Texas 78234-5012				b. ADDRESS Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL PRUITT, B A				c. NAME OF PRINCIPAL INVESTIGATOR MC MANUS, W F			
d. TELEPHONE NUMBER (include area code) 512-221-2720				d. TELEPHONE NUMBER (include area code) 512-221-3301			
21. GENERAL USE  MILITARY/CIVILIAN APPLICATION				f. NAME OF ASSOCIATE INVESTIGATOR (if available)			
				g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Heterograft; (U) Resuscitation; (U) Homograft; (U) Air Evacuation; (U) Thermal Injury; (U) Topical Therapy;							
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)							
22. (Continued) (U) Volunteers; (U) Autograft; (U) RAI							
23. (U) The Clinical Division of this Institute is the major treatment center for thermally injured military personnel of all services as well as other eligible beneficiaries. The goals of the Division, in addition to the specialized care of severely injured patients, include the investigation of diagnostic and therapeutic technics to improve the survival and function of injured patients as well as promulgation of scientific medical information to health professionals. A literature search is conducted for each protocol initiated.							
24. (U) Thermally injured patients from the Continental United States and throughout the world are transported to this Institute for intensive, specialized treatment. Carefully controlled evaluation of new treatment technics is conducted by the professional staff.							
25. (U) 8601 - 8612. Two hundred and six seriously burned patients were admitted and treated at this Institute during calendar year 1986. Current clinical research activities include host resistance studies, endocrine changes following injury, development of optimal nutritional support of the burned patient, the use of skin substitutes, and studies in the control of postinjury infection.							



## ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: CLINICAL OPERATION, CENTER FOR TREATMENT OF  
BURNED SOLDIERS

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 January 1986 - 31 December 1986

### INVESTIGATORS

William F. McManus, MD, Colonel, MC  
Khan Z. Shirani, MD, Lieutenant Colonel, MC  
George M. Vaughan, MD, Lieutenant Colonel, MC  
Donna W. Kyzar, RN, Lieutenant Colonel, AN  
Thomas B. Dougherty, MD, Major, MC  
James C. McKay, MD, Major, MC  
Anne E. Missavage, MD, Major, MC  
Steven I. Schmidt, MD, Major, MC  
Anthony A. Smith, MD, Major, MC  
William G. Cioffi, Jr., MD, Captain, MC  
Gary R. Culbertson, MD, Captain, MC  
Theresa A. Graves, MD, Captain, MC  
Mark R. Jackson, MD, Captain, MC  
Judson C. Lively, MD, Captain, MC  
David W. Mazingo, MD, Captain, MC  
L. Willis Roberts, MD, Captain, MC  
Frank M. Robertson, MD, Captain, MC  
Patricia S. Latona, RN, Major, AN  
Rosendo T. Gutierrez, Captain, SP  
Stephen H. Luster, Captain, SP  
Kathleen F. McCoy, Captain, SP  
Susan W. Wilson, Captain, SP  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: CLINICAL OPERATION, CENTER FOR TREATMENT OF  
BURNED SOLDIERS

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Jan 86 through 31 Dec 86

INVESTIGATORS: William F. McManus, MD, Colonel, MC  
Khan Z. Shirani, MD, Lieutenant Colonel, MC  
George M. Vaughan, MD, Lieutenant Colonel, MC  
Donna W. Kyzar, RN, Lieutenant Colonel, AN  
Thomas B. Dougherty, MD, Major, MC  
James C. McKay, MD, Major, MC  
Anne E. Missavage, MD, Major, MC  
Steven I. Schmidt, MD, Major, MC  
Anthony A. Smith, MD, Major, MC  
William G. Cioffi, Jr., MD, Captain, MC  
Gary R. Culbertson, MD, Captain, MC  
Theresa A. Graves, MD, Captain, MC  
Mark R. Jackson, MD, Captain, MC  
Judson C. Lively, MD, Captain, MC  
David W. Mozingo, MD, Captain, MC  
L. Willis Roberts, MD, Captain, MC  
Gary R. Culbertson, MD, Captain, MC  
Patricia S. Latona, RN, Major, AN  
Rosendo T. Gutierrez, Captain, SP  
Stephen H. Luster, Captain, SP  
Kathleen F. McCoy, Captain, SP  
Susan W. Wilson, Captain, SP  
Basil A. Pruitt, Jr., MD, Colonel, MC

Two hundred and six patients were admitted to this Institute during calendar year 1986. Principal activities included care of severely burned patients, research to improve survival and function of such patients, and education and training of health care professionals and paraprofessionals. The areas of research included a study to evaluate the effectiveness and safety of Artificial Skin in the treatment of third degree flame or scald injuries, an ongoing study of 5% aqueous mafenide acetate soaks for the topical treatment of burn wounds following grafting, studies of neuroendocrine abnormalities in burn injuries, evaluation of imipenem-cilastatin sodium for prophylactic activity against bacterial pneumonias in burned patients with inhalation injury, a clinical study of the safety and efficacy of ceftazidime in the parenteral therapy of infections in hospitalized burn patients, evaluations of immunoglobulin G and thyroxine therapy,

studies of thiamine levels, and antithrombin deficiency in thermally injured patients, and a project to characterize certain biochemical indicators of infection in the thermally injured.

AEROMEDICAL TRANSFER  
BIOLOGIC DRESSINGS  
CEFTAZIDIME  
ELECTROLYTE BALANCE  
EXCISION  
IMIPENEM-CILASTATIN SODIUM  
IMMUNOMODULATION  
INHALATION INJURY  
METABOLISM  
NEUROENDOCRINE ABNORMALITIES  
NUTRITION  
RESUSCITATION  
SYNTHETIC SKIN SUBSTITUTES  
THERMAL INJURY  
THIAMINE LEVELS  
TOPICAL THERAPY  
VASOACTIVE HORMONES

**CLINICAL OPERATION  
CENTER FOR TREATMENT OF BURNED SOLDIERS**

**INTRODUCTION**

During calendar year 1986, 206 patients were admitted to this Institute and there were 207 patient dispositions during the same period. Statistical data are based on the 207 patient dispositions during calendar year 1986. There were 168 males and 39 females with an average age of 27.8 yr, ranging from 6 wk to 83 yr of age. Fifty-three patients were <15 yr of age (25.6%) and 34 patients were >45 yr of age (16.4%). The average total burn size of the entire population was 27.1% of the total body surface area, with a 12.1% average extent of full-thickness injury. The average hospital stay of all patients, excluding convalescent leave for active duty military patients, was 44.6 days. One hundred and fifty-one patients were admitted within 48 h of injury (73.0%).

During calendar year 1986, 791 operative procedures were performed on 143 patients, an average of 5.53 operative procedures per patient. Four hundred and ten anesthetics were given to 143 patients for an average of 2.9 anesthetics per patient. One hundred and thirty-six patients received a total of 619,025 ml of blood for an average of 4,551.7 ml of blood per patient.

**ADMISSIONS DATA**

The Clinical Division of this Institute admitted 206 soldiers and other authorized patients with thermal, chemical, or electrical injury during calendar year 1986. Aeromedical teams from the Institute conducted 85 missions within the Continental United States to transfer 97 of the 206 patients (47.1%) admitted. Twenty-two missions were carried out by rotary-wing aircraft (25.9%) and 63 by fixed-wing aircraft (74.1%). One hundred and thirty-eight of the 206 patients (67.0%) were admitted within 24 h of injury and 151 (72.8%) were admitted within 48 h of injury. One hundred and sixty-three patients were male and 43 were female.

**DISPOSITIONS DATA**

The following statistics are based on 207 patient dispositions during calendar year 1986. The ages of these 207 patients ranged from 6 wk to 83 yr, with an average age of 27.8 yr. Burn sizes averaged 27.1% of the total body surface area, with an average full-thickness component of 12.1%. Fifty-three patients were in the pediatric age group (age 15 and under), with an average age of 5.6 yr and an average burn size of 23.2% of the total body surface area. The average hospital stay of all dispositions was 44.6 days when convalescent leave for active duty military patients was included in the calculation

and 42.6 days when convalescent leave was excluded. There were 8 patients with high voltage electrical injury and 3 patients with chemical injury. The sources of admission are identified in Table 1 and the causes of burn injury are detailed in Table 2.

Five patients required hemodialysis for acute renal failure. Acute myocardial infarctions were seen in 5 patients and acute pulmonary emboli in 6 patients. Inhalation injury was identified in 60 patients (29.0% based on admissions). Eighty patients (38.8%) had some associated injury (includes 60 patients with inhalation injury) which included fractures or dislocations in 4 patients and lacerations in 9 patients.

**Morbidity and Mortality.** Twenty-nine of the 207 dispositions (14.1%) died during calendar year 1986. Autopsies were performed in 19 (65.5%) of these hospital deaths. The average burn size of patients who died was 59.8% of the total body surface area and the full-thickness average was 41.4% of the total body surface area. Age ranged from 6 wk to 83 yr. Fourteen of these patients (48.3%) had inhalation injury as a primary or contributing cause of death. Nine patients had burn injuries exceeding 80% of the total body surface area (31.0%). Five patients died with acute myocardial infarctions. Five of the 29 deaths (17.2%) occurred in pediatric patients. These children had an average total body surface area burn of 61.6% and an average full-thickness burn of 49.7%. The average age of children who died was 19 months (6 wk through 4 yr). Two of these children had autopsies.

Infection was once again the most common complication following thermal injury, with bacterial pneumonia occurring in 49 patients. The most common organisms isolated in patients with bacterial pneumonia were Staphylococcus aureus in 19 patients, Pseudomonas aeruginosa in 12 patients, and Klebsiella species in 10 patients. However, only 13 patients demonstrated bacterial septicemia and no patient had bacterial invasion of the burn wound identified during this calendar year.

Table 3 lists the effect of age and extent of injury on survival and Table 4 lists mortality rates associated with increments of 10% of the total body surface area for the years 1979 through 1986. Table 5 summarizes the survival of patients with extensive burns from 1958 through 1986. Table 6 compares mortality before and after the use of topical chemotherapy on the burn wound. Table 7 lists the causes of death for calendar year 1986.

#### EDUCATIONAL ACTIVITIES

During calendar year 1986, the professional staff of the Clinical Division continued to provide education to professional and paraprofessional groups at the local, national, and international levels. A total of 31 resident

TABLE 1. Sources of Admission (1986)\*

AREA	A	AD	AF	AFD	N/MC	ND	VAB	OTHER	TOTAL
First Army	2	7	0	1	2	0	0	0	12
Third Army	3	0	2	0	6	1	7	1	20
Fifth Army	16	15	5	8	5	1	9	83	142
Sixth Army	2	1	1	1	1	1	1	0	8
Germany	4	1	1	0	1	1	0	0	8
Honduras	2	0	0	0	0	0	0	0	2
Norway	0	0	0	0	3	0	0	0	3
Hawaii	1	0	0	0	0	0	0	1	2
Alaska	1	0	0	0	0	0	0	0	1
Korea	3	0	0	1	0	0	0	0	4
Micronesia	0	0	0	0	0	0	0	1	1
Bermuda	0	0	0	0	1	0	0	0	1
Newfoundland	0	0	0	0	1	0	0	0	1
New Zealand/ Antartica	0	0	0	0	1	0	0	0	1
Guam	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>1</u>
TOTAL	34	24	9	11	21	5	17	86	207

\*A = Army, AF = Air Force, N = Navy, M = Marine Corps, D = Dependent, VAB = Veterans Administration Beneficiary, and OTHER = Civilian Emergency, US Public Health Service Beneficiary, and Bureau of Employees Compensation Beneficiary.

TABLE 2. Burn Etiology (1986)

Causes	Number of		Disposition (%)	Deaths	Mortality (%)
	Patients				
Gasoline, Diesel, and Kerosene	60	29.0	6	10.0	
Structural Fires	37	17.9	8	21.6	
Hot Liquids	30	14.5	4	13.3	
Butane, Propane, or Natural/Sewer Gas Explosions	13	6.3	4	30.8	
Electrical	13	6.3	-	-	
Motor Vehicle Accidents	11	5.3	-	-	
Open Flames	11	5.3	-	-	
Smoking, Clothes Ignition	8	3.9	5	62.5	
Other	6	2.9	-	-	
Bomb, Shell, Simulator Grenade, and Gunpowder Explosions	5	2.4	-	-	
Contact	5	2.4	-	-	
Welding	5	2.4	2	40.0	
Chemical	3	1.4	-	-	
TOTAL	207	100.0	29	14.0	

TABLE 3. Age, Body Surface Involvement, and Mortality (1986)

Age (Years)	Total Body Surface Area Burn (%)										Total	
	0-10	10-20	20-30	30-40	40-50	50-60	60-70	70-80	80-90	90-100	Cases	Total Deaths Mortality (%)
0 - 1	1	1	-	1	-	-	1	-	1	-	5	2 40.0
1 - 2	4	2	1	1	-	1	1	-	-	-	10	1 10.0
2 - 3	2	-	1	-	1	-	-	-	-	-	4	1 25.0
3 - 4	1	-	-	1	-	1	-	-	-	-	3	- -
4 - 5	2	1	2	-	1	-	-	-	-	-	6	1 16.7
5 - 10	3	2	1	3	1	1	-	-	-	-	11	- -
10 - 15	8	2	2	-	2	-	1	-	-	-	15	- -
15 - 20	5	2	2	2	-	-	1	-	-	-	12	1 8.3
20 - 30	21	11	11	9	6	3	1	2	1	3	68	6 8.8
30 - 40	4	8	7	-	4	-	1	4	1	-	29	2 6.9
40 - 50	3	3	1	1	-	-	4	1	-	1	14	4 28.6
50 - 60	2	1	1	1	1	-	1	-	1	1	9	4 44.4
60 - 70	2	4	1	2	2	1	-	-	-	-	12	3 25.0
70 - 80	3	2	1	-	-	-	-	-	-	-	6	2 33.3
80 - 90	-	1	1	-	1	-	-	-	-	-	3	2 66.7
90 - 100	-	-	-	-	-	-	-	-	-	-	-	- -
Total Cases	61	40	32	21	19	7	11	7	4	5	207	
Total Deaths	1	2	2	2	5	2	4	2	4	5	29	
Mortality (%)	1.6	5.0	6.3	9.5	26.3	28.6	36.4	28.6	100.0	100.0		14.0



TABLE 4. Total Body Surface Burn Involvement (%) and Mortality (1983-1986)

	<u>0-10</u>	<u>10-20</u>	<u>20-30</u>	<u>30-40</u>	<u>40-50</u>	<u>50-60</u>	<u>60-70</u>	<u>70-80</u>	<u>80-90</u>	<u>90-100</u>	<u>Total</u>
<u>1986</u>											
Number of Patients	61	40	32	21	19	7	11	7	4	5	207
Number of Deaths	1	2	2	2	5	2	4	2	4	5	29
MORTALITY (%)	1.6	5.0	6.3	9.5	26.3	28.6	36.4	28.6	100.0	100.0	14.0
<u>1985</u>											
Number of Patients	41	46	28	28	19	11	9	6	5	4	197
Number of Deaths	2	3	5	3	7	3	5	5	5	4	42
MORTALITY (%)	4.9	6.5	17.9	10.7	36.8	27.3	55.6	83.3	100.0	100.0	21.3
<u>1984</u>											
Number of Patients	46	38	31	23	18	13	7	5	6	3	190
Number of Deaths	-	-	2	8	4	6	2	3	6	3	34
MORTALITY (%)	-	-	6.5	34.8	22.2	46.2	28.6	60.0	100.0	100.0	17.9
<u>1983</u>											
Number of Patients	47	31	30	30	13	8	6	4	5	5	179
Number of Deaths	1	3	6	7	3	3	5	3	4	5	40
MORTALITY (%)	2.1	9.7	20.0	23.3	23.0	37.5	83.3	75.0	80.0	100.0	22.3

TABLE 5. Survival and Nonsurvival by Year for Patients with Burns >30% of the Total Body Surface Area (1962-1986)

Year	SURVIVORS			NONSURVIVORS		
	Number of Cases	Average Burn (%)		Number of Cases	Average Burn (%)	
		Total	3 <sup>o</sup>		Total	3 <sup>o</sup>
1986	178	21.8	7.3	29	59.8	41.4
1985	48	43.6	21.7	42	54.3	37.1
1984	43	46.4	24.8	32	59.5	38.7
1983	37	43.5	17.5	30	62.8	50.7
1982	53	43.7	24.8	54	53.9	38.3
1981	54	42.7	17.5	43	62.2	39.8
1980	62	42.7	15.1	66	64.3	41.8
1979	61	45.4	13.4	74	65.0	37.0
1978	67	45.7	14.8	69	55.2	33.0
1977	66	42.2	14.4	70	56.9	29.0
1976	69	45.5	15.0	79	64.2	31.1
1975	80	46.1	14.7	94	61.3	32.8
1974	55	43.9	12.2	97	60.8	35.9
1973	47	43.7	19.6	113	60.3	36.2
1972	62	42.0	17.2	103	56.7	35.9
1971	63	41.9	14.0	68	60.8	38.0
1970	92	39.4	10.7	70	51.9	32.6
1969	113	43.2	11.1	70	58.7	26.4
1968	143	44.2	12.6	38	54.6	24.6
1967	103	42.7	13.3	51	59.9	32.3
1966	68	41.5	14.9	59	59.9	31.3
1965	47	43.8	21.0	33	66.0	33.4
1964	40	41.8	14.8	37	65.0	42.4
1963	28	45.8	19.6	57	69.0	41.0
1962	18	42.7	21.4	54	59.1	46.2



TABLE 7. Causes of Death (1986)

Patient	Age	Sex	BURN (%)		Postburn Day	Cause of Death	
			Total	3			
1	60	M	43	31	14	43% total body surface area burn with inhalation injury, cirrhosis of the liver, and cardiomyopathy.	
2	27	F	39	34	19	39% total body surface area burn with inhalation injury and Staphylococcal pneumonia.	
3	26	F	92	90	43	*92% total body surface area burn with inhalation injury and bronchopneumonia.	
4	60	M	19	13	21	19% total body surface area burn with inhalation injury and bronchopneumonia.	
5	63	M	30	27	28	30% total body surface area burn with pneumonia and acute renal failure.	
6	82	M	45	18	30	45% total body surface area burn with inhalation injury and acute myocardial infarction.	
7	58	F	48	39	10	48% total body surface area burn with inhalation injury and acute myocardial infarction.	
8	65	M	60	36	33	60% total body surface area burn with cytomegaloviral pneumonia and viremia and acute myocardial infarction.	

\*Autopsy not performed.

TABLE 7 (Continued)

Patient	Age	Sex	BURN (%)		Postburn Day	Cause of Death	
			Total	3			
9	24	M	96	94	25	96% total body surface area burn with inhalation injury and Staphylococcal pneumonia.	
10	2	M	49	31	27	*49% total body surface area burn with anoxic encephalopathy.	
11	43	M	79	70	13	79% total body surface area burn with inhalation injury and Staphylococcal pneumonia.	
12	36	M	71	54	131	71% total body surface area burn with Aspergillus abscesses of the myocardium and bacterial pneumonia.	
13	36	M	83	56	15	83% total body surface area burn with acute myocardial infarction and adrenal infarction (massive).	
14	2	M	64	62	4	64% total body surface area burn with Candida tracheobronchitis and pneumonia.	
15	28	F	52	33	32	*52% total body surface area burn with inhalation injury and pneumonia.	
16	46	M	68	30	21	68% total body surface area burn with acute myocardial infarction.	
17	19	M	28	21	29	28% total body surface area burn with Staphylococcal and Pseudomonas pneumonia.	

\*Autopsy not performed.

TABLE 7 (Continued)

Patient	Age	Sex	BURN (%)		Postburn Day	Cause of Death	
			Total	3			
18	77	F	15	1	35	*15% total body surface area burn with <i>Klebsiella pneumoniae</i> .	
19	58	F	88	88	39	*88% total body surface area burn with inhalation injury and pneumonia.	
20	29	M	90	60	9	90% total body surface area burn with herpes virus pneumonia and acute myocardial infarction.	
21	0	M	89	65	27	89% total body surface area burn with inhalation injury and pneumonia.	
22	73	F	10	5	71	*10% total body surface area burn with <u>Staphylococcus aureus</u> bronchopneumonia.	
23	42	M	68	59	13	*68% total body surface area burn with inhalation injury and acute renal failure.	
24	0	M	63	47	7	*63% total body surface area burn with <i>Enterobacter</i> species bronchopneumonia.	
25	83	F	26	10	17	26% total body surface area burn with inhalation injury and acute myocardial infarction.	
26	20	M	92	10	16	92% total body surface area burn with massive acute myocardial infarction.	

\*Autopsy not performed.

TABLE 7 (Continued)

Patient	Age	Sex	BURN (%)		Postburn Day	Cause of Death	
			Total	3			
27	59	M	93	52	21	93% total body surface area multiple organ failure.	burn with
28	4	M	44	44	25	*44% total body surface area inhalation injury and pneumonia.	burn with
29	41	M	93	20	11	*93% total body surface area multiple organ failure.	burn and

\*Autopsy not performed.

physicians were attached for periods of 1-3 months, including 4 each from Letterman Army Medical Center, Wilford Hall Medical Center, William Beaumont Hospital (Royal Oak, Michigan), and the Naval Aerospace Medical Institute, 3 each from Providence Hospital (Southfield, Michigan) and Fitzsimons Army Medical Center, 2 each from William Beaumont Army Medical Center and Travis Air Force Base Medical Center, and 1 each from the Louisiana State Hospital System, Brooke Army Medical Center, Walter Reed Army Medical Center, Butterworth Hospital (Grand Rapids, Michigan), and UMD - University Hospital (Newark, New Jersey). A total of 17 medical students rotated through the Institute, including 7 health profession scholarship medical students, 3 students from the Indiana University School of Medicine, 2 students from Columbia University, and 1 student each from the University of Iowa, the University of Michigan, East Tennessee State University, Texas Tech University, and Oral Roberts University. A total of 18 physicians visited from foreign countries for periods ranging from 1 day to 1 year, which included 4 from the Dominican Republic, 3 from Pakistan, 2 each from China, Japan, and Great Britain, and 1 each from Israel, Sweden, the Philippines, Norway, and Spain. The Respiratory Therapy Branch had 120 trainees, the Physical Therapy Branch had 26 trainees, and the Occupational Therapy Branch had 32 trainees. Fifteen scientific publications appeared in refereed medical journals and approximately 131 scientific presentations were conducted for military and civilian audiences. Numerous scientific presentations were made at the Academy of Health Sciences and various military installations throughout the continental United States, to include support of the Battlefield Medicine Course for the United States Air Force and the Combat Casualty Care Courses for the United States Army. In addition, weekly professional staff conferences were conducted for and by Institute personnel.

#### PRESENTATIONS

**Luster SH:** Occupational therapy in burn rehabilitation. Presented to the Occupational Therapy Assistant Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 7 January 1986.

**Roberts LW:** Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 14 January 1986.

**Pruitt BA Jr:** The hemodynamic response to burn injury and resuscitation. Presented at the Carnegie-Mellon University Research Seminar, Pittsburgh, Pennsylvania, 16 January 1986.

**Pruitt BA Jr:** Epidemiology and pathophysiology of burn injury. Presented at the US Army Institute of Surgical Research OT/PT Short Course, Fort Sam Houston, San Antonio, Texas, 21 January 1986.



**Gutierrez RT:** Physical therapy in burn care. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Fort Sam Houston, San Antonio, Texas, 21-31 January 1986.

**McCoy KF:** Biomechanical complications of thermal injury. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Fort Sam Houston, San Antonio, Texas, 21-31 January 1986.

**McManus WF:** Management of burns in the theater of operations. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Fort Sam Houston, San Antonio, Texas, 21-31 January 1986.

**Wilson SW:** Nutritional management of the burn patient. Presented to the Dietetic Interns, Baptist Memorial Hospital, San Antonio, Texas, 28 January 1986.

**Culbertson GR:** Burns. Presented to the Special Operations Medical Sergeants Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 30 January 1986.

**Pruitt BA Jr:** Metabolic management of burn patients. Presented as Visiting Professor at the Albany Medical College, Albany, New York, 5-7 February 1986.

**McManus WF:** Management of burns. Presented to the Flight Surgeons, Randolph Air Force Base, San Antonio, Texas, 10 March 1986.

**Pruitt BA Jr:** Opportunistic infections in injured patients. Presented as Visiting Professor to the Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, 12 March 1986.

**Gutierrez RT:** Physical therapy and occupational therapy of burns. Presented to the Advanced Physical Therapy Course from Wilford Hall Medical Center, Fort Sam Houston, San Antonio, Texas, 18 March 1986.

**McManus WF:** Pathophysiology and anatomy of the burn wound. Presented to the USAF Advanced Physical Therapy Course, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, 18 March 1986.

**Pruitt BA Jr:** Fluid resuscitation of the burn patient. Presented as Visiting Professor at the University of Illinois College of Medicine, Champaign, Illinois, 20-21 March 1986.

**Pruitt BA Jr:** Infection and burn problems. Presented to the Physician's Assistant Course (C4A), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 March 1986.

**McManus WF:** Assessment and management of the burn patient. Presented at the Second Annual Tri-State Trauma Symposium, Lubbock, Texas, 28 March 1986.

**Pruitt BA Jr:** The burn patient as the universal trauma model. Presented as Visiting Professor at the Albany Medical College, Albany, New York, 1-2 April 1986.

**Pruitt BA Jr:** Infection/drugs/topical therapy. Presented at the Eighteenth Annual Meeting of the American Burn Association, Chicago, Illinois, 11 April 1986.

**Shirani KZ:** The influence of inhalation injury and pneumonia on burn mortality. Presented at the Eighteenth Annual Meeting of the American Burn Association, Chicago, Illinois, 11 April 1986.

**Pruitt BA Jr:** Infection and burn problems. Presented to the Physician's Assistant Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 16 April 1986.

**Jordan BS:** Team effort with burn care management. Presented at the INTRACORP Seminar, Dallas, Texas, 1-2 May 1986.

**McCoy KF:** Costs of physical therapy/occupational therapy in burn care. Presented at the INTRACORP Seminar, Dallas, Texas, 1-2 May 1986.

**McCoy KF:** Team effort with burn care management. Presented at the INTRACORP Seminar, Dallas, Texas, 1-2 May 1986.

**Missavage AE:** Team effort with burn care management. Presented at the INTRACORP Seminar, Dallas, Texas, 1-2 May 1986.

**Pruitt BA Jr:** Current management of the burn patient. Presented as Visiting Lecturer to the North Dakota Chapter of the American College of Surgeons and the North Dakota Medical Society, Grand Forks, North Dakota, 1-2 May 1986.

**Pruitt BA Jr:** Diagnosis and treatment of opportunistic infections in injured man. Presented as Visiting Lecturer to the North Dakota Chapter of the American College of Surgeons and the North Dakota Medical Society, Grand Forks, North Dakota, 1-2 May 1986.

**McManus WF:** Resuscitation of thermal, chemical, and electric-injured patients. Presented to the 1986 Military Medical/Surgical Congress, Garmisch, West Germany, 6-9 May 1986.

**Cozean KL:** Occupational therapy in burn rehabilitation. Presented to the Occupational Therapy Assistant Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 9 May 1986.

**Pruitt BA Jr:** Infection and burn problems. Presented to the Physician's Assistant Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 21 May 1986.

**Roberts LW:** Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 6 June 1986.

**Roberts LW:** Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 20 June 1986.

**Pruitt BA Jr:** Individualized fluid resuscitation of the burn patient. Presented as Invited Speaker to the 50th Annual Anniversary Course, Trauma and Critical Care Surgery, University of Minnesota, Minneapolis, Minnesota, 20-21 June 1986.

**Pruitt BA Jr:** Burns during pregnancy. Presented as Invited Speaker to the Burns Management Course, New Delhi, India, 23 June-4 July 1986.

**Pruitt BA Jr:** Chemical burns. Presented as Invited Speaker to the Burns Management Course, New Delhi, India, 23 June-4 July 1986.

**Pruitt BA Jr:** Local burn wound infection. Presented as Invited Speaker to the Burns Management Course, New Delhi, India, 23 June-4 July 1986.

**Pruitt BA Jr:** Inhalation burns. Presented as Invited Speaker to the Burns Management Course, New Delhi, India, 23 June-4 July 1986.

**Pruitt BA Jr:** The systemic response to burn injury - pathophysiology. Presented as Invited Speaker to the Burns Management Course, New Delhi, India, 23 June-4 July 1986.

**McCoy KF:** Physical therapy in burn care. Presented to the US Army-Baylor Physical Therapy Program, Fort Sam Houston, San Antonio, Texas, 24 June 1986.

**Roberts LW:** Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 24 June 1986.

**McCoy KF:** Care of the thermally injured patient. Presented to the Physical Therapy Specialist Course (91J),

Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 25 June 1986.

**Roberts LW:** Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 15 July 1986.

**Pruitt BA Jr:** Infection: cause or effect of pathophysiologic change in burn and trauma patients. Presented as participant in the NATO-Sponsored Seminar on Lipid Mediators and Immunology in Trauma, Helsingor, Denmark, 20-25 July 1986.

**Pruitt BA Jr:** Treatment of thermal injuries. Presented as Visiting Professor to the Department of Surgery, University of South Alabama College of Medicine, Mobile, Alabama, 8 August 1986.

**Cozean KL:** Elastomier pressure devices in control of scar tissue. Presented to the Orthopedic Hand Service, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 14 August 1986.

**Pruitt BA Jr:** The history of animal research. Presented at the Harvey Beffa Conference, Shriners Hospital for Crippled Children, Cincinnati, Ohio, 7-9 September 1986.

**Luster SH:** Occupational therapy in burn rehabilitation. Presented to the Occupational Therapy Assistant Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 9 September 1986.

**Pruitt BA Jr:** The burn patient as a trauma model. Presented as the Curtis Artz Lecturer to the South Carolina Chapter of the American College of Surgeons, Greenville, South Carolina, 12-13 September 1986.

**Pruitt BA Jr:** Necrotizing soft tissue infections: new concepts in the management of surgical infections. Presented to the Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, 7 October 1986.

**Pruitt BA Jr:** Resuscitation and fluid management. Presented at the Buffalo Burn Symposium, Department of Surgery, State University of New York at Buffalo, Buffalo, New York, 10-11 October 1986.

**Pruitt BA Jr:** Diagnosis and treatment of inhalation injury and other pulmonary complications. Presented at the Buffalo Burn Symposium, Department of Surgery, State University of New York at Buffalo, Buffalo, New York, 10-11 October 1986.

**Pruitt BA Jr:** What's new in trauma and burns. Presented to the American College of Surgeons Clinical Congress, New Orleans, Louisiana, 14-25 October 1986.

McManus WF: Burns. Presented to the Officers' Basic Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 15 October 1986.

McCoy KF: Care of the thermally injured patient. Presented to the Physical Therapy Specialist Course (91J), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 23 October 1986.

McManus WF: Thermal injury. Presented to Federal Drug Enforcement Agency pilots, Randolph Air Force Base, San Antonio, Texas, 29 October 1987.

Pruitt BA Jr: Thermal injuries - update 1986. Presented to the Association of Military Surgeons of the United States, San Antonio, Texas, 3 November 1986.

McCoy KF: Physical therapy in burn care. Presented to students from Southwest Texas State University, Fort Sam Houston, San Antonio, Texas, 3 November 1986.

Cioffi WG Jr: Pulmonary and systemic vascular reactivity in thermal injury. Presented at the Twentieth Annual Meeting of the Association for Academic Surgery, Washington, DC, 5 November 1986.

Pruitt BA Jr: Infection and burn problems. Presented to the Physician's Assistant Course (C4A), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 6 November 1986.

Summers TM: Introduction to the hospital ministry course. Presented at Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 10 November 1986.

McManus WF: Resuscitation of the thermally injured patient. Presented at the Trauma Conference, William Beaumont Army Medical Center, El Paso, Texas, 13 November 1986.

Mozingo DW: Chemical burns. Presented at the Trauma Conference, William Beaumont Army Medical Center, El Paso, Texas, 13 November 1986.

McManus WF: Massive burn injury. Presented at the Ninety-Fourth Annual Meeting of the Western Surgical Association, Dearborn, Michigan, 18 November 1986.

Kyzer DW: Nursing administrator overview of the US Army Institute of Surgical Research. Presented to the United States Army Recruiting Service Nursing Educator Tour, Fort Sam Houston, San Antonio, Texas, 20 November 1986.

Pruitt BA Jr: Fluid resuscitation and wound care. Presented to the Department of Surgery, University of Oklahoma

College of Medicine, Oklahoma City, Oklahoma, 11-12 November 1986.

Luster SH: Acute burn care: new approaches. Presented at the Occupational Therapy Symposium for American Military Surgeons of the United States, San Antonio, Texas, 11 November 1986.

Latona PS: Initial management of the burn patient. Presented to the AMEDD Advanced Course at the Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 11 December 1986.

#### PUBLICATIONS

Shirani KZ, McManus AT, Vaughan GM, McManus W, Pruitt BA Jr, and Mason AD Jr: Effects of environment on infection in burn patients. Arch Surg 121(1):31-36, January 1986.

Pruitt BA Jr: Host-opportunistic interactions in surgical infection. Arch Surg 121(1):13-22, January 1986.

Yukioka T, Yukioka N, Aulick LH, Goodwin CW, Mason AD Jr, Sugimoto T, and Pruitt BA Jr: Evaluation of (1-sarcosine, 8-isoleucine) angiotensin II as a therapeutic agent for oleic acid-induced pulmonary edema. Surgery 99(2):235-244, February 1986.

Aulick LH, McManus AT, Pruitt BA Jr, and Mason AD Jr: Effects of infection on oxygen consumption and core temperature in experimental thermal injury. Ann Surg 204(1):48-52, July 1986.

Strome DR, Aulick LH, Mason AD Jr, and Pruitt BA Jr: Thermoregulatory and nonthermoregulatory heat production in burned rat. J Appl Physiol 61(2):688-693, August 1986.

Mason AD Jr, McManus AT, and Pruitt BA Jr: Association of burn mortality and bacteremia. A 25-year review. Arch Surg 121(9):1027-1031, September 1986.

Scott DE, Vaughan GM, and Pruitt BA Jr: Hypothalamic neuroendocrine correlates of cutaneous burn injury in the rat: I. Scanning electron microscopy. Brain Res Bull 17(3):367-378, September 1986.

Farrell KJ, McManus WF, Mason AD Jr, and Pruitt BA Jr: Interrelationship of cardiac index and hemoglobin concentration in a subset of hyperdynamic septic burn patients. Surg Forum 37:75-78, 1986.

Kingsley CP, Schmidt SI, and Reynolds WT: A method for securing "piggyback" infusions (letter). Anesth Analg 65(2):209-210, 1986.

Missavage AE, McManus WF, and Pruitt BA Jr: Suppurative thrombophlebitis. In Current Therapy in Vascular Surgery. Ernst CB and Stanley JC (eds). Burlington: BC Decker, Inc, 1986.

Pruitt BA Jr: The acute burn patient. In Trauma - Emergency Surgery and Critical Care. Siegel JH (ed). New York: Churchill Livingstone, 1986, pp 1099-1132.

Pruitt BA Jr: Diagnosis and treatment of sepsis in the burn patient. In Trauma and Critical Care Surgery. Najarian JS and Delaney JP (eds). Boca Raton: Year Book Medical Publishers, Inc, 1986, pp 443-458.

Pruitt BA Jr: Individualized fluid resuscitation of the burn patient. In Trauma and Critical Care Surgery. Najarian JS and Delaney JP (eds). Boca Raton: Year Book Medical Publishers, Inc, 1986, pp 417-429.

Pruitt BA Jr and Goodwin CW Jr: Burns: including cold, chemical, and electrical injuries. In Textbook of Surgery. Sabiston DB Jr (ed). Philadelphia: WB Saunders Publishing Co, Chapter 12, 1986, pp 214-243.

Pruitt BA Jr, Goodwin CW, Vaughan GM, Aulick LH, Newman JJ, Strome DR, and Mason AD Jr: The metabolic problems of the burn patient. Acta Chir Scand (Suppl) 522:119-139, 1986.

Pruitt BA Jr and Mason AD Jr: Writing an effective abstract. In Principles and Practices of Research - Strategies for Surgical Investigators. Troidl H, Spitzer WO, McPeck B, et al (eds). New York: Springer-Verlag, Inc, 1986, pp 233-235.

Vaughan GM: Human melatonin in physiologic and diseased states: neural control of the rhythm. J Neural Transm (Suppl) 21:199-215, 1986.

Vaughan GM, Lasko J, Coggins SH, Pruitt EA Jr, and Mason AD Jr: Rhythmic melatonin response of the Syrian hamster pineal gland to norepinephrine in vitro and in vivo. J Pineal Res 3(3):235-249, 1986.

Vaughan GM, Mason AD Jr, and Reiter RJ: Serum melatonin after a single aqueous subcutaneous injection in Syrian hamsters. Neuroendocrinology 42(2):124-127, 1986.

Vaughan GM, Pruitt BA Jr, Shirani KZ, Vaughan MK, and Mason AD Jr: The thyroid axis and brain 5'-monodeiodination of thyroxine in the burned rat model of nonthyroidal illness. Neuroendocrinol Lett 8(5):221-226, 1986.

Vaughan GM and Reiter RJ: Pineal dependence of the Syrian hamster's nocturnal serum melatonin surge. J Pineal Res 3(1):9-14, 1986.

Yurt RW and Pruitt BA Jr: Burns. In Surgical Emergencies. Gardner B and Shaftan GW (eds). Philadelphia: JP Lippincott Co, 1986, pp 538-545.

MOTION PICTURES

Pruitt BA Jr and McManus WF: Critical Decisions in Surgery  
#2: Management of Severe Burns. New York: Park Row  
Publishers, 1986.



ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: CLINICAL OPERATION, CENTER FOR TREATMENT OF  
BURNED SOLDIERS: Anesthesiology

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 January 1986 - 31 December 1986

INVESTIGATORS

Thomas B. Dougherty, MD, PhD, Major, MC  
Steven I. Schmidt, MD, Major, MC  
Charles P. Kingsley, MD, Captain, MC  
William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: CLINICAL OPERATION, CENTER FOR TREATMENT OF  
BURNED SOLDIERS: Anesthesiology

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Jan 86 through 31 Dec 86

INVESTIGATORS: Thomas B. Dougherty, MD, PhD, Major, MC  
Steven I. Schmidt, MD, Major, MC  
Charles P. Kingsley, MD, Captain, MC  
William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC

During the period of this report, 410 anesthetics were administered to 143 patients, an average of 2.87 anesthetics per patient. The most commonly used anesthetic agent was enflurane (66.34%), followed by ketamine (15.37%), halothane (8.54%), and isoflurane (5.61%). Due to the nature and combinations of procedures now performed, regional anesthesia is no longer used.

ANESTHESIA  
ENFLURANE  
KETAMINE  
HALOTHANE  
ISOFLURANE

## ANESTHESIOLOGY

### PREOPERATIVE PROCEDURES

**Evaluation.** Most burn patients are several days postinjury when first seen by the anesthesiologist. In the immediate postburn period, time is used to gain abundant physiologic data from routine monitoring of various indices, i.e., hematologic (hematocrit, electrolytes, liver and renal function tests), pulmonary (arterial blood gases, respiratory rate, chest roentgenograms), cardiovascular (blood pressure, central venous pressure, cardiac output), and renal (urine output, urine chemistry), in addition to the usual preoperative patient interview and physical examination. All patients, regardless of age, who have electrical injuries are required to have a preoperative electrocardiogram performed to rule out possible myocardial damage.

**Preparation.** All patients are placed on NPO status after 2400 h the day prior to surgery with the exception of children, who may receive clear liquids up to 5 h prior to surgery. Due to extraordinary fluid requirements in most burn patients, an intravenous infusion, if not already in place, is begun the evening prior to surgery.

**Premedication.** Glycopyrrolate (Robinul<sup>R</sup>), from 0.005 mg/kg to a maximum dose of 0.4 mg/kg, is given intramuscularly 30 min prior to anesthesia or intravenously upon entering the operating room. No other premedications are routinely used with the exception of diazepam preceding ketamine anesthetic.

**Fluids.** All fluids, except hyperalimentation solutions, are changed to 5% glucose in water or Ringer's lactate on arrival in the operating room. Hyperalimentation solutions are continued throughout operative procedures.

### TYPES OF ANESTHESIA

The pattern of anesthetic administration has changed from previous years and involves a greater use of enflurane, having been used in more than 60% of all anesthetic procedures. Ketamine, halothane, and isoflurane are used, but to a much lesser extent (Table 1).

**Enflurane (Ethrane<sup>R</sup>).** Enflurane is a halogenated ether which provides rapid induction and good muscle relaxation. Biotransformation amounts to 2 to 2.5% of an inhaled dose, which perhaps accounts for the few clinical toxic effects observed. Plasma fluoride levels in hypermetabolic burn patients during and after enflurane administration have been measured and found not to be in the toxic range. Enflurane is presently the most commonly used anesthetic agent at this Institute.

TABLE 1. Pattern of Anesthesia Administration (1983-1986)

Agent	1983		1984		1985		1986	
	Number	%	Number	%	Number	%	Number	%
Enflurane	184	63.23	290	62.91	279	71.91	272	66.34
Ketamine	66	22.68	88	19.09	52	13.40	63	15.37
Halothane	0	0.00	0	0.00	2	0.52	35	8.54
Isoflurane	0	0.00	0	0.00	35	9.02	23	5.61
Local	13	4.47	14	3.04	10	2.58	10	2.44
Other	6	2.00	42	9.11	10	2.58	7	1.71
Nitrous oxide	22	7.56	27	5.86	0	0.00	0	0.00
TOTAL	291	100.00	461	100.00	388	100.00	410	100.00

**Halothane (Fluothane<sup>R</sup>).** Halothane is a halogenated alkane that has met with only limited use over the last 4 yr. Biotransformation can account for as much as 25% of an inhaled dose. Halothane hepatitis, although rare, fortunately has not been reported in burn patients. Since the successful introduction of enflurane, few indications for halothane's use exist in this patient population that may be predisposed to hepatitis from multiple transfusions with blood products. However, its use is indicated primarily in the burned pediatric patient who requires that his airway be secured by an endotracheal tube. Halothane hepatitis has not been reported to be an issue in the pediatric population. Therefore, its use was increased in the burned pediatric patient population over the past year.

**Isoflurane (Forane<sup>R</sup>).** Isoflurane, which is an isomer of enflurane, is the most recent halogenated ether to be introduced. Biotransformation amounts to only 0.25% of an inhaled dose and no toxic reactions to the metabolic products have been reported to date. It has a rather pungent odor that tends to limit its use for inhalational induction. It is noted for producing minimal myocardial depression and a marked reduction in systemic vascular resistance. At this time, isoflurane has found limited use at this Institute, but as more experience with this agent is gained, its use will probably increase.

**Nitrous Oxide.** This agent is used in concentrations of 50 to 60% with oxygen. It is used mainly in conjunction with other analgesic or anesthetic agents.

**Ketamine.** This agent is used both intramuscularly and intravenously to produce its characteristic dissociative state with preservation of basal functions and laryngeal reflexes plus stimulation of the cardiovascular system. Unfortunately, ketamine shares with its parent compound, phenycyclidine, the production of a high incidence of unpleasant hallucinogenic side effects. There seems to have been a "batch" difference in ketamine and that possessed by this Institute in the past has produced an almost 100% incidence of these side effects. New methods of administering the drug as well as various methods of premedication and patient preparation appear to have reduced the unpleasant emergence reactions to a level where they are of little consideration in the well-selected patient. Laryngospasm, airway obstruction, and regurgitation can occur with ketamine. Pronounced blepharospasm prevents its use in eye cases. All ketamine anesthetics, other than in children, are preceded by intravenous administration of diazepam (0.15 to 0.2 mg/kg).

**Succinylcholine.** Succinylcholine has not been used for any purpose at this Institute for more than 10 yr. On the other hand, nondepolarizing muscle relaxants (vecuronium bromide,

pancuronium bromide, and atracurium besylate) have been used in 22% of the operative cases over the past year.

**Regional Anesthetics.** Regional anesthetics are generally considered one of the safest methods available, but its use in the thermally injured patient is limited for several reasons. Sepsis and infection of the skin over or near the site of injection are contraindications for use and multiple-site operations also limit the practicality of this method.

### MONITORING TECHNIQUES

**Cardiovascular System.** Monitoring includes the precordial and/or esophageal stethoscope, peripheral pulse, blood pressure, central venous pressure, Swan-Ganz catheter, electrocardiogram, and urine output.

The Dinamap<sup>TM</sup> blood pressure instrument is routinely used for intraoperative blood pressure monitoring. Since it can be used over dressings and is noninvasive, it is a most practical method of monitoring blood pressure in our patient population. Usually, blood pressure is monitored at two sites. Direct arterial lines are used when necessary.

**Respiratory System.** Monitoring includes the rate, auscultation, arterial blood gases, pulmonary functions (pre and intraoperative), hemoglobin oxygen saturation, and end tidal carbon dioxide. During the past year, the introduction of new noninvasive monitors has made a significant contribution to the management of the thermally injured patient. The measurement of hemoglobin oxygen saturation by pulse oximetry, end-tidal carbon dioxide, and pulmonary function parameters all represent no risk to the patient, are easily obtainable, and are accurate. These monitors have become standard in our anesthetic care of the burn patient.

**Body Temperature.** In most cases, a temperature monitor is employed. Because of the greatly increased evaporative losses in burn patients, hypothermia is a serious problem. Several methods are employed to maintain body temperature during anesthesia. Ambient temperatures were maintained between 82 and 87°F in the past; however, patient cooling still occurred. Maintaining the room temperature above 88°F appears to have corrected the problem. Anesthetic gases are heated and humidified. Radiant heat lamps used alone have been found to have little effect in preventing patient cooling. The K-thermia<sup>TM</sup> heating blanket is also sometimes used. It is probably used most effectively on children weighing <10 kg and febrile patients.

### RESULTS

**Complications.** There were no intraoperative complications during this reporting period.

**Patient Data.** Tables 2 and 3 provide overall anesthetic patient data.

**Operative Procedures.** Table 4 illustrates recent trends in operative procedures.

#### PRESENTATIONS/PUBLICATIONS

Kingsley CP, Schmidt SI, and Reynolds WJ: A method for securing "piggyback" infusions (letter). Anesth Analg 65(2):209-210, 1986.

TABLE 2. Frequencies of Use for Selected Intraoperative Monitors/Parameters (1986)

Monitor/Parameter	Number of Intraoperative Uses	Total Anesthetics (%)
Electrocardiogram	410	100.00
Dinamap <sup>R</sup> (blood pressure)	408	99.51
Temperature	397	96.83
Pulse oximeter (hemoglobin saturation)	370	90.24
End-tidal carbon dioxide	356	86.83
Inspired oxygen concentration	356	86.83
Pulmonary function	332	80.98
Arterial line	38	9.27
Central venous pressure	9	2.20
Swan-Ganz catheter	9	2.20



TABLE 3. Overall Anesthetic Patient Data (1971-1986)

Year	Number of Patients	Number of Patients Anesthetized	% of All Patients	Total Anesthetics Given	Average Anesthetics Per Patients Anesthetized
1971	301	179	59.47	475	2.65
1972	301	183	60.80	575	3.14
1973	273	141	51.65	377	2.67
1974	226	123	54.42	380	3.09
1975	254	142	55.91	490	3.45
1976	277	139	50.18	476	3.42
1977	242	129	53.30	344	2.67
1978	268	151	56.34	435	2.88
1979	267	161	60.30	554	3.44
1980	243	148	60.91	531	3.59
1981	208	127	61.06	404	3.18
1982	231	151	65.37	532	3.52
1983	179	98	54.75	291	2.97
1984	190	139	73.16	461	3.32
1985	197	133	67.51	388	2.92
1986	207	143	69.08	410	2.87

TABLE 4. Recent Trends in Operative Procedures (1982-1986)

Procedure	1982		1983		1984		1985		1986	
	Number	%	Number	%	Number	%	Number	%	Number	%
Excision	257	33.29	196	42.06	323	41.04	304	43.37	303	38.31
Autograft	405	52.46	203	43.56	371	47.14	304	43.37	372	47.03
Orthopedic	31	4.01	22	4.72	30	3.81	19	2.71	29	3.67
Chondrectomy	0	0.00	2	0.43	4	0.51	0	0.00	1	0.13
Eye and lid	14	1.81	8	1.72	18	2.29	9	1.28	19	2.40
Intra-abdominal	6	0.78	2	0.43	5	0.64	12	1.71	4	0.51
Plastic	15	1.94	2	0.43	5	0.64	9	1.28	5	0.63
Other	44	5.70	31	6.65	31	3.94	44	6.28	58	7.33
TOTAL	772	100.00	466	100.00	787	100.00	701	100.00	791	100.00

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1. AGENCY ACCESSION	2. DATE OF SUMMARY	REPORT CONTROL SYMBOL
				DAOG6971	87 10 01	DD-DRAB(IAR) 836
3. DATE PREV SUMMARY	4. KIND OF SUMMARY	5. SUMMARY SCTY	6. WORK SECURITY	7. REGRADING	8. DISB'N INSTR'N	9. LEVEL OF SUM A. WORK UNIT
86 10 01	D	U	U		CX	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY	62787A	3S162787A874	AD	162		
b. CONTRIBUTING						
c. CONTRIBUTING	DA LRRDAP, FY88-01					
11. TITLE (Precede with Security Classification Code)						
(U) Evaluation of Burn Wound Care in Troops with Burn Injury						
12. SUBJECT AREAS						
06 05 Medicine and Medical Research 06 13 Microbiology 06 15 Pharmacology						
13. START DATE	14. ESTIMATED COMPLETION DATE	15. FUNDING ORGANIZATION	16. PERFORMANCE METHOD			
76 10	99 09	DA	C			
17. CONTRACT GRANT MILITARY RELEVANCY CERTIFICATE						
a. DATE EFFECTIVE	b. EXPIRATION DATE	c. FISCAL YEARS	a. PROFESSIONAL WORK YEARS	b. FUNDS (in thousands)		
b. CONTRACT/GRANT NUMBER			87	1.5	95	
c. TYPE	d. AMOUNT	88		1.5	103	
e. KIND OF AWARD	f. CUM/TOTAL					
19. RESPONSIBLE DOD ORGANIZATION			20. PERFORMING ORGANIZATION			
a. NAME			a. NAME			
US Army Institute of Surgical Research			US Army Institute of Surgical Research			
b. ADDRESS (include zip code)			b. ADDRESS			
Fort Sam Houston San Antonio, Texas 78234-5012			Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL			c. NAME OF PRINCIPAL INVESTIGATOR			
PRUITT, B A			MC MANUS, W F			
d. TELEPHONE NUMBER (include area code)			d. TELEPHONE NUMBER (include area code)			
512-221-2720			512-221-3301			
21. GENERAL USE			f. NAME OF ASSOCIATE INVESTIGATOR (if available)			
FINA			g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
MILITARY/CIVILIAN APPLICATION: M						
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Burn Injury; (U) Topical Therapy; (U) Mafenide Acetate; (U) 5% Mafenide Acetate Solution; Volunteers;						
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)						
22. (Continued) (U) Autograft; (U) RAI						
23. (U) The cause of infection in the wounds of burn patients continues to be a major area of study in order to improve the survival of the severely burned soldier. This study is designed to evaluate the efficacy of 5% aqueous mafenide acetate-soaked dressings, employed either for final debridement of burn wounds or following application of meshed cutaneous autograft, to prevent infection and desiccation of the tissue exposed in the interstices of such grafts. A literature search is conducted for each protocol initiated.						
24. (U) Patients admitted to this Institute for care following thermal, chemical, or electric injury are treated with 5% aqueous mafenide acetate soaks daily.						
25. (U) 8601 - 8612. One hundred and forty-one patients were treated with 5% aqueous mafenide acetate soaks during calendar year 1986. Nineteen of these 141 patients exhibited mild cutaneous atopy. This low incidence of mild side effects of 5% aqueous mafenide acetate and its continued clinical effectiveness speak for the continued use of this valuable therapeutic agent.						

**ANNUAL RESEARCH PROGRESS REPORT**

**PROJECT NUMBER:** 3S162787A874-00, APPLIED RESEARCH

**PROJECT TITLE:** EVALUATION OF BURN WOUND CARE IN TROOPS WITH  
BURN INJURY: E-Z Derm<sup>TM</sup> and Biobrane<sup>R</sup>: A  
Comparative Study

**US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012**

**1 October 1986 - 30 September 1987**

**INVESTIGATORS**

Stephen M. Pratt, MD  
L. Willis Roberts, MD, Captain, MC  
William F. McManus, MD, Colonel, MC  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: EVALUATION OF BURN WOUND CARE IN TROOPS WITH  
BURN INJURY: E-Z Derm<sup>TM</sup> and Biobrane<sup>R</sup>: A  
Comparative Study

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: Stephen M. Pratt, MD  
L. Willis Roberts, MD  
Bryan S. Jordan, RN, Captain, AN  
William F. McManus, MD, Colonel, MC  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

Biologic and synthetic dressings offer utility in excised burn wounds when immediate autografting cannot be performed. Traditionally, allograft has been of demonstrated efficacy for this purpose, yet inherent limitations have prompted a search for alternative materials. A controlled prospective trial was conducted comparing a semisynthetic bilaminate (Biobrane<sup>R</sup>) and an aldehyde-treated xenograft preparation (E-Z Derm<sup>TM</sup>) on paired excised burn wounds prior to autografting. Each material was evaluated using a wound dressing index to numerically rate five factors, i.e., adherence, conformation, pliability, granulation tissue formation, and suppuration. Both materials were highly rated in each category and thus appear to be suitable substitutes for allograft. E-Z Derm<sup>TM</sup> appeared to promote formation of a better and more graftable wound bed ( $P=0.001$ ) and Biobrane<sup>R</sup> was judged more pliable ( $P=0.03$ ). No significant differences were noted in the other three categories or in autograft take following dressing removal. However, considerable variability between sites was noted for both materials.

A consistent and objective means for evaluating wound dressings is presented and used to assess the efficacy of E-Z Derm<sup>TM</sup> and Biobrane<sup>R</sup> as temporary covers on excised burn wounds prior to autografting. The wound dressing index presented facilitates comparison of various materials and assists in defining the utility of each dressing in burn care.

## E-Z Derm<sup>TM</sup> AND Biobrane<sup>R</sup> - A COMPARATIVE STUDY

### INTRODUCTION

Closure of the burn wound is sine qua non to the recovery of the thermally injured patient. Because lack of available donor sites often delays wound closure, alternatives to immediate autografting have been advanced as temporizing measures. Allograft has been widely regarded as the "gold standard" for temporary wound closure since its use in burns was first advanced by Pollack in 1870 (1). Control of fluid, electrolyte, and protein loss from the wound, support of the production of a graftable fibrovascular bed, control of microbial proliferation, and pain control are among the recognized benefits of allograft use (2,3). Additionally, increased survival with early burn wound excision and allograft coverage has been documented in an animal model (4); however, matching allograft availability with need, the diminished effectiveness of frozen and lyophilized preparations, eventual rejection, and storage requirements have imposed limitations on its use. More recently, the potential for disease transmission bodes ill for the widespread medical use of almost any human material. As a result of these limitations, xenograft has been utilized as an alternative to allograft for many years, with porcine skin comprising the bulk of commercially available products today. However, less than optimum durability and wound adherence properties along with an incommensurate antimicrobial effect have been drawbacks of porcine skin graft use. For these reasons, a great deal of interest has been generated in the development of modified biologic dressings and synthetic materials to serve as temporary substitutes for autograft. A collagen-synthetic bilaminate membrane has been documented to be efficacious when compared with porcine xenograft and human allograft. Recently, E-Z Derm<sup>TM</sup>, an aldehyde-treated porcine dermal preparation, has been introduced and reportedly shares some of the desirable properties of xenograft with the added advantages of room temperature storage, longer wound retention times, and decreased antigenicity (5,6). Both of these materials would therefore appear to be useful alternatives to allograft use in the treatment of partial-thickness wounds and as temporizing measures in excised full-thickness wounds when donor site availability limits definitive autografting.

To evaluate the latter, a controlled prospective comparative trial of these two dressings on excised burn wounds prior to autografting was conducted. Utilizing a previously described wound dressing index to quantify differences in each of five categories regarded as essential properties of wound dressings (7), meaningful data was obtained to facilitate efficacy determinations. Use of this system allows for comparison of the various biologic and synthetic dressings which are becoming available for clinical use.

## MATERIALS AND METHODS

Sixteen sites were compared in 11 patients with a mean age of 32 yr (range 24-68 yr) and a mean total body surface area (TBSA) burn of 54% (range 42-88%). Sites were comparable with respect to anatomic location, method and depth of excision, and size. In all cases, tangential excision (11 sites) or fascial excision (5 sites) to the level of viable tissue was followed by immediate dressing placement after hemostasis was obtained (Table 1). E-2 Derm<sup>TM</sup> (Genetics Laboratories, St. Paul, MN) was applied in 3-in wide strips, with either side placed against the wound surface. These sites were subsequently wrapped with light gauze dressings for 18 to 24 h to prevent early mechanical disruption during transport and recovery from anesthesia, following which the test sites were left open for observation. Biobrane<sup>R</sup> (Winthrop Pharmaceuticals, Santa Anna, CA) of appropriate size was expanded until taut and wrinkle-free and stapled into place. All excesses were trimmed as necessary. An occlusive dressing was subsequently applied for 24-36 h to allow for initial adherence of the Biobrane<sup>R</sup> to the wound.

**Evaluation.** Conformation of the dressing to the wound surface was assessed by the patient's primary operating surgeon at the initial dressing application and numerically rated as deemed appropriate (Table 1). Dressing pliability was likewise rated from observations made at application and during the course of treatment. Daily observations were recorded by the patient's primary physician for the purpose of assessing adherence of the test dressing and the presence of air pockets, fluid, or frank suppuration beneath the material. Large areas of nonadherence or suppuration beneath the dressing necessitated removal, culture, and treatment of the site with topical agents (mafenide acetate and silver sulfadiazine) applied twice daily. Small areas of fluid accumulation were locally excised and treated topically until reapplication of the dressing was clinically indicated. When adequate donor sites were available and the patient's condition permitted, dressing removal and autografting were performed. At this time, the formation of a graftable bed of granulation tissue at the wound dressing interface was assessed. Each dressing was therefore compared with respect to these five properties essential to the biologic and mechanical function of the material. Additionally, autograft "take" on each test site was recorded.

**Statistical Analysis.** The Wilcoxon matched-pair signed-rank's test and the Friedman two-way analysis of variance were used to test against the null hypothesis that no difference exists between the two test materials in each category assessed.

TABLE 1. Definition of Grading Scales

Formation of Granulation Tissue

- 1 = None
- 2 = Scanty with irregular distribution and wound debris
- 3 = Irregular surface with wound debris or superficial exudate
- 4 = Clean granulating surface with minimal fibrosis or debris
- 5 = Beefy red, uniformly smooth, clean

Presence of Suppuration

- 1 = Frankly purulent collection beneath dressing
- 2 = Moderate seropurulent collection beneath dressing
- 3 = Slight seropurulent collection beneath dressing
- 4 = Slight serous collection beneath dressing
- 5 = None

Adherence to Test Dressing

- 1 = Slides off test site spontaneously
- 2 = Easily dislodged
- 3 = Easily removed with forceps
- 4 = Strips off with resistance
- 5 = Strips off with resistance and brisk bleeding

Conformation to Wound Surface

- 1 = Buckled, wrinkled, poor wound contact
- 2 = Conforms only to flat wound surface
- 3 = Torsion and tension must be applied to gain maximal wound surface contact with minimal wrinkling present
- 4 = Torsion and tension must be applied to gain maximal wound surface contact with no wrinkling present
- 5 = Mimics skin

Pliability of Test Dressing

- 1 = Stiff prior to wound application
- 2 = Loses pliability unrelated to recipient test site condition
- 3 = Loses pliability related to absorption of wound exudate
- 4 = Maintains most of its pliability despite absorption of wound exudate
- 5 = Mimics skin

For each of the five factors listed, a rank of 1 is the least desirable rank and 5 is the most desirable rank. These ranks have been tailored for evaluation of Biobrane<sup>R</sup> and porcine.



## RESULTS

The mean scores in each of the five categories assessed in the 16 paired sites and the percent graft take in the 10 sites which were grafted are presented in Table 2. Statistically, significant differences were noted in two categories when comparing E-Z Derm<sup>TM</sup> and Biobrane<sup>R</sup>.

Granulation tissue formation beneath the dressing at the time of definitive autografting was rated better on the E-Z Derm<sup>TM</sup> sites ( $P=0.001$ ). This difference was particularly notable over wound beds excised to fat. Nonhypertrophic, beefy red granulation tissue was felt to represent an optimum site for autografting. Prior experience has demonstrated that removal of adherent dressing on the "best" sites was accompanied by brisk bleeding and some resistance to the removal of the test dressing. Graft "take" on each of these sites which progressed to autografting was evaluated, resulting in 94 and 85% for E-Z Derm<sup>TM</sup> and Biobrane<sup>R</sup>, respectively, although this difference failed to reach statistical significance in the 10 sites which were grafted. The control of wound suppuration was essentially equal for both materials, with both materials controlling wound exudate relatively well for the initial 14 days of application. After 14 days postapplication, both materials were noted to have small serous fluid collections to a greater extent, necessitating local debridement. Additionally, frank purulence on three separate Biobrane<sup>R</sup> study sites was noted on postapplication days 15, 17, and 18, necessitating total Biobrane<sup>R</sup> removal from two sites and partial removal in the third. All fluid collections were cultured and correlated with the clinical course. Similarly, in two patients with E-Z Derm<sup>TM</sup> placed on nonexposed surfaces (posterior thighs and legs), nonadherence as a result of shear and fluid at the wound-dressing interface necessitated removal. Biobrane<sup>R</sup> was rated higher in pliability than E-Z Derm<sup>TM</sup>, conforming to any surface well. This was particularly advantageous over joints where Biobrane<sup>R</sup> could be applied, permitting continued joint motion with little disruption of the wound bed.

Both materials were highly rated with regard to conformation to the wound surface, receiving equivalent scores. Likewise, adherence was comparable. In these categories, however, considerable site specificity was noted. E-Z Derm<sup>TM</sup> performed better on flat anterior surfaces while Biobrane<sup>R</sup> performed better on dependent surfaces, particularly when applied circumferentially.

Dressings were permitted to remain in place until autografting, patient death, or suppuration. E-Z Derm<sup>TM</sup> remained adherent an average of 18.5 days (range 8-46 days) and Biobrane<sup>R</sup> 13 days (range 7-21 days). Suppuration beneath the dressing constituted the major reason for removal of dressings prior to autografting.

TABLE 2. E-Z Derm<sup>TM</sup> and Biobrane<sup>R</sup>: Wound Dressing Index Values

Factors	Sites	E-Z Derm <sup>TM</sup>	Biobrane <sup>R</sup>
Adherence	16	3.9	3.6
Conformation	16	3.8	4.1
Granulation tissue	16	4.5*	2.9*
Pliability	16	3.4**	4.3**
Suppuration	16	4.3	3.4
Graft take	10	94%	85%

\*P=0.005.

\*\*P=0.03.

In one patient with septicemia and pneumonia, *Pseudomonas aeruginosa* was cultured from beneath both dressing sites after removal for progressive suppuration. Positive cultures necessitated wet-to-dry treatment of the wound with mafenide acetate-soaked dressings twice daily until such time as biologic dressing could again be applied.

When primary physician preference was recorded at completion of each study patient, there was no significant difference noted between the dressings (Table 3). No adverse local or systemic reactions were noted during the course of the study.

#### DISCUSSION

In recent years, biomedical technology has afforded the clinician caring for the thermally injured patient with a number of biologic and synthetic dressings for use when wound coverage is problematic (4,8,9). This group includes patients where adequate donor sites or general condition prohibits definitive autografting following excision of nonviable tissue.

The necessary mechanical and physical properties of skin substitutes and biosynthetic materials available for topical wound closure have been outlined. Roberts et al (7) has previously defined characteristics important to temporary burn wound dressings and outlined a wound dressing index for use in comparing various materials. A biologic dressing should

TABLE 3. Physician Preference for Future Use

	E-Z Derm <sup>TM</sup>	Biobrane <sup>R</sup>
Definitively	6	3
Probably	1	3
Maybe	3	4
No	1	1

control water evaporation and protein loss from the wound, support production of a graftable fibrovascular tissue bed, facilitate infection control at the wound interface, remain adherent, and conform to the wound surface until definitive wound autografting can be effected. Optimally, these materials should be easily stored, applied, and maintained. Autograft has been traditionally used for this purpose, but availability and cost can greatly limit its utility (10). Xenograft has thus subsequently enjoyed wide use and is generally more available than allograft, although this material, too, is not without certain limitations (11). Storage requirements, the need for frequent replacement, and the less than optimal handling characteristic of lyophilized and frozen preparations have inspired the search for alternative materials. Numerous biologic materials, synthetic polymers, and combinations of these have been marketed with fervor in recent years. A great deal of interest has been generated comparing the properties of the many new dressings now available. The recent advances in the field, however, militate for a standardized set of criteria for use in comparing various biologic dressings and skin substitutes. Only then can consistency be achieved in evaluations within and between burn centers. Data controlled with regard to each dressing can thus be analyzed more effectively to define important properties of each material and optimize their use.

In the current study, both dressings appear to be suitable substitutes for allograft. On certain excised sites, each dressing has been shown to be advantageous as outlined. E-Z Derm<sup>TM</sup> proved superior to Biobrane<sup>R</sup> in the promotion of a graftable fibrovascular bed. This was particularly noteworthy on wounds excised to fat. Likewise, patient needs would be better served by the use of Biobrane<sup>R</sup> on dependent, nonexposed surfaces and over joints.

Using a standardized wound dressing index, current and new biologic and synthetic dressings can be systematically

evaluated in a prospective fashion with better definition of the advantages and limitations of each. The use of a uniform grading system will allow for a more meaningful analysis of results.

#### PRESENTATIONS/PUBLICATIONS

None.

#### REFERENCES

1. Freshwater MF and Krizek TJ: Skin grafting of burns: a centennial. J Trauma 11:862-865, 1971.
2. Pruitt BA Jr and Levine NS: Characteristics and use of biological dressings and skin substitutes. Arch Surg 119:312-322, 1984
3. Miller TA, Switzer WE, Foley FD, et al: Early homografting of second degree burns. Plast Reconstr Surg 40:117-125, 1967.
4. Levine NS, Salisbury RE, and Mason AD Jr: The effect of early surgical excision and homografting on survival of burned rats and of intraperitoneally-infected burned rats. Plast Reconstr Surg 56:423-429, 1975.
5. Piccolo NA, Petro JA, and Salisbury RE: Increased adherence time of porcine xenograft pretreated with a cross-linking agent. Proceedings of the American Burn Association (Abstract 44):51-52, 1983.
6. Schechter I: Prolonged retention of glutaraldehyde-treated skin allografts and xenografts: immunological and histological studies. Ann Surg 182:699-704, 1975.
7. Roberts LW, McManus WF, Shirani KZ, et al: BiobraneR and porcine for the excised wound: a comparative study. J Trauma (in press).
8. Robson MC and Krizek TJ: The effect of human amniotic membranes on the bacterial population of infected rat burns. Ann Surg 177:144-149. 1973.
9. Lawrence JC: What materials for dressings? Injury 13:500-512, 1980.
10. Namba K, Koga Y, Mukae N, et al: Clinical effects of allograft. JBCR 5:38-43, 1984.
11. Wang H-J, Yeap CL, and Heimbach DM: Allograft vs. xenograft in preparation of wound for autograft. JBCR 5:116-118, 1984.

## ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: EVALUATION OF BURN WOUND CARE IN TROOPS WITH  
BURN INJURY: A Study to Evaluate the  
Effectiveness and Safety of Artificial Skin in  
the Treatment of Third Degree Flame or Scald  
Injuries

U.S. ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

### INVESTIGATORS

Stephen M. Pratt, MD  
Bryan S. Jordan, RN, Captain, AN  
William F. McManus, MD, Colonel, MC  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

**PROJECT NUMBER:** 3S162787A874-00, APPLIED RESEARCH

**PROJECT TITLE:** EVALUATION OF BURN WOUND CARE IN TROOPS WITH  
BURN INJURY: A Study to Evaluate the  
Effectiveness and Safety of Artificial Skin in  
the Treatment of Third Degree Flame or Scald  
Injuries

**INSTITUTION:** US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

**PERIOD COVERED IN THIS REPORT:** 1 Oct 86 through 30 Sep 87

**INVESTIGATORS:** Stephen M. Pratt, MD  
Bryan S. Jordan, RN, Captain, AN  
William F. McManus, MD, Colonel, MC  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

The evaluation of a collagen-based synthetic wound dressing in the treatment of full-thickness burn injury was conducted at this Institute as part of a multicenter study of this material. Artificial Skin, a bilaminate membrane which consists of a distinct dermal and epidermal portion, was compared to autograft and allograft after excision of full-thickness burn wounds.

Seven patients were entered into the study since its inception, including 3 patients during the period of this report. The average total body surface area burn was 45% (range 29-70%). Artificial Skin was used on sites averaging 9% of the total body surface area (range 6-13%). Autograft served as the control site in 6 patients and allograft was used as a temporary wound dressing on the control site in 1 patient. Mean healing time from initial excision was 61 days (range 51-81 days) for the Artificial Skin sites after definitive epidermal autografting, 35 days (range 14-63 days) for autografted control sites, and 67 days for the site initially covered with allograft prior to autografting.

Complications with the use of Artificial Skin included total loss of the material secondary to infection (1 patient), premature separation of a portion of the Silastic<sup>R</sup> component (4 patients), shallow wrinkling in the initial postoperative period (1 patient), hematoma beneath the collagen matrix requiring evacuation and replacement of the dressing (1 patient), significant loss of the epidermal grafts (1 patient), and failure of the neodermis to vascularize sufficiently to accept epidermal grafts (1 patient). No deaths or septic complications attributable to the material were observed.

As a dressing on excised burn wounds prior to definitive autografting, Artificial Skin served to protect the wound from infection (6/7 patients) and provide a graftable fibrovascular bed (4/7 patients). Additionally, donor site healing time for the thin "epidermal" grafts was significantly shorter than the standard 0.004-in split-thickness grafts, 9.6 days vs. 14 days, respectively ( $P < 0.001$ ).

**A STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY  
OF ARTIFICIAL SKIN IN THE TREATMENT  
OF THIRD DEGREE FLAME OR SCALD INJURIES**

**INTRODUCTION**

Tangential excision of full-thickness burn wounds with immediate autografting are the standard in modern burn care. However, in extensive burn injury, the limitation of donor site availability is often problematic. Additionally, repeated autograft harvesting and the application of widely meshed autograft to achieve coverage provide for less than optimal long-term coverage. The promotion of a "scar epithelium" is the end result, with a tendency for contracture, breakdown, and poor cosmesis. To date, no acceptable permanent replacement for autograft has been developed, although biologic dressings and skin substitutes are now extensively used to meet the immediate needs of wound coverage when autograft is not available (1-7).

Artificial Skin (Integra<sup>R</sup>, Marion Laboratories, Kansas City, MS) was designed to achieve the advantages of immediate coverage and to provide for a long-term analogue to skin (8). Artificial Skin is a bilaminate material consisting of distinct dermal and epidermal analogues. Composed of a polymer of chondroitin-6-sulfate and collagen, the dermal portion provides a template for the ingrowth of capillaries and fibroblasts with, in theory, the formation of a neodermis onto which definitive "epidermal" grafts can be placed to effect final wound closure (9-11). The outer "silastic" portion, which is ultimately removed prior to epidermal grafting, is designed to meet the immediate short-term needs of a temporary wound cover, i.e., control of water and protein loss, reduction of heat loss, provision of a barrier to bacterial invasion, and pain control. Composed of a 0.1-mm Silastic<sup>R</sup> sheet, it is designed to be removed after formation of the neodermis and at a time when the patient's condition permits epidermal autografting. Unlike autografting in the traditional sense, which has a significant dermal element, the recipient neodermis requires only a thin epidermal graft (0.004 in). The end result is coverage with a better dermal base than could be achieved normally when donor sites are limited. The donor site is also reported to heal more rapidly, allowing for more frequent epidermal harvests (9-11).

Artificial Skin was used in this study in a prospective trial on paired full-thickness burn wounds following excision. Objectives assessed included the ability of Artificial Skin to effect immediate wound coverage, the healing time of Artificial Skin sites, the quality of healed sites, adverse reactions, and effects on patient management. Subjective evaluations for each site by each patient and the investigator were also recorded one month and two months following definitive closure.



## MATERIALS AND METHODS

**Patient Criteria.** Patients eligible for entry into this study were those hospitalized with extensive thermal injuries which were life-threatening and/or covered at least 10% of the total body surface area and, in the opinion of the investigator, would not heal within 3 wk and were amenable to excisional therapy. All patients were hospitalized within 24 h of the burn and underwent excisional therapy of their wounds. The wounds utilized for evaluation were similar in size and site. Excision of the wound was initiated within 7 days of injury and was completed within 21 days of injury.

**Wound Management.** Burn wounds were excised to the level of viable tissue as judged by color, texture, and the presence of punctate bleeding. Both tangential and fascial excision were employed as appropriate. Tourniquets, topical thrombin, and warm laparotomy sponges were used to effect hemostasis as needed.

Using a computer-generated randomization scheme, comparative sites were designated to receive either Artificial Skin or coverage with autograft or allograft. Autograft was meshed either 1.5:1 or 3.0:1 and expanded as appropriate. Prior to coverage, each site was biopsied for microbiologic assessment. Autograft and Artificial Skin are stapled into place using small surgical clips prior to coverage with an occlusive dressing treated with mafenide acetate. Immobilization as appropriate was also employed.

Autografted site dressings were removed on either the third or fourth postoperative day and as necessary thereafter. Artificial Skin dressings were removed on the third postoperative day and subsequently left exposed. Fluid collections beneath the dermal element or the Silastic<sup>R</sup> were aspirated and cultured. Nonadherent areas were sharply debrided. Control autograft sites were routinely treated. At approximately 14 days after application, epidermal autografting was performed. Under general anesthesia, epidermal grafts were taken with the Padgett dermatome set at 0.004 inch. These were meshed 1.5:1 and applied to the neodermis after Silastic<sup>R</sup> removal. Epidermal grafts were then dressed with a single layer of fine-mesh gauze followed by an occlusive layer of coarse-mesh gauze treated with mafenide acetate. Because of the extremely friable nature of these thin grafts, dressings were allowed to remain in place until the fifth postoperative day, at which time the coarse-mesh layer was removed. Clean fine-mesh gauze was permitted to remain in place until the seventh to tenth postoperative day. Occlusive dressings were employed at this stage for approximately two more weeks.

**Effectiveness Evaluation.** Artificial Skin was compared to conventional covers. The primary end point for evaluating the efficacy of Artificial Skin was the time from placement of the

definitive epidermal autograft to final closure. Additionally, the "take" of Artificial Skin to the wound bed, the maintenance of the Silastic<sup>R</sup> "epidermis" to the "dermal" element, and the "take" of the final epidermal graft to the neodermis were evaluated for Artificial Skin. The "take" of the other dressing to the wound bed and the "take" of the definitive autograft were evaluated. The method of removal of nonautograft dressing and the difficulties encountered in their removal were recorded. Another parameter assessed was infection at the sites. Following excision, the wounds were cultured. Following removal of the Silastic<sup>R</sup>, the dermis was cultured and after removal of the comparative cover at the time of autograft, the wound was also cultured. At any time when clinical evidence of sepsis or infection was apparent, a culture of both the Artificial Skin and the comparative site were obtained from the area that was clinically determined most likely to be infected.

Rates of wound healing were compared between the two materials used. Both wounds were rated after final healing as to percent of autoepidermal or autograft "take" and serviceability of the cover. Comparisons also included the cosmetic appearance of the wound sites. Photographic documentation of all sites was obtained. Subjective evaluations by the participating patient and the investigator were made at one and two-month periods after initial placement of the material.

**Safety Evaluation.** Patient safety was evaluated by obtaining vital signs at a minimum of every 6 h until the patient was felt to be clinically normal. Intake and output were continuously monitored at a minimum of every 24 h. SMAC profiles, routine hematologies, and urinalysis were obtained just prior to the first application of Artificial Skin, weekly thereafter until all comparative and the noncomparative study sites were grafted and healed, and on the last day of hospitalization. Each patient had blood samples drawn for determination of antibody formation to Artificial Skin, bovine collagen types I, II, and III, and human collagen types I, II, and III. Tissue samples were taken by biopsy from the sites at which Artificial Skin was applied for histologic evaluation of the neodermis at defined intervals during the initial two months after application. Adverse reactions, including both clinical events and laboratory values attributable to the use of Artificial Skin, were noted.

**Analysis of Results.** The various assessment parameters that were considered in this study included time to final wound cover, percent "take" of autograft, percent "take" of Artificial Skin, level of bacterial invasion at each site, relationship of septicemia to site invasion, incidence of adverse reactions, immunological changes (tissue and/or blood), final cosmetic outcome, and patient's subjective assessment. Application of the Fisher sign test, in most cases, was used to

test against the null hypothesis that no difference exists between Artificial Skin and control materials. The student's t-test was used where applicable to healing times.

### RESULTS

Seven patients (6 male, 1 female) were entered into the study. Mean patient age was 30 yr (range 21-38 yr). Average total body surface area burn size was 47% (range 24-70%) with an average full-thickness burn size of 31% (range 18-45%). Study sites ranged in size from 6 to 13% of the total body surface area (mean 9%). All patients received initial placement of the Artificial Skin and control cover within 6 days postburn. Control sites were covered with 0.015-in thick split-thickness autografts in 6 patients and allograft in 1 patient (see Table 1).

Figure 1 shows the excision to viable tissue, while Figure 2 depicts the postoperative result in one patient who underwent autograft placement to the right chest (control site) and Artificial Skin application to the left chest. Following initial excision and Artificial Skin placement, definitive autografting of the neodermis was conducted as determined by an obligatory 10 to 14-day period for graftable neodermis formation, availability of donor sites, remaining wound status, and overall patient condition. Neodermis following Silastic<sup>®</sup> removal has the appearance of a smooth, uniform fibrovascular bed (Fig 3) to which harvested epidermal autografts (0.004 in thick) were applied (Figs 4 and 5). Although vigilance was necessary so as not to damage these extremely delicate grafts, technique was otherwise similar to traditional autografting.

Table 2 depicts the number of days postburn for excision and application of Artificial Skin and the control cover, the number of days after Artificial Skin application for epidermal grafting, and the number of days postburn and postexcision to achieve a healed wound for each site. The end point of final closure denotes 100% epithelial coverage exclusive of subsequent breakdown secondary to trauma, blistering, etc., which in some cases resulted in prolonged hospitalization or the need for further operative intervention. In all cases, the achievement of a healed wound was effected sooner on the control site as compared to the Artificial Skin site, an observation which is not surprising given the results achieved with the current method of split-thickness skin grafting. The final coverage achieved with epidermal autografting, however, appeared to be much the same as traditional autografting in the early period after wound closure (Fig 6). No differences were noted in wound texture, pliability, tendency for breakdown, edema, or blistering by the investigator or the patient at one and two months following definitive closure. Artificial Skin and autograft "take" to the excised bed, final epidermal graft "take" to the neodermis on the Artificial Skin sites, and

TABLE 1. Extents of Injury and Treatment Sites

Patient Number	Total Body Surface Area Burn (%)		Total Body Surface Area Studied (%)	
	2	3	Artificial Skin Site	Control Site
1	23.5	7.5	6.0	6.0
2	26.0	4.0	9.5	9.0
3	55.0	14.5	10.5	10.5
4	39.5	22.8	10.5	10.5
5	23.0	20.5	13.0	13.0
6	7.5	21.5	6.0	6.0
7	5.0	48.0	6.5	6.5*

\*Allograft.



FIGURE 1. Patient after laparotomy excision to level of viable tissue.



FIGURE 2. In accordance to the randomization scheme, Artificial Skin has been applied to the left chest and control material (in this case autograft) has been placed on the left chest.



FIGURE 3. Neodermis after Silastic<sup>R</sup> removal 19 days after Artificial Skin placement. The bed has a characteristic appearance not unlike granulation tissue and appears to be the ready recipient of a graft.




FIGURE 4. Epidermal autograft harvested with the Padgett dermatome set at 0.004 in. The composition of this thin graft is mostly epidermis with very little dermis present.





FIGURE 5. Epidermal autografts applied to the neodermis and stapled into place prior to dressing. Note the control site on the right chest that has already healed.

TABLE 2. Graft "Take" After Initial Procedure (%)

Patient Number	Postburn Day of Excision	Artificial Skin Healed Wound		Control Site Healed Wound	
		Time from Epidermal Grafting	Time from Burn Wound Excision	Time from Burn Wound Excision	
1	5	26	53	14	
2	4	21	51	16	
3	4	37	81	63	
4	3	14	68	51	
5	3	28	53	53	
6	4	20	60	14	
7	3	35	64	67	



FIGURE 6. Control and Artificial Skin sites 3 wk after final epidermal autografting. Differences in color are the result of grafts taken from previously harvested donor sites.

autograft "take" to the control site initially prepared with allograft (patient 7) are noted in Table 3.

**Complications.** Fluid collection beneath the Silastic<sup>R</sup> layer and separation of the Silastic<sup>R</sup> from the dermal analogue were major complications (Table 3). Near total Silastic separation before epidermal autografting occurred in patients 1 and 2, necessitating coverage of the neodermis with biologic dressing and the utilization of 5% mafenide acetate soaks. Silastic separation in patients 3 and 4 prior to epidermal autografting was, however, only 10% (Fig 1). Small fluid collections have usually been in areas of wrinkling and have been sterile in all cases. In patient 3, who had Artificial Skin placement on postburn day 3, wrinkling was a prominent feature and attributed to a postresuscitation decrease in peripheral edema. "Take" of Artificial Skin to the excised bed was unaffected in this patient, yet wrinkling of the Silastic<sup>R</sup> required frequent evacuation of fluid and sharp debridement of the wrinkled areas.

In patient 1, postoperative bleeding required evacuation of a hematoma from a previously dry graft bed both control and Artificial Skin sites one day postoperative. Reapplication of autograft and Artificial Skin resulted in 100% "take" on both sites. No septic complications have resulted to date. Complications are summarized in Table 4.

**Donor Sites.** Donor site healing times were recorded in all cases for the purpose of comparing differences between the traditional thickness autografts (0.015 in) and epidermal autograft (0.004 in) used to graft the neodermis. In most cases, because control sites were autografted at the initial operative procedure placement, most of these donor sites were previously unharvested (8 sites) or had only one prior harvest (2 sites). Epidermal autografts to the neodermis were initial harvest (1 site), second harvests (6 sites), third harvests (5 sites), and four harvests (1 case) of the same site. Healing times for each donor site thickness are depicted in Table 5. Donor site healing was constant regardless of the number of prior harvests. Without regard to prior harvests, thin autograft donor sites healed faster than thick autograft donor sites, 9.6 days and 13.6 days, respectively ( $P < 0.001$ ).

**Subjective Evaluation.** No significant site preference was noted at the one-month or two-month physician evaluation. Two patients preferred control autograft sites to Artificial Skin sites, 1 patient preferred the Artificial Skin site, and 1 patient expressed no preference.

**Immunology and Biopsy Results.** No significant host antibody response to human collagen or bovine collagen at 3 and 6 wk postapplication was noted.

TABLE 3. Results of Grafting (%)

Patient Number	Artificial Skin "Take"		Control Graft "Take"	
	Collagen Matrix	Epidermal Grafting	Initial Cover*	Final Autograft
1	100	75	N/A	100
2	100	70	N/A	100
3	100	90	N/A	90
4	95	75	N/A	95
5	60	90	N/A	5
6	100	10	N/A	100
7	0	N/A**	95	99

\*Initial cover was autograft in 6 of 7 cases. Patient 7 was initially covered with allograft.

\*\*Collagen matrix not sufficiently vascularized and thus no epidermal grafting was performed.

TABLE 4. Complications with the Use of Artificial Skin

Patient Number	Premature Silastic Loss (%)	Fluid Accumulation Beneath Silastic	Wrinkling of Artificial Skin	Hematoma
1	86%	3X	No	Yes
2	90%	2X	Yes	Yes
3	10%	6X	No	No
4	10%	1X	Yes	No
5	60%	>10X	Yes	No
6	20%	-	No	No
7	17%	7X	Yes	No

TABLE 5. Donor Site Comparisons

Prior Harvesting	Epidermal Autograft (0.004 In)	Standard Autograft (0.015 In)
0	1/8	8/13.5
1	6/9	2/14
2	5/10.4	-
3	1/11	-
TOTAL	13/9.6*	10/13.6*

#### DISCUSSION

The relatively small size of our study population precludes reaching any definitive conclusions regarding the overall safety and efficacy of Artificial Skin. However, when analyzed from the multicenter study population of 150 patients, results should provide for more conclusive observations as to the utility of this wound dressing.

Experience to date does show that this material may be useful in patients with very large burns where excision is desirable, yet donor site availability is limiting with respect to wound closure. In these patients, Artificial Skin that requires a minimum of care until final closure can be effected may provide a means for covering large surface areas of excised wound. Thin "epidermal" grafts appear to provide adequate coverage with the added advantage of more rapid donor site healing.

Subjectively, Artificial Skin appeared to be more successful on large, relatively flat, nondependent, nonmobile surfaces. Excess wrinkling of the collagen mat and silastic layer was observed about joints. Shear of the material was observed on dependent surfaces.

While infection beneath the material was not a major problem at this center and septic complications as a result of Artificial Skin placement were not observed, Artificial Skin was observed to separate rapidly from an infected wound bed (patient 5). In this patient, 40% of the collagen mat required removal from the study site and near total autograft loss on the control site was observed.

More widespread use of this skin substitute will permit definition of the patient population for which Artificial Skin has utility, identification of the optimum manner in which it

is to be used to maximize its unique properties, and delineation of its overall impact on patient management and outcome. Only by further prospective analysis can these and other important questions be answered in a meaningful fashion, with the inclusion or exclusion of Artificial Skin to the developing treatment armamenture.

#### PRESENTATIONS/PUBLICATIONS

None.

#### REFERENCES

1. Yannas IV and Burke JF: Design of an artificial skin. I. Basic design principles. J Biomed Matr Res 14:65-81, 1980.
2. Yannas IV, Burke JF, Gordon PL, et al: Design of an artificial skin. II. Control of chemical composition. J Biomed Matr Res 14:107-131, 1980.
3. Dagalakis N, Flink J, Stasikelis P, et al: Design of an artificial skin. Part III. Control of pore structure. J Biomed Matr Res 14:511-528, 1980.
4. Pruitt BA Jr and Levine NS: Characteristics and uses of biologic dressings and skin substitutes. Arch Surg 119:312-322, 1984.
5. Hermans MHE and Hermans RP: Preliminary report on the use of a new hydrocolloid dressing in the treatment of burns. Burns 11:125-129, 1984.
6. Lawrence JC: What materials for dressings? Injury 13:500-512, 1981.
7. Levine NS, Lindberg RA, Salisbury RE, et al: Comparison of coarse mesh gauze with biologic dressings on granulating wounds. Am J Surg 131:727-729, 1976.
8. Nathan P, Robb EC, Dressler D, et al: A silicone-nylon laminated dressing (IP-758) for closure of excised or debrided burn wounds. Burns 8:328-332, 1981.
9. Sagi A, Walter P, Walter MH, et al: Dermodress: a new, temporary skin substitute for extensive deep burn coverage. Plast Reconstr Surg 75:223-226, 1985.
10. Barlett RH: Skin substitutes. J Trauma 21:731-732, 1981.
11. Burke JF, Yannas IV, Quinby WC, et al: Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann Surg 194:413-428, 1981.



ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3S62787A874-00, APPLIED RESEARCH

PROJECT TITLE: EVALUATION OF BURN WOUND CARE IN TROOPS WITH  
BURN INJURY: 5% Aqueous Sulfamylcn<sup>R</sup> Soaks Used  
in Topical Treatment of Burned Soldiers

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

INVESTIGATORS

William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: EVALUATION OF BURN WOUND CARE IN TROOPS WITH  
BURN INJURY: 5% Aqueous Sulfamylon<sup>R</sup> Soaks Used  
in Topical Treatment of Burned Soldiers

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC

During this reporting period, 5% aqueous mafenide acetate dressings have continued to be an efficacious treatment modality in the care of the burn wound. One hundred and seventy-five patients were treated with 5% aqueous mafenide acetate dressings, employed either for final debridement of a wound or following application of meshed cutaneous autograft to prevent desiccation of tissue exposed in the interstices of such grafts. An 11.4% incidence of skin rash (atopy) was noted as the only adverse reaction. The clinical results achieved by the use of 5% aqueous mafenide acetate solution strongly support its continued use.

BURN INJURY  
TOPICAL THERAPY  
5% MAFENIDE ACETATE SOLUTION  
VOLUNTEERS

## 5% AQUEOUS SULFAMYLON<sup>R</sup> SOAKS USED IN TOPICAL TREATMENT OF BURNED SOLDIERS

During this reporting period, the evaluation of 5% aqueous mafenide acetate solution for topical treatment of the burn wound has continued at this Institute where it was used in 175 of 216 patients (81.2%). The 5% aqueous mafenide acetate-soaked dressings are used as wet-to-dry dressings to debride nonviable tissue elements in preparation for split-thickness autograft procedures or as continuous wet dressings to protect freshly excised wounds that are not autografted. In addition, when meshed cutaneous autografts are applied, dressings are soaked with 5% aqueous mafenide acetate solution to decrease the rate of bacterial growth and to prevent desiccation of tissue exposed in the interstices of such grafts.

Twenty patients (11.4%) demonstrated allergic reactions (atopy) with the use of 5% aqueous mafenide acetate solution and these 20 patients demonstrated rapid resolution of the atopic reaction following administration of an antihistamine and/or discontinuation of the 5% aqueous mafenide acetate-soaked dressings. Saline or other aqueous topical antimicrobial agents were substituted when 5% aqueous mafenide acetate-soaked dressings were discontinued and no other adverse reactions were noted in this group of patients.

The use of 5% aqueous mafenide acetate-soaked dressings has continued to be efficacious, both in the preparation of the burn wound for cutaneous autografting and in the prevention of desiccation of ungrafted granulation tissue. In addition, 5% aqueous mafenide acetate solution is most helpful in preventing desiccation or premature bacterial colonization of meshed cutaneous autografts. The dressings over such meshed autografted skin can be left in place for an average of 3 days, allowing development of good adherence of the autografts prior to the first dressing change. The efficacy and the low incidence of adverse side effects speaks for continued use of this solution.

### PRESENTATIONS/PUBLICATIONS

None.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL	
				DACG6970	87 10 01	DD-DRAB (AR) 636	
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCTY	6 WORK SECURITY	7 REGRADING	8 DISB'N INSTR'N	9 LEVEL OF SUM A WORK UNIT	
36 10 01	D				CX		
10 NO CODES		PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY		6135A	38162587A874	AD	163		
b. CONTRIBUTING							
c. CONTRIBUTING		DA ARDAP	FY88-01				
11 TITLE (Precede with Security Classification Code)							
(U) Studies of the Neuroendocrine Abnormalities in Burn Injury							
12 SUBJECT AREAS							
06 03 Medicine and Medical Research 06 15 Pharmacology							
13 START DATE		14 ESTIMATED COMPLETION DATE		15 FUNDING ORGANIZATION		16 PERFORMANCE METHOD	
79 10		99 09		DA		C	
17 CONTRACT GRANT MILITARY RELEVANCY CERTIFIED							
a. DATE EFFECTIVE				b. RESOURCES ESTIMATE			
APPROVED BY <i>Ben L. A. Smith</i>							
c. CONTRACT GRANT NUMBER				d. FISCAL YEARS		e. PROFESSIONAL WORK YEARS	
				87		1.7	
f. TYPE				g. AMOUNT		h. FUNDS (in thousands)	
				88		1.7	
i. KIND OF AWARD				j. TOTAL			
19 RESPONSIBLE DOW ORGANIZATION				20 PERFORMING ORGANIZATION			
a. NAME				b. NAME			
US Army Institute of Surgical Research				US Army Institute of Surgical Research			
c. ADDRESS (include zip code)				d. ADDRESS			
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012			
e. NAME OF RESPONSIBLE INDIVIDUAL				f. NAME OF PRINCIPAL INVESTIGATOR			
BRUITT, B A				VAUGHAN, G M			
g. TELEPHONE NUMBER (include area code)				h. TELEPHONE NUMBER (include area code)			
512-221-2720				512-221-5416			
21 GENERAL USE				i. NAME OF ASSOCIATE INVESTIGATOR (if available)			
FINA							
j. NAME OF ASSOCIATE INVESTIGATOR (if available)							
MILITARY CIVILIAN APPLICATION				M			
22 KEYWORDS (Precede EACH with Security Classification Code) (U) Pineal; (U) Indoles; (U) Catecholamines; (U) Volunteers; (U) Lab Animals; (U) Hamsters; (U) Rats; (U) RAI							
23 TECHNICAL OBJECTIVE 24 APPROACH 25 PROGRESS (Precede text of each with Security Classification Code)							
23. (U) To characterize sympathetic control of pineal activity in burned soldiers in order to improve survival. A literature search was conducted.							
24. (U) To assess biological rhythms under nontrauma stress.							
25. (U) 8610 - 3709. Seven healthy males, 25-34 yr old, were studied at intervals around the clock in two sessions, one before (S1) and one 6 months after (S2) beginning a surgical residency. Stress was monitored by standard tests of mood and simple reaction time for visual vigilance and urinary cortisol. The end of nocturnal sleep and the rhythms of measured sleepiness, overall mood score, oral temperature, and urinary Na+/K+ ratio were all significantly phase-advanced in S2 vs. S1. Scores for mood and vigilance (24-h pooled estimates) were both worse in S2 vs. S1. Though urinary cortisol excretion exhibited a raised curve average in S2 vs. S1, there was no difference in the amplitude or timing of the rhythm. The 24-h rhythm of urinary melatonin sulfate (reflecting pineal melatonin secretion) was unaffected in S2 vs. S1. Control of the timing for rhythm of melatonin and cortisol can be exerted independently from that of rhythms of temperature, sleep, and mood. Nontrauma stress can result in desynchronizing of biorhythms, raising the question of the role of possible dysynchrony in severe traumatic stress.							

DD FORM 1498  
13 MAR

EDITION OF MAR 68 IS OBSOLETE

GPO : 1988-491-003/50329

## ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: STUDIES OF THE NEUROENDOCRINE ABNORMALITIES IN  
BURN INJURY: Alterations of Temperature,  
Sleepiness, Mood, and Performance in A  
Nontrauma, Nonillness Stress Model Are Not  
Associated With Changes in Sulfatoxymelatonin  
Excretion

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

### INVESTIGATORS

George M. Vaughan, MD, Lieutenant Colonel, MC  
Katherine A. Sharp, PhD\*  
David J. Kennaway, PhD\*\*  
Basil A. Pruitt, Jr., MD, Colonel, MC

\*Medical Resource Group  
Blue Bell, Pennsylvania

\*\*University of Adelaide Medical School  
Adelaide, South Australia

## ABSTRACT

PROJECT NUMBER: 3S162787A874-00, APPLIED RESEARCH

PROJECT TITLE: STUDIES OF THE NEUROENDOCRINE ABNORMALITIES IN  
BURN INJURY: Alterations of Temperature,  
Sleepiness, Mood, and Performance in A  
Nontrauma, Nonillness Stress Model Are Not  
Associated With Changes in Sulfatoxymelatonin  
Excretion

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: George M. Vaughan, MD, Lieutenant Colonel, MC  
Katherine H. Sharp, PhD  
David J. Kennaway, PhD  
Basil A. Pruitt, Jr., MD, Colonel, MC

Residency training may disrupt normal sleep/wake cycles, resulting in mood and performance deficits and alterations in biological rhythms. To characterize such disturbances and determine whether they are associated with an alteration in the day/night pattern of melatonin excretion, measurements were obtained around-the-clock in 7 male subjects, each studied in two 48-h sessions. Session 1 was conducted during the week before beginning a residency, and Session 2 at 6 months into a first-year surgical residency. The mean time of the end of nocturnal sleep and the timing of the temperature rhythm were both approximately 2.3 h earlier in Session 2 ( $P < 0.01$  vs. Session 1). The sleepiness rhythm and the overall mood score rhythm were also phase-advanced in Session 2 ( $P < 0.05$ ). The mean value of mood around-the-clock was significantly worse due to increased anger, tension, confusion, depression, and fatigue in Session 2. Vigilance, tested by simple reaction time, did not exhibit a 24-h rhythm and was worse in Session 2 with an increase in lapse time (microsleep,  $> 1$  sec latency,  $P < 0.01$ ). The urinary cortisol rhythm exhibited a raised curve average value (mesor) in Session 2 ( $P < 0.05$  vs. Session 1), but no difference was revealed in amplitude or acrophase. Urinary excretion of  $\text{Na}^+$ ,  $\text{K}^+$ , and  $\text{Cl}^-$  did not differ between sessions, though the  $\text{Na}^+/\text{K}^+$  ratio peaked earlier in Session 2 ( $P < 0.05$ ).

The urinary 6-sulfatoxymelatonin rhythm did not differ in timing, amplitude, or mesor between sessions. A residency training schedule can be associated with altered timing in rhythms of sleep, sleepiness, temperature, and mood, and deterioration of mood and performance without detectable alteration of the endogenous melatonin pattern as exhibited by the excretion rate of the principal urinary metabolite.

Nontrauma stress can result in desynchronizing of biorhythms, raising the possibility of dyssynchrony in severe traumatic stress as well.

PINEAL  
MELATONIN  
ELECTROLYTES  
SULFATOXYMELATONIN  
PERFORMANCE  
STRESS  
SLEEP DEPRIVATION  
VOLUNTEERS

ALTERATIONS OF TEMPERATURE, SLEEPINESS, MOOD, AND PERFORMANCE  
IN A NONTRAUMA, NONILLNESS STRESS MODEL ARE NOT ASSOCIATED  
WITH CHANGES IN SULFATOXYMELATONIN EXCRETION

INTRODUCTION

The pineal gland has a profound influence on thyroid and reproductive function in experimental animals (1), though pineal control of these systems in humans has not yet been documented. However, burn injury causes marked suppression of the thyroid and reproductive axes in humans (2), as well as suppression of the nocturnal surge of melatonin (3), so far the only major pineal hormone recognized. Whether these phenomena are connected in a mechanistic way has not yet been determined.

First, it was necessary to address the question of whether the alteration of the melatonin rhythm in burn injury is related to injury/illness or is a nonspecific concomitant of stress in general. In this report, we have utilized a model (residency training) that contains many elements of stress not connected with trauma or illness per se in order to assess potential changes in the excretion of the principle melatonin metabolite, which has been shown to be an excellent marker for pineal function.

Serum concentrations and urinary excretion of the pineal hormone, melatonin (N-acetyl-5-methoxytryptamine (aMT)) and its major metabolite, 6-sulfatoxymelatonin (aMT.6s), are highest at night (4). Although administration of aMT reportedly induces sleepiness, apparently normal sleep during the day or night can occur without an acute surge of aMT, and sleep deprivation does not acutely disturb the nocturnal aMT surge (5,6). However, the rhythm shifts over 1-2 wk to accommodate a change in the timing of sleep and darkness (7,8). On the basis of (a) deteriorations of mood observed after acute (9) or chronic (10) administration of large doses of aMT, (b) the ability of exogenous aMT to induce sleepiness (11-13), (c) the blunted endogenous nocturnal surge of aMT seen in depressed patients (14-17), (d) the occurrence of jet lag symptoms early in the course of phase-shifting the aMT rhythm (18), and (e) the covariation of urinary aMT, fatigue, and depressed performance within a 24-h time frame (19), the question arises as to whether temperature, sleepiness, mood, or performance might be controlled by the rhythm or endogenous levels of aMT. The literature on sleep deprivation in residents is scarce and to our knowledge no study has been conducted using circadian principles. It is well known, however, that residency training requires a diurnal working schedule with additional night work.

Negative mood changes and impaired performance have been reported in this population as a result of rigorous training schedules (20-28). We have therefore tested the hypothesis that changes in sleepiness, mood, and performance in residency



training might be associated with a detectable alteration of the melatonin metabolite excretion rhythm. Because the urinary aMT.6s rhythm is a good reflection of the serum aMT rhythm and it was not possible to obtain blood samples in this study, we have used urinary aMT.6s to assess the melatonin rhythm. We also assessed the characteristics of temperature, cortisol, and electrolyte fluctuation under the same conditions.

#### MATERIALS AND METHODS

This investigation was conducted in two 48-h sessions for each subject, i.e., within the week prior to a first-year surgical residency (Session 1) and approximately 6 months into residency (Session 2). The protocol was approved by the Institutional Review Board of the Youngstown Hospital Association, Youngstown, Ohio, where 5 subjects were studied. Two subjects were studied at the Harrisburg Polyclinic, Harrisburg, Pennsylvania, with an identical protocol. All subjects provided informed consent.

**Subjects.** Seven males entering a first-year surgical residency volunteered for this study. The residency program involved at least one on-call night every 4 days, including approximately 2 weekends per month, without a day off duty after an on-call night, resulting in 85 to 130 h of service per week. Subjects were considered healthy by means of clinical and laboratory examinations and ranged in age from 25-34 yr, in weight from 59-108 kg, and height from 165-189 cm. Prior to residency, they did not have a history of trouble sleeping. No subjects reported any mental illness during their lives or in their families. No subjects had crossed time zones within 2 wk prior to Session 1. Subjects followed a normal diet with no restrictions, were nonsmokers, and agreed not to consume alcohol during periods of testing.

**Sleep/Wake Log.** Each subject kept a sleep/wake log in which he recorded his sleep/wake schedule for 2 to 3 days prior to Session 1 and for 1-2 wk prior to Session 2. Assessments of sleep related to a session were based on mean or pooled sleep data for a given subject over this period. During each session, light exposure (100-1000 lux in the hospital) was uncontrolled with the exception of subject testing rooms (<100 lux). Sleep (in the dark) was interrupted for nocturnal testing unless the subjects were already awake in relation to work.

**Stanford Sleepiness Scale (SSS).** This scale was designed to quantify stages of the alertness-sleepiness continuum (29). At 3-h intervals concurrent with temperature recording and urine voiding, subjects circled 1 item in a scale with values from 1 (feeling active and vital, wide awake) to 7 (almost in reverie, sleep onset soon, lost struggle to remain awake), with actual sleep time being 8.

**Temperature (Temp).** Oral temp was recorded at 3-h intervals throughout each 48-h session. The subjects were instructed not to exercise, shower, eat, or drink within 0.5 h before temp measurement.

**Urinary Collection.** Under close supervision, each subject was provided with sterile plastic containers without added chemicals and was instructed to collect all urine for each separate 3-h interval with a voiding at the end of each interval. After storage at 4°C for up to 3 h, volumes were recorded and specimens were aliquoted into polypropylene tubes and stored at -60°C until analysis.

**The Profile of Mood States (POMS).** A standardized, self-rated 5-point scale (ranging from 0 = "not at all" to 4 = "extremely") for 65 mood adjectives, this test (30) was administered every 6 h, taking approximately 2 min. It yields 6 component variables, i.e., tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, confusion-bewilderment, and an integrated overall score representing a global index of mood and constituting the 7th POMS variable.

**The Serial Search Test (SST).** The SST (31) was given at 6-h intervals and required approximately 1 min. The subject was presented with a line of 30 random upper case letters on the video screen and searched for the occurrence of the letter "E". The time (to the nearest 10 msec) required to signal its presence or absence was recorded for 32 trials per test to calculate a mean latency. The very few errors were not excluded from the analyzed data.

**The Verbal Reasoning Task (VRT).** The VRT (31) included a randomly shuffled set of 32 statements describing a letter pair, e.g., "M does not precede C. CM."). Approximately 2 min were required to obtain a set of responses ("true" or "false") for which a mean latency (not excluding the very few errors) was calculated at 6-h intervals.

**The Wilkinson's Unprepared Simple Reaction Time Test (USRT).** The USRT is a 15-min, 150-trial response latency test of vigilance with the advantage of being relatively free of any practice effects (32). At random intertrial intervals ranging from 1-10 sec, a randomly chosen 3-digit number on a video screen began rapidly incrementing by 1, providing a stimulus for the subject to press a button as quickly as possible. The resulting response times (to the nearest 10 msec) were electronically stored for computation of mean latency. Errors of commission (button pressed prior to the stimulus onset, false hits), and errors of omission (lapse times or "microsleeps", latencies >1 sec) were excluded from the results of mean latency per test. This test was given at 6-h intervals.

**Protocol.** During each of the two 48-h sessions, the procedures occurring at 3-h intervals (SSS, urine voiding, and temp measurement) together required about 3-5 min and were scheduled for 0800, 1100, 1400, 1700, 2000, 2300, 0200, and 0500 h; those at 6-h intervals (POMS, SST, VRT, USRT) required about 20 min and were performed at 0930, 1530, 2130, and 0330 h. These latter tests were administered on Apple Macintosh computers. The subjects responded by moving the vide screen cursor with a positioning device ("mouse") and pressing the mouse button. For the USRT, subjects simply pressed the mouse button. At no time were subjects required to use the computer keyboard. Vide screen brightness was controlled to maintain approximately 100 lux in front of the screen. To reduce practice effects, the computer operation and the tests were thoroughly explained and the subjects practiced the battery of tests until they were familiar with the computer and the tests. During Session 2, each subject was on-call at least one of the two nights, but this did not interfere with sampling or testing.

**Assays.** Separate aliquots of each 3-h urine sample were used for determination of Na<sup>+</sup> and K<sup>+</sup> by ion selective electrode and Cl<sup>-</sup> by thiocyanate colorimetry; cortisol (33) by methylene chloride extraction, HPLC separation, UV detection, and recovery correction for each sample with 6-OH-progesterone as an internal standard (performed at the Nichols Institute (San Juan Capistrano, California); and aMT.6s by a sensitive and specific RIA (34) on samples diluted 1:50. The aMT.6s antibody was generously supplied by Dr. J. Arendt, and the standard was prepared by the method of Fellenberg *et al* (35).

**Analysis.** Measurements made during 48-h around-the-clock were subjected to 24-h periodic regression (36) which yields a mesor (average predicted ordinate value of the best-fit curve over time as the abscissa), amplitude (best-fit curve peak minus mesor), and acrophase (time of the best-fit curve peak). Urinary data were assigned the times of the midpoints of the urine collections. The cosinor system software (generously provided by Mark Vokac (37) of Oslo, Norway for the Apple II) or the BMDP software for the VAX 11/780 (38) were used for the analyses. The significance of the rhythm was assessed by a standard regression analysis of variance determining likelihood of a zero amplitude, the acrophase provides an index of the timing of the rhythm, and the mesor reflects the central value for the entire sampling period. Each of these parameters could be obtained for each subject and separately for the pooled data among subjects for a given session. If a rhythm was not detected in the pooled data, overall between-subject (mesor) variation was removed to test for significance of the group rhythm. If the group rhythm of a variable was significant in both sessions, a paired t-test was used to evaluate individual subjects' amplitudes and acrophases for a difference between sessions for that variable. Individual

mesors were used to assess the difference (paired t-test) in overall magnitude between sessions.

### RESULTS

Prior to residency, all subjects reported regular nocturnal sleeping habits of 6-8 h per 24-h period. The group mean sleep obtained from sleep/wake records before Session 1 was 7.35 h per 24-h period (Fig 1). The mean sleep after 6 months of residency, still almost entirely at night, was 4.87 h per 24 h period in the 1-2 wk prior to Session 2 (including on-call and off-call times), indicating a significant reduction of 2.48 h per 24-h period ( $P=0.014$ , paired t-test). The mean sleep episode duration (Fig 1) was also reduced prior to Session 2, and the number of sleep episodes per 24-h period (not shown) did not differ significantly between sessions. The end of the last episode of nocturnal sleep was earlier for Session 2 than for Session 1 (Figs 2 and 3), though there was no difference in the beginning time of nocturnal sleep.




FIGURE 1. Mean sleep prior to the measurements in each session (mean  $\pm$  SE).

Cosinor results are indicated in Table 1. Most variables were rhythmic in both sessions, with the exception of SST, VRT, USRT, and some POMS components. There were no differences in amplitude for any variable between sessions. Cortisol excretion and POMS Overall, Tension, and Anger exhibited significantly higher mesors in Session 2. (For the Overall POMS and each POMS component except Vigor, a higher score indicates worse mood.) USRT (excluding latencies  $>1$  sec) exhibited a higher latency mesor in Session 2. Among the variables with significant group rhythms in both sessions, sleepiness (SSS), temp, and the POMS Overall score were significantly phase-advanced in Session 2 (vs. Session 1).




FIGURE 2. Mean + SE for temperature and urinary variables and best-fit pooled 24-h periodic regression curves. Session 1 = closed circles, unbroken lines; Session 2 = open circles, broken lines. Arrows (Session 1 = unbroken; Session 2 = broken) above the abscissa in 2nd and 4th panels (applicable to each panel) indicate the mean time between sleep onset and the end of the last nocturnal sleep episode.

Figure 2 shows the group patterns for temp and urinary hormones and ratio of  $\text{Na}^+/\text{K}^+$  concentration and indicates the highly rhythmic nature of these variables (each  $P < 0.001$  in both sessions). However, between-subject variation in rhythm timing (acrophase) does not allow this display adequately to represent between-session changes in timing. Figure 3, based on the between-session acrophase mean for individuals, shows that whereas temp and  $\text{Na}^+/\text{K}^+$  ratio became phase-advanced in Session 2, there was no such change in the urinary cortisol or aMT.6s rhythms.

Figure 4 highlights the between-session differences in the POMS variables. A mean value for each subject over the entire testing time was used to calculate a group mean for each session. Paired t-tests indicate that each component except Vigor was significantly worse in Session 2. Since there were only four measurements per 24-h period for these variables and the actual times of the tests occasionally varied from an exact

TABLE 1. Cosinor Parameters of Group Pooled Data in Each Session

Variable	Mesor		Amplitude		Acrophase (h)	
	Session 1	Session 2	Session 1	Session 2	Session 1	Session 2
Temp ( $^{\circ}$ F)	97.5	97.3	0.72*	0.55*	1752	1531**
SSS	3.30	3.30	2.34*	1.93*	0320	0154***
Urinary Na <sup>+</sup> (meq/L)	8.24	9.61	1.29***	2.43**	1858	1723
Urinary K <sup>+</sup> (meq/L)	2.61	2.87	1.19*	1.38*	1437	1250
Urinary Cl <sup>-</sup> (meq/L)	7.73	8.23	1.40*	2.13**	1433	1421
Urinary Cortisol (g/h)	1.10	1.40***	0.95*	1.00*	0919	0829
Urinary aMT.6s (g/h)	1.17	1.21	1.24*	1.30*	0426	0320
POMS Overall (%)	16.4	20.9***	5.9*	4.7***	0323	0102***
POMS Tension (%)	10.8	18.1***	-	-	-	-
POMS Anger (%)	3.54	8.13	-	-	-	-
POMS Fatigue (%)	27.5	35.4	17.2*	-	0307	-
POMS Vigor (%)	46.6	43.1	17.5*	17.7*	1501	1316
POMS Confusion (%)	21.3	24.2	11.1**	7.2*	0312	0215
POMS Depression (%)	4.0	6.0	-	-	-	-
SST (msec)	3396	3350	-	291***	-	0617
VRT (msec)	4057	4158	-	394***	-	0509
USRT (msec)	334	365***	-	-	-	-

\* $p < 0.001$ , \*\* $p < 0.01$ , \*\*\* $p < 0.05$  (for mesor and acrophase, comparison of Session 2 vs. Session 1; for amplitude, within-session significance of the group rhythm). No amplitudes were significantly different between sessions. Acrophase is given as clock hour (h and min), mesor and amplitude as units associated with the variable name. Differences between sessions were tested by use of parameters from regressions for individuals in each session. For parameters significantly different between sessions, the mean difference is given in Table 2.


US ARMY INSTITUTE OF SURGICAL RESEARCH ANNUAL RESEARCH  
PROGRESS REPORT FOR FISCAL YEAR 1987(U) ARMY INST OF  
SURGICAL RESEARCH FORT SAM HOUSTON TX B A PRUITT

UNCLASSIFIED 01 OCT 87

F/G 6/5

NL

The figure displays a 5x15 grid of 75 small images. Each image shows a different pattern of light and dark regions, likely representing different stages of a process or different conditions. The patterns include horizontal lines, vertical lines, dots, and larger irregular shapes. The images are arranged in a grid, with the first row containing the most complex patterns and the subsequent rows showing simpler variations.








FIGURE 3. The end of the last nocturnal sleep episode and the acrophases (time of best-fit curve maxima) for oral temperature (temp) and urinary  $\text{Na}^+/\text{K}^+$  ratio, cortisol, and aMT.6s, expressed for the group as mean time  $\pm$  SE (abscissa) before or after the within-subject midpoint (mean) between each's respective two values (one for each session). \* $P < 0.05$ , \*\* $P < 0.01$  for phase-advancement in Session 2 (paired t-test on the actual clock values). The abscissal time zero (mean within subject mid-value between sessions) is indicated above each panel.

6-h interval, the mesors (Table 1) and overall means vary slightly in their representation of the central tendency in the data. Analyses of the mesors indicate worsening of Tension and Overall POMS; whereas, analyses of the overall means indicate worsening of Anger, Fatigue, Confusion, and Depression as well.

Figure 5 shows that the overall SST and VRT scores were not different between sessions, but in Session 2, there developed a significant rhythm in speed of response not detected in Session 1 (Table 1). USRT performance, excluding latencies  $> 1$  sec, was significantly worse in Session 2 (Figure 5) and did not exhibit a 24-h rhythm (Table 1). When the latency difference for each subject between sessions was calculated (not shown), this difference exhibited a 12-h rhythm ( $P < 0.02$ ). Lapse time (microsleep, latency  $> 1$  sec) was significantly greater in Session 2 (Fig 5).

### DISCUSSION

The times used in these observations were read directly from the clock that was reset off daylight savings time about two months prior to the measurements in Session 2. This resetting ("fall back") automatically phase-delays the clock and all activities synchronized to it (arising, going to work, going to bed, etc.) by 1 h, and this is normally reflected in a similar delay in the aMT/6.s and cortisol excretion rhythm (34). In the present observations, such a phenomenon is recorded as a phase change of zero and probably explains no observed between-session phase change in aMT.6s and cortisol,

## Profile of Mood States





FIGURE 4. Mean  $\pm$  SE for POMS components by hour of testing and 24-h means. Ordinate units are expressed as percent of the minimum/maximum range for each variable. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  (Session 2 vs. 1).




FIGURE 5. Mean  $\pm$  SE for SST, VRT, and USRT response latencies and USRT mean of total lapse time (latency >1 sec) per test (msec). \* $P < 0.05$ , \*\* $P < 0.01$  (Session 2 vs. 1).

both likely phase-delayed along with the autumn clock resetting and the timing of activity and onset of sleep and dark exposure, well before the measurements in Session 2. Our use of the actual clock times allows the between-session comparison to include the same influence that the timing of the clock had for both sessions.

It is not possible to completely separate influences of the light/dark and sleep/wake cycles in sighted humans, because subjects typically sleep in the dark with eyes closed. In these studies, we focused on the sleep/wake cycle because it was not possible to control or monitor 24-h light exposure in the days prior to the physiological and psychological measurements taken. We assessed sleep prior to the measurements because circadian rhythms are entrained to the sleep/wake and/or dark/light cycle as it is in the days leading up to the measurements (6,7,18).

The reduction in amount of sleep for Session 2 can be viewed as chronic sleep loss. Thus, the increased USRT latencies are consistent with decreased alertness measured by self-ratings in shift workers with a sustained 2-3 h/day sleep loss (39,40). Our results suggest that a performance deficit in residents more reflects vigilance during a routine and reflexive task rather than activity requiring a level of conscious thinking effort, as in the SST and VRT. Disrupted sleep and chronic sleep deprivation enhance the secondary arousal, though that normally occurs in the afternoon (41). In our subjects, this likely was reflected in greater USRT latency at 0330 and at 1530 h in Session 2 (vs. Session 1) and a bimodal (12-h) rhythm in the latency difference between sessions. Sleep deprivation has previously been associated with an increased frequency of brief lapses of consciousness or "microsleeps" (42). Thus, in addition to a general deterioration in response latency, more lapses of >1 sec were apparent in Session 2. It is likely that sleep deprivation during residency was a major contributor to decrements in performance and mood and to elevated cortisol excretion as a reflection of stress.

During residency training (Session 2), sleep tended to end earlier in the morning. Since the SSS included actual sleep as the most intense indicator of sleepiness, the measurement of sleepiness tended to confirm a phase advancement of sleep rhythm in Session 2. The earlier end of nocturnal sleep suggests advancement of the activity rhythm. Along with this advancement in the sleep/activity rhythm, the rhythms of temp, Overall mood, and the urinary Na<sup>+</sup>/K<sup>+</sup> ratio were similarly advanced in Session 2, indicating phase advancement of a substantial element of the circadian system in residency training.

Cortisol levels have been shown to be unchanged or decreased in sleep deprivation (43,44), possibly as a result of

boredom in laboratory-controlled sleep deprivation. In contrast, residents are required to maintain a high level of psychological activation and alertness, which may provide stress in attempting to override fatigue and thus may have contributed to higher cortisol mesors. It is possible that the altered timing of the Na<sup>+</sup>/K<sup>+</sup> ratio in Session 2 partly reflected aldosterone secretion in that this hormone tends to restrict Na<sup>+</sup> excretion and promote K<sup>+</sup> excretion. The assessment of excretion rhythms of electrolytes is difficult in the present study because dietary intake was not measured or kept constant.

The magnitudes of the residency-induced alterations in timing that were observed in those rhythms with significant altered timing were small (Table 2). Lack of detectable changes in melatonin and cortisol rhythm timing does not exclude the possibility that greater phase alteration of temperature, sleepiness, and mood produced by some other technique would then change melatonin and cortisol phasing. More frequent sampling of circulating melatonin or cortisol might have more sensitively revealed residency-induced small changes in rhythm timing. However, since sulfatoxymelatonin and cortisol were sampled at least as frequently as for those variables showing a changed rhythm phasing, sampling frequency is not likely a major factor in the apparently different responsiveness of rhythm timing to residency training among measured variables. Further, in that the changes observed in the residents involved more than altered timing of several rhythms and included sleep deprivation, an earlier final awakening time, overall worsening of mood and vigilance performance, and raised cortisol levels, it is important to note that the overall level and pattern of melatonin excretion was not significantly changed. These results do not support the notion that rhythm changes in or deteriorations of sleep, mood, and vigilance seen in residency training provoke or depend upon a major alteration of the melatonin rhythm. Changes in melatonin that occur in illness or injury may thus result from factors other than those associated with the general aspects of stress. However, nontrauma stress can result in desynchronizing of biorrhythms, raising the possibility of dyssynchrony in traumatic stress as well.

TABLE 2. Mean Within-Subject, Between Session Difference  $\pm$ SE in the 7 Subjects for Cosinor Parameters Significantly Different Between Sessions (from Table 1)

Variable	Parameter	Difference (Session 2 Minus Session 1)
Temp	Acrophase*	-2.26 $\pm$ 0.48++
SSS	Acrophase**	-1.55 $\pm$ 0.62+
POMS Overall	Acrophase***	-3.10 $\pm$ 1.18+
Urinary Cortisol	Mesor	0.304 $\pm$ 0.12+
POMS Overall	Mesor	5.53 $\pm$ 1.71+
POMS Tension	Mesor	7.69 $\pm$ 2.99+
USRT	Mesor	30.7 $\pm$ 8.5+

\*Rhythmicity regressional variation ( $r^2$ ) as % of total variation in individual subjects (mean  $\pm$  SE): Session 1, 62 $\pm$ 5; Session 2, 50 $\pm$ 9 (all  $P < 0.05$  for rhythmicity in both sessions except for 1 subject in Session 2). \*\* $r^2$ : Session 1, 74 $\pm$ 5; Session 2, 56 $\pm$ 2 (all  $P < 0.05$  in both sessions). \*\*\* $r^2$ : Session 1, 47 $\pm$ 8 ( $P < 0.05$  in 1 of 7 subjects); Session 2, 47 $\pm$ 8 ( $P < 0.05$  in 4 of 7 subjects). Acrophase computations for all subjects were included in the between-session tests, because in both sessions, the group rhythms were significant (Table 1). + $P < 0.05$ , ++ $P < 0.01$  (Session 2 vs. Session 1, paired t-test). Acrophase difference is in decimal h, negative numbers meaning earlier timing (phase advance) in Session 2. Mesor units (as in Table 1) are those for the measurements of the respective variables.

#### PRESENTATIONS/PUBLICATIONS

Vaughan GM: Alterations of temperature, sleepiness, mood, and performance in a nontrauma nonillness stress model are not associated with changes in sulfatoxymelatonin excretion. Presented to the 69th Annual Meeting of The Endocrine Society, Indianapolis, Indiana, 10-12 June 1987.

#### REFERENCES

1. Vaughan GM and Pruitt BA Jr: Pineal-induced depression of free thyroxine in Syrian hamsters. J Pineal Res 2:325-330, 1985.
2. Plymate SR, Vaughan GM, Mason AD Jr, and Pruitt BA Jr: Central hypogonadism in burned men. Horm Res 27:152-158, 1987.

3. Vaughan GM, Taylor TJ, Pruitt BA Jr, and Mason AD Jr: Pineal function in burns: melatonin is not a marker for general sympathetic activity. J Pineal Res 2:1-12, 1985.
4. Arendt JC, Bojkowski C, Franey J, and Marks V: Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 60:1166-1173, 1985.
5. Akerstedt T, Froberg JE, Friberg Y, and Wetterberg L: Melatonin excretion, body temperature, and subjective arousal during 64 hours of sleep deprivation. Psychoneuroendocrinology 4:219-225, 1979.
6. Vaughan GM: Human melatonin in humans. Pineal Res Rev 2:141-201, 1984.
7. Wetterberg L: Melatonin in humans, physiological and clinical studies. J Neural Transmn (Suppl) 13:289-310, 1978.
8. Vaughan GM: Human melatonin in physiologic and diseased states: neural control of the rhythm. J Neural Transmn (Suppl) 21:199-215, 1986.
9. Lieberman HR, Garfield G, Waldhauser F, et al: Possible behavioral consequences of light-induced changes in melatonin availability. Ann NY Acad Sci 453:242-252, 1985.
10. Carman JS, Post RM, Buswell R, and Goodwin FK: Negative effects of melatonin on depression. Am J Psychiat 133:1181-1186, 1976.
11. Cramer J, Rudolph J, Consbruch U, and Kendel K: On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharm 11:187-191, 1974.
12. Vollrath L, Semm P, and Gammel G: Sleep induction by intranasal application of melatonin. In Advances in Bioscience. Czeisler CA and Erlich S (eds). Vol 29, 1981, pp 327-329.
13. Lieberman HR, Waldhauser F, Garfield G, et al: Effects of melatonin on human mood and performance. Brain Res 232:201-207, 1984.
14. Wirz-Justice A and Arendt J: Diurnal, menstrual cycle, and seasonal indole rhythms in man and their modification in affective disorders. In Biol Psychiatry Today. Obiols J, Ballus C, Monclus EG, and Pujol J (eds). Amsterdam: Elsevier/Biomedical Press, 1979, pp 294-302.

15. Branchey L, Weinberg U, Branchey M, et al: Simultaneous study of 24-hour patterns of melatonin and cortisol secretion in depressed patients. Neuropsychobiol 8:225-232, 1982.
16. Clausturat PJ, Fraser S, Sammons R, and Green AR: A chronobiologic study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiat 19:1215-1228, 1984.
17. Beck-Friis J, Ljunggren J-G, Thoren M, et al: Melatonin, cortisol and ACTH in patients with major depressive disorder and healthy humans with special reference to the outcome of the dexamethasone suppression test. Psychoneuroendocrinol 10:173-186, 1985.
18. Fevre-Montange M, Van Cauter E, Refetoff S, et al: Effects of "jet lag" on hormonal patterns. II. Adaptation of melatonin circadian periodicity. J Clin Endocrinol Metab 52:642-649, 1981.
19. Akerstedt T, Gillberg M, and Wetterberg L: The circadian covariation of fatigue and urinary melatonin. Bio Psych 17:547-554, 1982.
20. Friedman RC, Bigger JT, and Kornfeld DS: The intern and sleep loss. New Engl J Med 285:201-203, 1971.
21. Friedman RC, Kornfeld DS, and Bigger JT: Psychological problems associated with sleep deprivation in interns. J Med Educ 48:436-441, 1973.
22. Wilkinson RT, Tyler PD, and Varey CA: Duty hours of young hospital doctors: Effects on the quality of work. Journal of Occupational Psychology 48:219-229, 1975.
23. Poulton EC, Hunt GM, Carpenter A, and Edwards RS: The performance of junior hospital doctors following reduced sleep and long hours of work. Ergonomics 21:279-295, 1978.
24. Asken JJ and Raham DC: Resident performance and sleep deprivation: a review. J Med Educ 58:382-388, 1983.
25. Donnelly JC: Coping and development during internship. In The Physician: A Professional Under Stress. Callan JP (ed). Norwalk, Connecticut: Appleton-Century-Crofts, 1983, pp 46-90.
26. Pfifferling J-H: Coping with residency distress. Resident and Staff Physician 29:105-111, 1983.



27. McCue J: The stresses of graduate medical training. New Engl J Med 312:449-452, 1985.
28. Mizrahi T: Getting rid of patients: contradictions in the socialization of internists to the doctor-patient relationship. Society of Health and Illness 7:214-235, 1985.
29. Hoddes E, Zarcone V, Smythe H, et al: Quantification of sleepiness: A new approach. Psychophysiology 10:431-436, 1973.
30. McNair DM, Lorr M, and Dropleman LF: Profile of Mood States Manual. San Diego, California: Educational and Industrial Testing Service, 1971.
31. Monk TH, Weitzman ED, Fookson JE, and Moline ML: Circadian rhythms in human performance efficiency under free-running conditions. Chronobiologia 11:343-354, 1984.
32. Wilkinson RT and Houghton D: Field test of arousal: a portable reaction timer with data storage. Human Factors 24:487-493, 1982.
33. Canalis E, Reardon G, and Caldarella A: A more specific, liquid chromatography for free cortisol in urine. Clin Chem 28:2418-2420, 1982.
34. Kennaway DJ and Royles P: Circadian rhythms of 6-sulphatoxy melatonin, cortisol, and electrolyte excretion at the summer and winter solstices in normal men and women. Acta Endocrinologica 113:450-456, 1986.
35. Fellenberg AJ, Phillipou G, and Seamark RF: Specific quantitation of urinary 6-hydroxymelatonin sulphate by gas chromatography mass spectrometry. Biomed Mass Spectrometry 7:84-87, 1980.
36. Batchelet E: Statistical rhythm evaluation. In Biorhythms and Human Reproduction. Ferin M, Halberg F, Richart RM, and Vande Wiele RL (eds). New York: John Wiley & Sons, 1974, pp 25-35.
37. Vokac M: A comprehensive system of cosinor treatment programs written for the Apple II microcomputer. Chronobiology Int 1:87-92, 1984.
38. Dixon WJ (ed): BMDP Statistical Software. Berkeley: University of California Press, 1983.

39. Wilkinson RT, El-Beheri S, and Ceiseking CC: Performance and arousal as a function of incentive, information load, and task novelty. Psychophysiology 9:580-599, 1972.
40. Carskadon MA and Dement WC: Effects of total sleep loss on sleep tendency. Percept Mot Skills 48:495-506, 1979.
41. Akerstedt T and Gillberg M: Displacement of the sleep period and sleep deprivation. Human Neurobiol 1:163-171., 1982.
42. Dement WC and Mitler MM: Sleep deprivation and the organization of the behavioral states. In Sleep and the Maturing Nervous System. Clemente CD, Purperts DP, and Mayer RE (eds). New York: Academic press, 1974.
43. Kollar EJ, Slater GR, Palmer JO, et al: Stress in subjects undergoing sleep deprivation. Psychosomatic Med 28:101-113, 1966.
44. Akerstedt T and Froberg JE: Sleep and stressor exposure in relation to circadian rhythms in catecholamine excretion. Biol Psych 8-69-80, 1979.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1. AGENCY ACCESSION	2. DATE	3. SUMMARY	REPORT CONTROL SYMBOL
4. DATE PREPARED	5. DATE OF SUMMARY	6. SUMMARY	7. WORK SECURITY	8. DISSEMINATION	DD-DR-6 (Rev. 83) 636		
				9. LEVEL OF SUMMARY WORK UNIT			
10. NO. OF PAGES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
11. PRIMARY	12. DATE	13. PROJECT NUMBER	14. AD	156			
16. CONTRACTING AGENCY							
17. TITLE (Precede with Security Classification Code)							
18. SUBJECT AREAS							
19. START DATE							
20. ESTIMATED COMPLETION DATE							
21. FUNDING ORGANIZATION							
22. PERFORMANCE METHOD							
23. CONTRACT GRANT							
24. DATE EFFECTIVE							
25. EXPIRATION DATE							
26. CONTRACT GRANT NUMBER							
27. AMOUNT							
28. KIND OF AWARD							
29. RESPONSIBLE ORGANIZATION							
30. NAME							
31. ADDRESS (include zip code)							
32. NAME OF RESPONSIBLE INDIVIDUAL							
33. TELEPHONE NUMBER (include area code)							
34. NAME OF ASSOCIATE INVESTIGATOR (if available)							
35. NAME OF ASSOCIATE INVESTIGATOR (if available)							
36. KEYWORDS (Precede with Security Classification Code)							
37. High Frequency Ventilation; (M) Inhalation Injury; (T) Thermal Injury; (P) Pneumonia; (U) Mortality;							
38. Technical Subject (39) Approach; 40. Progress (Precede text of each with Security Classification Code)							
41. Volunteers; (U) PAII							
42. To evaluate the effect of high frequency ventilation in the treatment of respiratory failure in patients with inhalation injury with respect to incidence of pneumonia, time of initial onset and duration of pneumonia, total duration of ventilatory support, and the age and burn associated mortality. A literature search was conducted.							
43. Initial high frequency ventilation support will be established by adjustment of the driving pressure, rate, and inspiratory-expiratory ratio. A chest x-ray will be obtained and sputum or endotracheal secretions will be examined by culture and Gram stain. It will then be determined how high frequency ventilation affects outcome after inhalation injury with respect to several well defined factors as compared to the historical report using conventional ventilation. The incidence of pneumonia will be related to burn size by appropriate burn-size stratification within the study group.							
44. 8701 - 8709. This project was approved by The Surgeon General's Human Subjects Research Review Board on 26 February 1987. One patient has been entered into the study. After the entry of 50 patients, the effects of high frequency ventilation on the outcome after inhalation injury with respect to several well-defined factors will be compared to a historical report on which conventional ventilation was used.							

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL DD-DR&RIAR 436	
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCS	6 WORK SECURITY	7 RE GRADING	8 DISSEMINATION	9 LEVEL OF SUMMARY WORK UNIT	
10 NO CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a PRIMARY	62787A	3814787A874	AD	147			
b CONTRIBUTING							
c CONTRIBUTING	CATEREDAP FY68-71						
11 TITLE (Precede with Security Classification Code) (U) Quantification of Dynamic Splint Forces on Metacarpophalangeal Function Recovery							
12 SUBJECT AREAS							
13.17 Medicine and Medical Research							
13 START DATE	14 ESTIMATED COMPLETION DATE	15 FUNDING ORGANIZATION	16 PERFORMANCE METHOD				
17 CONTRACT GRANT	18.18 EVANCY CERTIFIED	18. RESOURCES ESTIMATE					
a DATE EFFECTIVE	EXPIRATION	FISCAL YEARS	a PROFESSIONAL WORK YEARS	b FUNDS in thousands			
b CONTRACT GRANT NUMBER							
c TYPE	d AMOUNT	87	0.0	0			
e KIND OF AWARD	f CUM TOTAL	88	1.0	45			
19 RESPONSIBLE DOD ORGANIZATION				20 PERFORMING ORGANIZATION			
a NAME				b NAME			
US Army Institute of Surgical Research				US Army Institute of Surgical Research			
c ADDRESS (include zip code)				d ADDRESS			
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012			
e NAME OF RESPONSIBLE INDIVIDUAL				f NAME OF PRINCIPAL INVESTIGATOR			
LUSTE, S H				LUSTER, S H			
g TELEPHONE NUMBER (include area code)				h TELEPHONE NUMBER (include area code)			
512-221-2721				512-221-5957			
21 GENERAL USE				i NAME OF ASSOCIATE INVESTIGATOR (if available)			
CINA				PATERSON, P E			
j NAME OF ASSOCIATE INVESTIGATOR (if available)				CIOFFI, W S			
22 KEYWORDS (Precede EACH with Security Classification Code) (U) Metacarpophalangeal Joint Stiffness; (U) Dynamic Flexion Splint; (U) Force Quantification; (U) Volunteers;							
23 TECHNICAL OBJECTIVE 24 APPROACH 25 PROGRESS (Precede text of each with Security Classification Code)							
22. (Continued) (U) RAIL.							
23. (U) The objectives of this study are to design and construct a dynamic splint device to monitor selected characteristics of the hand during therapy and to quantify initial stiffness, laxity of joints, and changes in joint characteristics as a response to changes in treatment regimens and to develop guidelines for the appropriate use of dynamic splints. Data from this study will enhance the knowledge and therefore the quality of hand rehabilitation of injured soldiers as well as others. A literature search provided only anecdotal information regarding the forces applied to joints during splinting procedures.							
24. (U) A dynamic splint force/angle monitoring device will be designed and developed. Patients will be entered into the study after meeting the patient entry criteria and giving their signed consent. A classification of the burned hand will be made by the attending physician and an occupational therapist based upon the depth and location of the burn. Baseline data will be collected for each patient, to include burn location, joint range-of-motion at the target joints, digit circumference measurements, two-point discrimination sensation at the digit tips, electromyographic activity of the extensor digitorum communis muscle group, and the patient's perception of pain using a visual analog scale. The patient will then be placed in the splint device. Within each group, subjects will be randomly assigned to treatment groups in which force being							

DD FORM 1498  
13 MAR

EDITION OF MAR 68 IS OBSOLETE

GPO: 1968-491-003 50329

CONTINUATION OF DD FORM 1498 FOR "QUANTIFICATION OF DYNAMIC  
SPLINT FORCES ON METACARPOPHALANGEAL FUNCTION RECOVERY"

exerted by the splint is 5, 25, or 50 g greater than the measured stiffness of the metacarpophalangeal joint. The time required to cause observed changes, electromyograph readings associated with the change, and force history leading to the changes will be measured. A 4 (qualitative hand classification) X 3 (levels of force) analysis of variance will be used in analyzing the effects of the splint treatments. A stepwise multiple regression analysis will be performed on the data.

25. (U) 8610 - 8709. This project was approved as a minimal risk protocol by the US Army Institute of Surgical Research Human Use Committee on 11 September 1987.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL	
				DAOG6972	87 10 01	DD-DRAB (AR) 036	
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCTY	6 WORK SECURITY	7 REGRADING	8 DISB'N INSTR'N	9. LEVEL OF SUM A. WORK UNIT	
86 10 01	D	U	U		CX		
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a. PRIMARY	61102A	3MI61102BS14	BD	301			
b. CONTRIBUTING							
c. CONTRIBUTING	DA LRRDAP, FY88-01						
11. TITLE (Precede with Security Classification Code) (U) Studies of Infection and Microbiologic Surveillance of Troops with Thermal Injury							
12. SUBJECT AREAS							
06 05 Medicine and Medical Research 06 13 Microbiology 06 15 Pharmacology							
13. START DATE	14. ESTIMATED COMPLETION DATE		15. FUNDING ORGANIZATION		16. PERFORMANCE METHOD		
76 10	99 09		DA		C		
17. CONTRACT GRANT NUMBER RELEVANCY CERTIFIED							
a. DATE EFFECTIVE	b. FISCAL YEARS		c. PROFESSIONAL WORK YEARS		d. FUNDS (in thousands)		
APR 1987	87 88		0.5 0.5		256 269		
18. CONTRACT GRANT NUMBER							
19. RESPONSIBLE DOD ORGANIZATION							
a. NAME				a. NAME			
US Army Institute of Surgical Research				US Army Institute of Surgical Research			
b. ADDRESS (include zip code)				b. ADDRESS			
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL				c. NAME OF PRINCIPAL INVESTIGATOR			
PRUITT, B A				MC MANUS, A T			
d. TELEPHONE NUMBER (include area code)				d. TELEPHONE NUMBER (include area code)			
512-221-2720				512-221-3411			
21. GENERAL USE				f. NAME OF ASSOCIATE INVESTIGATOR (if available)			
FINA							
MILITARY CIVILIAN APPLICATION M				g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Pseudomonas; (U) Klebsiella; (U) Staphylococcus; (U) Wound Infection; (U) Antibiotic Resistance;							
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)							
22. (Continued) (U) Sepsis; (U) Topical Chemotherapy; (U) Volunteers: (U) Adults; (U) Children; (U) Lab Animals: (U) Rats; (U) Guinea Pigs; (U) Mice; (U) RAI							
23. (U) Burns constitute a large component of military injuries sustained in combat. Military relevance of this research lies in the fact that infection and ensuing sepsis are major problems among burned soldiers. Control of surface infection is a major objective and species of organisms causing sepsis, epidemiology, response of significant species to topical chemotherapy modalities, and relationship of antibiotics to sepsis control are major study areas. A literature search is conducted for each protocol initiated.							
24. (U) Cultures of human wounds, tissues, and body fluids are carried out with precise strain speciation and differentiation being employed. Virulence is assessed in burn wound models which are also used to assess effectiveness of experimental drugs, both topical and systemic.							
25. (U) 8601 - 3612. Microbiologic surveillance was carried out on 200 of the 206 admitted and discharged burn patients. More than 8,307 isolates were recovered. As has been the experience in recent years, relative isolation of Gram-negative organisms continued to be low. The most common Gram-negative isolate was <u>Pseudomonas aeruginosa</u> , but was recovered in <3%							

CONTINUATION OF DD FORM 1498 FOR "STUDIES OF INFECTION AND MICROBIOLOGIC SURVEILLANCE OF TROOPS WITH THERMAL INJURY"

of the patients and 8% of the total flora. Positive blood cultures were recovered from 20 patients, with Staphylococcus aureus being the most common offender.

ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: STUDIES OF INFECTION AND MICROBIOLOGIC SURVEIL-  
LANCE OF TROOPS WITH THERMAL INJURY

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 January 1986 - 31 December 1986

INVESTIGATORS

Albert T. McManus, PhD  
Jack R. Henderson, PhD  
Timothy E. Lawson, Staff Sergeant  
Charles H. Guymon, Sergeant  
Aldo H. Reyes, Staff Sergeant  
Kenneth Hawthorne, Staff Sergeant  
Anne Lasko, Sergeant  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC



## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: STUDIES OF INFECTION AND MICROBIOLOGIC SURVEILLANCE OF TROOPS WITH THERMAL INJURY

INSTITUTION: US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Jan 86 through 31 Dec 86

INVESTIGATORS: Albert T. McManus, PhD  
Jack R. Henderson, PhD  
Timothy E. Lawson, Staff Sergeant  
Charles H. Guymon, Sergeant  
Aldo H. Reyes, Staff Sergeant  
Kenneth Hawthorne, Staff Sergeant  
Anne Lasko, Sergeant  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

During calendar year 1986, 200 burned patients were cultured and 8,223 isolates were identified. A relatively low colonization frequency (<25%) with Gram-negative organisms has continued for the fifth reporting period. This was also reflected in an increase in Gram-positive organisms in blood cultures. Staphylococcus aureus and Staphylococcus epidermidis represented 39.7% of the bacteremia cases. The computerized microbial culture surveillance system has been extended to include infection control and antibiotic usage data bases. This system is being evaluated for its use in predicting infecting organisms from previous sites of colonization and antibiotic usage.

BURN MICROBIOLOGY  
PSEUDOMONAS  
KLEBSIELLA  
STAPHYLOCOCCUS  
ANTIBIOTIC RESISTANCE  
BLOOD CULTURE  
BIOPSY  
HUMANS

## STUDIES OF INFECTION AND MICROBIOLOGIC SURVEILLANCE OF TROOPS WITH THERMAL INJURY

### INTRODUCTION

This report is produced from microbiology data collected for patients admitted during calendar year 1986. Data were collected from admission through disposition. This is the second report that is based on calendar year rather than fiscal year. This change more nearly aligns culture results with the annual research progress report produced by the Clinical Division for the same patient population.

### AUTOMATED MICROBIOLOGY DATA BASE

The microbiology data base now contains complete surveillance data for >1,000 burn patient admissions. Epidemiologic use of these data has resulted in several publications. The microbiology data base has been aligned with antibiotic use and infection control data bases. This has improved the utility of the system for prospective use in identifying outbreaks and aiding empiric therapy by predicting on a statistical basis the probable antibiotic sensitivity patterns of infecting organisms.

### ANTIBIOTIC SENSITIVITY DETERMINATION

The 1986 antibiotic testing panels are presented in Table 1. Bacterial organisms were tested by agar overlay disc diffusion. Broth dilution minimal inhibitory concentrations and minimal bactericidal concentrations were available upon specific request. The protocol for selecting organisms for in vitro sensitivities was isolation from blood cultures, predominant organisms in biopsy cultures, predominant organisms in sputum and in urine cultures with >10<sup>5</sup> cfu/ml, Staphylococcus aureus isolates, Pseudomonas aeruginosa isolates, and other organisms as requested.

### MICROBIAL SURVEILLANCE

The microbial surveillance protocol established in fiscal year 1983 was continued in calendar year 1986 (1). Patients were cultured from wound, sputum, urine, and rectum on admission. Thereafter, sputum and urine were cultured three times per week and stools and wound surfaces twice per week. Patients transferred to the convalescent ward and hospitalized >30 days were cultured once per week. Gentamicin-resistant Gram-negative organisms from sputum or stool specimens were screened by plating on MacConkey agar containing gentamicin sulfate (25 µg/ml).

TABLE 1. In vitro Sensitivity Panels (1986)

Enteric Organisms	Nonenteric Gram-Negative Organisms	Gram-Positive Organisms
1. Amikacin <sup>a,b</sup>	1. Amikacin <sup>a,b</sup>	1. Amikacin <sup>a,b</sup>
2. Gentamicin <sup>a,b</sup>	2. Gentamicin <sup>a,b</sup>	2. Gentamicin <sup>a,b</sup>
3. Tobramycin <sup>a</sup>	3. Tobramycin <sup>a,b</sup>	3. Tobramycin <sup>a,b</sup>
4. Ticarcillin <sup>a</sup>	4. Ticarcillin <sup>a</sup>	4. Ticarcillin
5. Mezlocillin <sup>a,b</sup>	5. Mezlocillin <sup>a,b</sup>	5. Mezlocillin <sup>a,b</sup>
6. Piperacillin <sup>a,b</sup>	6. Piperacillin <sup>a,b</sup>	6. Piperacillin <sup>a,b</sup>
7. Moxalactam <sup>a,b</sup>	7. Moxalactam <sup>a,b</sup>	7. Moxalactam <sup>b</sup>
8. Cefotaxime <sup>a</sup>	8. Cefotaxime <sup>a</sup>	8. Cefotaxime
9. Cefoperazone	9. Cefoperazone <sup>a</sup>	9. Cefoperazone
10. Sulfadiazine	10. Cefsulodin <sup>a</sup>	10. Cefsulodin
11. Netilmicin <sup>a</sup>	11. Colistin	11. Sulfadiazine
12. Kanamycin	12. Sulfadizine <sup>a</sup>	12. Oxacillin <sup>a</sup>
13. Chloramphenicol	13. Netilmicin	13. Cephalothin <sup>a</sup>
14. Tetracycline	14. Kanamycin	14. Vancomycin <sup>a,b</sup>
15. Cefoxitin <sup>a</sup>	15. Chloramphenicol	15. Kanamycin
16. Cefamandole <sup>a</sup>	16. Tetracycline	16. Chloramphenicol <sup>a</sup>
17. Ampicillin <sup>a</sup>	17. Imipenem-Cilastatin <sup>b</sup>	17. Tetracycline
18. Trimethoprim	18. Azlocillin <sup>a</sup>	18. Ampicillin
19. Trimeth and Sulfa	19. Norfloxacin	19. Imipenem-Cilastatin <sup>b</sup>
20. Nalidixic Acid	20. Aztreonam	20. Clindamycin <sup>a</sup>
21. Imipenem-Cilastatin <sup>b</sup>	21. Ticarcillin	21. Penicillin <sup>a</sup>
22. Streptomycin		22. Erythromycin <sup>a</sup>
23. Aztreonam		23. Streptomycin
24. Norfloxacin		

<sup>a</sup>Reported daily on daily clinical microbiology report (hard copy).<sup>b</sup>Reported on computer screen from patient data base.

## MICROBIOLOGIC FINDINGS IN BURN PATIENTS

A total of 200 patients admitted in 1986 were cultured. Species isolated and number of patients yielding each species are presented in Table 2. Because of the decreased host resistance of the patient population, no organism is considered "normal" flora and all isolated organisms are reported to the physician. A summary of the 10 most common isolates is presented in Table 3. The table contains 81% of the species identified. The relative frequencies of sites of isolation are presented in Figure 1. The relative frequencies of sites of isolation of Gram-negative organisms, Gram-positive organisms, and yeast are shown in Figure 2.

### FLORA RECOVERED FROM RESPIRATORY SYSTEM SPECIMENS

A total of 6,211 organisms were recovered from respiratory system specimens. The majority of these were sputum cultures collected in the surveillance program. The 10 most frequent species are presented in Table 4, which represents 81.61% of the respiratory isolates. Of particular note is the continued decline of Gram-negative isolates. *Pseudomonas aeruginosa* was not in the top 10 organisms, with only 28 of the 184 patients colonized. This frequency was not significantly different from calendar years 1984 and 1985.

### FLORA RECOVERED FROM WOUND SURFACE SPECIMENS

A total of 1,138 contact plate surface cultures were taken and 452 isolates were made. Relative frequencies of isolated species are presented in Figure 3. Subsurface flora, as measured by biopsy specimens, was measured in 162 biopsies taken from 35 patients. Organisms were recovered from 20 of the biopsied patients. The 10 most common organisms are presented in Table 5. Filamentous fungi remained the principal isolate with *Aspergillus* being the most common fungal genus. *Pseudomonas aeruginosa* was recovered from 9 biopsies taken from 4 patients. The continued decrease in recovery of wound bacteria is best correlated with the decrease in resistance to topical and parenteral antimicrobial agents. The loss of competitive bacterial flora is a reasonable basis for the increased frequency of fungal isolates.

### FLORA RECOVERED FROM URINARY TRACT SPECIMENS

Urine specimens from 191 patients yielded 836 isolates. The 10 most common species are presented in Table 6.5 The top 10 organisms isolated from urine specimens with  $>10^5$  xfu/ml are presented in Table 7.

### FLORA RECOVERED FROM BLOOD CULTURES

Blood cultures were obtained from 110 patients for a total of 890 cultures. The principal organisms recovered are listed

TABLE 2. Distribution by Organism (1986)

Organism	Number of Isolates	Number of Patients Colonized	Organism	Number of Isolates	Number of Patients Colonized
Acinetobacter anitratus	137	14	Pseudomonas aeruginosa	567	64
Acinetobacter lwoffii	7	7	Pseudomonas cepacia	8	5
Aspergillus flavus	9	4	Pseudomonas maltophilia	2	2
Aeromonas hydrophila	4	1	Pseudomonas putida	3	2
Bacillus	13	17	Serratia marcescens	37	13
Branhamella catarrhalis	30	10	Staphylococcus aureus	1,455	146
Candida albicans	236	60	Staphylococcus epidermidis	270	105
Candida parapsilosis	4	3	Staphylococcus saprophyticus	70	35
Candida rugosa	87	13	Alpha Streptococcus	14	13
Candida tropicalis	31	13	Beta Streptococcus, Not	153	60
Citrobacter freundii	17	9	Group A, B, or D		
Citrobacter diversus	40	14	Group A Nonhemolytic Beta	1	1
Enterobacter aerogenes	91	31	Streptococcus		
Enterobacter agglomerans	25	14	Group D Streptococcus, Not	82	51
Enterobacter cloacae	42	24	Enterococcus		
Escherichia coli	330	79	Group D Enterococcus	127	54
Haemophilus influenzae	8	4	Nonhemolytic Streptococcus	12	12
Haemophilus parainfluenzae	2	2	Nonhemolytic Streptococcus,	1,193	201
Klebsiella oxytoca	42	20	Not Group D		
Klebsiella pneumoniae	350	79	Streptococcus pneumoniae	37	25
Morganella morganii	79	15	Streptococcus viridans	1,832	194
Neisseria mucosa	292	99	True Fungi Species (Other)	46	29
Propionibacterium acnes	1	1	Yeast Species (Other)	10	8
Proteus mirabilis	296	53			

Total Number of Isolates = 8,223

Total Number of Patients = 200

TABLE 3. Ten Most Frequent Isolates (1986)

Organism	Number of Patients Colonized	% Patients	Number of Isolates	% Total Isolates
Nonhemolytic Streptococcus, Not Group D	200	94.7	1,198	14.6
Streptococcus viridans	194	92.0	1,832	22.2
Staphylococcus aureus	146	69.0	1,455	17.7
Staphylococcus epidermidis	105	49.8	270	3.2
Neisseria mucosa	99	46.9	292	3.6
Klebsiella pneumoniae	79	37.0	350	4.3
Escherichia coli	79	37.4	330	4.0
Pseudomonas aeruginosa	64	30.3	567	6.7
Candida albicans	60	28.4	236	2.9
Beta Streptococcus, Not Group A, B, or D	60	28.4	<u>153</u>	<u>1.9</u>
			6,692	81.0
Total Number of Patients Cultured = 211				
Total Number of Isolates = 8,223				




FIGURE 1. Display of the relative frequency of specimen sources yielding isolates in 1986.




FIGURE 2A. Display of the relative frequency of specimen sources yielding Gram-negative organisms.






FIGURE 2B. Display of the relative frequency of specimen sources yielding Gram-positive organisms.




FIGURE 2C. Display of the relative frequency of specimen sources yielding yeast-like organisms.

TABLE 4. Ten Most Frequent Isolates from Respiratory Sources (1986)

Organism	Number of Patients Colonized	% Patients	Number of Isolates	% Total Isolates
Streptococcus viridans	190	97.9	1,807	29.1
Nonhemolytic Streptococcus, Not Group D	182	93.8	1,154	18.6
Staphylococcus aureus	128	65.9	1,102	17.7
Neisseria mucosa	99	51.0	291	4.7
Staphylococcus epidermidis	61	31.4	136	2.2
Beta-Hemolytic Streptococcus, Not Group A, B, or D	58	29.9	151	2.4
Group D Streptococcus, Not Enterococcus	52	26.8	82	1.3
Klebsiella pneumoniae	44	22.7	180	2.9
Candida albicans	43	22.2	104	1.7
Enterococcus species	31	15.9	63	1.0
			5,070	81.6
Total Number of Patients Cultured = 194				
Total Number of Isolates = 6,211				




FIGURE 3. Display of the relative frequency of organism types isolated from surface wound cultures.

TABLE 5. Principal Organisms Recovered in Biopsy Specimens (1986)

Organism	Number of Patients Colonized	% Patients	Number of Isolates	% Total Isolates
Filamentous fungi	11	31.4	32	38.5
Staphylococcus aureus	5	14.3	8	9.6
Escherichia coli	4	11.4	6	7.2
Pseudomonas aeruginosa	4	11.4	7	8.4
Candida albicans	2	6.1	3	3.6
Candida rugosa	2	5.7	8	9.6
Group D Enterococcus	2	5.7	4	4.8
Klebsiella pneumoniae	2	5.7	4	4.8
Proteus mirabilis	2	5.7	4	4.8
Aeromonas hydrophila	1	2.8	3	3.6
Citrobacter freundii	1	2.8	2	2.4
			81	97.5
Total Number of Patients Biopsied = 35				
Total Number of Isolates = 83				
Biopsies Taken = 162				

TABLE 6. Ten Most Frequent Organisms from Urinary Specimens (1986)

Organism	Number of Patients Colonized	% Patients	Number of Isolates	% Total Isolates
Klebsiella pneumoniae	53	27.7	106	12.7
Escherichia coli	47	24.6	110	13.2
Proteus mirabilis	39	20.4	142	16.9
Pseudomonas aeruginosa	31	16.2	112	13.4
Candida albicans	24	12.6	95	11.4
Staphylococcus aureus	22	11.5	34	4.1
Group D Enterococcus	19	9.9	32	3.8
Nonhemolytic Streptococcus, Not Group D	17	8.9	19	2.3
Streptococcus epidermis	14	7.3	18	2.2
Morganella morganii	11	5.8	18	2.2
			686	82.1
Total Number of Patients Cultured = 191				
Total Number of Isolates = 836				

TABLE 7. Ten Most Frequent Organisms from Urinary Specimens with  $>10^5$  cfu (1986)

Organism	Number of		% Patients	Number of Isolates	% Total Isolates
	Patients Colonized				
<i>Klebsiella pneumoniae</i>	35		36.0	60	13.5
<i>Escherichia coli</i>	32		32.9	63	14.2
<i>Proteus mirabilis</i>	28		28.9	84	18.9
<i>Pseudomonas aeruginosa</i>	22		22.7	55	12.4
<i>Candida albicans</i>	16		16.5	44	9.9
<i>Morganella morganii</i>	9		9.3	13	2.9
Nonhemolytic <i>Streptococcus</i> , Not Group D	9		9.3	9	2.0
<i>Acinetobacter anitratus</i>	6		6.2	21	4.7
<i>Enterobacter aerogenes</i>	6		6.2	13	2.9
Group D <i>Enterococcus</i>	6		6.2	9	2.0
				272	83.4

Total Number of Patients Cultured = 97  
Total Number of Isolates = 443

in Table 8. Positive cultures were obtained from 39 patients and 85 isolates were made from 82 positive cultures. Fifty-three cases of bacteremia were noted. A case of bacteremia was defined as isolation of an organism once or more than once with a 30-day period.

Intravenous catheter tips were cultured from 95 patients. Isolations were made from 47 patients and 159 isolates were made. Data are presented in Table 9. These data show an unexpectedly high incidence of contamination.

#### SUMMARY OF ANTIBIOTIC TESTING

A total of 3,003 bacterial isolates were tested for in vitro sensitivity to antibiotics. A comparison of sources of tested strains is presented in Figure 4. The relative frequency of tested organisms is presented in Figure 5.

Gentamicin resistance was again used as a plasmid surveillance marker. Testing was done on 2,997 isolates. Figure 6 displays the relative frequency of tested organisms. Figure 7 displays the frequency of resistant species. Only 100 Gram-negative isolates of 1,548 strains tested were resistant to gentamicin (6.5%). This is the lowest percentage ever reported from the Institute and is a direct marker of the success of infection control isolation techniques to prevent the accumulation of a resistant Gram-negative flora.

Staphylococcus aureus. The sources of Staphylococcus aureus strains tested for in vitro activity are presented in Figure 8. The incidence of multiply resistant Staphylococcus aureus was 46% of isolates and these strains were isolated from 83 patients. The resistant strains are multiply resistant with expression of gentamicin, erythromycin, oxacillin, and streptomycin resistance. Multiply resistant Staphylococcus aureus and gentamicin-sensitive strains are displayed separately in Table 10 and histograms are shown in Figure 9.

Pseudomonas aeruginosa. The frequency of sources of Pseudomonas aeruginosa strains tested in vitro is presented in Figure 10. The results of testing are presented in Table 11. Sensitivity to aminoglycoside antibiotics has remained high. The relative frequency of gentamicin resistance for recent reporting periods is presented in Figure 11. The relative frequency of sulfonamide resistance for recent reporting periods is presented in Figure 12. Histogram displays of the distributions of zone sizes for selected antibiotics are presented in Figure 13.

Klebsiella pneumoniae. A total of 215 isolates were tested for in vitro sensitivities to antibiotics. The sources of isolation for tested strains are presented in Figure 14. The results of in vitro antibiotic testing are presented in



TABLE 8. Principal Organisms Found in Blood Cultures (1986)

Organism	Number of Patients	% Patients Cultured	Number of Cases	% Cases	Number of Isolates	% Total Isolates
<i>Staphylococcus aureus</i>	11	10.0	11	20.3	18	21.2
<i>Staphylococcus epidermidis</i>	10	9.1	10	18.9	16	18.8
<i>Escherichia coli</i>	4	3.6	4	7.5	7	4.7
<i>Klebsiella pneumoniae</i>	4	3.6	4	7.5	7	4.7
<i>Candida rugosa</i>	3	2.7	3	5.7	13	15.3
<i>Proteus mirabilis</i>	3	2.7	3	5.7	5	3.6
<i>Acinetobacter anitratus</i>	2	1.8	2	3.8	2	2.4
<i>Micrococcus lutea</i>	2	1.8	2	3.8	2	2.4
<i>Pseudomonas aeruginosa</i>	2	1.8	2	1.9	2	2.4
<i>Candida albicans</i>	1	0.9	1	1.9	1	1.2
<i>Serratia marcescens</i>	1	0.9	1	5.7	1	1.2
			41	80.2	74	77.9

Total Number of Patients Cultured = 110  
 Total Number of Isolates = 85  
 Total Number of Cultures = 890

Total Number of Patient Positives = 41  
 Total Cases (Patients/Species) = 53

TABLE 9. Ten Most Frequent Organisms from Intravenous Catheters (1986)

Organism	Number of Patients Colonized	% Patients	Number of Isolates	% Total Isolates
Staphylococcus aureus	24	25.3	40	25.2
Staphylococcus epidermidis	18	18.9	22	13.8
Klebsiella pneumoniae	9	9.4	12	7.5
Group D Enterococcus	7	7.4	8	5.0
Proteus mirabilis	7	7.4	10	6.3
Pseudomonas aeruginosa	7	7.4	11	6.9
Candida rugosa	6	6.3	15	9.4
Acinetobacter anitratus	4	4.2	8	5.0
Enterobacter aerogenes	4	4.2	6	3.8
Candida albicans	5	5.2	<u>6</u>	<u>3.8</u>
			138	86.8

Total Number of Patients Cultured = 95

Total Number of Isolates = 159




FIGURE 4. Display of the relative frequency of sources yielding organisms tested for in vitro sensitivity to antibiotics in 1986.




FIGURE 5. Display of the relative frequency of organisms tested for in vitro sensitivity to antibiotics in 1986.




FIGURE 6. Display of the relative frequency of organisms tested for in vitro sensitivity to gentamicin in 1986.




FIGURE 7. Display of the relative frequency of gentamicin-resistant organisms isolated in 1986.




FIGURE 8. Display of the relative frequency of sources yielding Staphylococcus aureus tested for in vitro sensitivity to antibiotics in 1986.

TABLE 10A. Antibiotic Sensitivity Data for Staphylococcus aureus Sensitive to Oxacillin (1986)

Antibiotic	Resistant (%)	Intermediate (%)	Sensitive (%)
Amikacin	2	2	96
Cephalothin	-	1	99
Chloramphenicol	1	-	99
Erythromycin	7	4	89
Gentamicin	10	-	90
Oxacillin	-	-	100
Penicillin	90	2	8
Streptomycin	9	1	90
Sulfadiazine	11	14	75
Tetracycline	7	-	93
Vancomycin	-	-	100

119

TABLE 10B. Antibiotic Sensitivity Data for Staphylococcus aureus Resistant to Oxacillin (1986)

Antibiotic	Resistant (%)	Intermediate (%)	Sensitive (%)
Amikacin	1	32	67
Chloramphenicol	1	1	98
Clindamycin	4	-	96
Erythromycin	38	26	37
Gentamicin	92	1	7
Oxacillin	83	17	-
Penicillin	100	-	-
Streptomycin	93	-	7
Sulfadiazine	42	39	18
Tetracycline	1	-	99
Vancomycin	-	-	100








FIGURE 9A. Multiple resistant Staphylococcus aureus.






FIGURE 9A. Multiple resistant Staphylococcus aureus (continued).






FIGURE 9A. Multiple resistant Staphylococcus aureus (continued).






FIGURE 9A. Multiple resistant Staphylococcus aureus (continued).






FIGURE 9B. Histogram display of the distribution of zones of inhibition of growth of Staphylococcus aureus.









FIGURE 9B. Histogram display of the distribution of zones of inhibition of growth of Staphylococcus aureus (continued).



**FIGURE 9B.** Histogram display of the distribution of zones of inhibition of growth of Staphylococcus aureus (continued).






FIGURE 9B. Histogram display of the distribution of zones of inhibition of growth of Staphylococcus aureus (continued).






FIGURE 10. Display of the relative frequency of sources yielding Pseudomonas aeruginosa tested for in vitro sensitivity to antibiotics in 1986.

TABLE 11. Antibiotic Sensitivity Data for *Pseudomonas aeruginosa* (1986)

Antibiotic	RESISTANT		INTERMEDIATE		SENSITIVE		Total Number
	%	Number	%	Number	%	Number	
Amikacin	1.60	7	9.61	42	88.79	388	437
Azlocillin	13.50	71	2.85	15	83.65	440	526
Aztreonam	10.08	53	10.84	57	79.09	416	526
Cefoperazone	12.59	55	6.86	30	80.55	352	437
Cefotaxime	21.48	113	66.92	352	11.60	61	526
Cefsulodin	12.02	50	0.24	1	87.74	365	416
Chloramphenicol	76.43	402	22.62	119	0.95	5	526
Colistin	0.00	0	0.46	2	99.54	435	437
Gentamicin	6.27	33	20.72	109	73.00	384	526
Imipenem-Cilastatin	14.65	64	2.06	9	83.30	364	437
Sodium							
Kanamycin	95.82	504	3.04	16	1.14	6	526
Mezlocillin	21.67	114	24.71	130	53.61	282	526
Moxalactam	18.48	97	52.57	276	28.95	152	525
Netilmicin	25.10	132	0.76	4	74.14	390	526
Norfloxacin	0.00	0	1.14	6	98.86	520	526
Piperacillin	9.70	51	4.37	23	85.93	452	526
Sulfadiazine	41.14	216	7.43	39	51.43	270	525
Tetracycline	80.42	423	18.44	17	1.14	6	526
Tobramycin	14.07	74	9.89	52	76.05	400	526
Ticarcillin	9.89	52	4.18	22	85.93	452	526
TIM-85	10.77	56	4.04	21	85.19	443	520




FIGURE 11. Relative frequency of *Pseudomonas aeruginosa* resistant to gentamicin (%) for fiscal years 1981-1984 and calendar years 1985-1986.




FIGURE 12. Relative frequency of Pseudomonas aeruginosa resistance to sulfonamides (%) for fiscal years 1981-1984 and calendar years 1985-1986.






FIGURE 13. Histogram display of the distribution of zones of inhibition of growth of Pseudomonas aeruginosa.






FIGURE 13. Histogram display of the distribution of zones of inhibition of growth of Pseudomonas aeruginosa (continued).






FIGURE 13. Histogram display of the distribution of zones of inhibition of growth of Pseudomonas aeruginosa (continued).





FIGURE 13. Histogram display of the distribution of zones of inhibition of growth of Pseudomonas aeruginosa (continued).






FIGURE 14. Display of the relative frequency of sources yielding *Klebsiella pneumoniae* tested for in vitro sensitivity to antibiotics in 1986.

Table 12. Histogram displays of the distributions of zone sizes for selected antibiotics are presented in Figure 15.

TABLE 12. Antibiotic Sensitivity Data for *Klebsiella pneumoniae* (1986)

Antibiotic	RESISTANT		INTERMEDIATE		SENSITIVE		Total Number
	%	Number	%	Number	%	Number	
Amikacin	1.14	2	2.27	4	96.59	170	176
Ampicillin	69.77	150	13.49	29	16.74	36	215
Aztreonam	0.00	0	0.49	1	99.51	203	203
Cefamandole	4.2	9	2.34	5	93.46	200	214
Cefoperazone	2.27	4	3.41	6	94.32	166	176
Cefotaxime	0.00	9	0.00	0	100.00	215	215
Cefoxitin	0.47	1	0.93	2	98.60	212	215
Chloramphenicol	7.04	15	0.47	1	92.49	197	213
Gentamicin	4.19	9	0.47	1	95.35	205	215
Imipenem-Cilastatin Sodium	0.00	0	0.00	0	100.00	164	164
Kanamycin	4.19	9	1.86	4	93.95	202	215
Mezlocillin	5.58	12	27.91	60	66.51	143	215
Moxalactam	0.00	0	0.00	0	100.00	60	60
Nalidixic Acid	0.47	1	1.86	4	97.67	210	215
Netilmicin	3.26	7	0.47	1	96.28	207	215
Norfloxacin	0.00	0	0.00	0	100.00	214	214
Piperacillin	5.58	12	3.72	8	90.70	195	215
Sulfadiazine	59.53	128	3.26	7	37.21	80	215
Streptomycin	6.25	11	19.32	34	74.43	131	176
Tetracycline	13.02	28	5.12	11	81.86	176	215
Tobramycin	8.33	5	0.00	0	91.67	55	60
Ticarcillin	76.74	165	12.09	26	11.16	24	215
Trimethoprim	0.47	1	0.00	0	99.53	214	214
Trimeth & Sulfa	0.47	1	5.58	12	93.95	202	215






FIGURE 15. Histogram display of the distribution of zones of inhibition of growth of Klebsiella pneumoniae.






FIGURE 15. Histogram display of the distribution of zones of inhibition of growth of Klebsiella pneumoniae (continued).






FIGURE 15. Histogram display of the distribution of zones of inhibition of growth of Klebsiella pneumoniae (continued).

#### PRESENTATIONS/PUBLICATIONS

Shirani KZ, McManus AT, Vaughan GM, McManus WF, Pruitt BA Jr, and Mason AD Jr: Effects of environment on infection in burn patients. Arch Surg 121(1):31-36, January 1986.

Mason AD Jr, McManus AT, and Pruitt BA Jr: Association of burn mortality and bacteremia. A 25-year review. Arch Surg 121(9):1027-1031, September 1986.

#### REFERENCES

1. McManus AT, Henderson JR, Lawson TJ, et al: Studies of Infection and Microbiologic Surveillance of Infection in Troops with Thermal Injury. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1985, pp 146-194, c1987.

**ANNUAL RESEARCH PROGRESS REPORT**

**PROJECT NUMBER:** 3M161102BS14-00, BASIC RESEARCH

**PROJECT TITLE:** STUDIES OF INFECTION AND MICROBIOLOGIC SURVEILLANCE OF TROOPS WITH THERMAL INJURY: A Clinical Study of the Efficacy of Ceftazidime in the Parenteral Therapy of Infections in Hospitalized Burn Patients

**US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012**

**1 October 1986 - 30 September 1987**

**INVESTIGATORS**

Leslie B. Scorza, MD, Captain, MC  
Albert T. McManus, PhD  
William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC



## ABSTRACT

**PROJECT NUMBER:** 3M161102BS14-00, BASIC RESEARCH

**PROJECT TITLE:** STUDIES OF INFECTION AND MICROBIOLOGIC SURVEILLANCE OF TROOPS WITH THERMAL INJURY: A Clinical Study of the Efficacy of Ceftazidime in the Parenteral Therapy of Infections in Hospitalized Burn Patients

**INSTITUTION:** US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas 78234-5012

**PERIOD COVERED IN THIS REPORT:** 1 Oct 86 through 30 Sep 87

**INVESTIGATORS:** Leslie B. Scorza, MD, Captain, MC  
Albert T. McManus, PhD  
William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC

This study is designed to evaluate the efficacy of ceftazidime in comparison to agents currently used in combination in the treatment of acute bacterial infections in burned patients (piperacillin, amikacin, and/or vancomycin). Patients entered into this study are adult patients with burn injuries and clinical or laboratory indications of bacterial infection that require the use of intravenous antibiotics. The organism(s) causing the infection are proven or presumed susceptible to ceftazidime and a combination treatment prior to initiation of therapy. Patients entering this study are randomly assigned to either ceftazidime (n=25) or a drug combination (n=25). Evaluations will be made concerning the relative bacteriologic and clinical effectiveness as well as relative safety and tolerance of the treatments. The clinical and bacteriologic course of each patient is followed and documented. Laboratory and clinical data to assess safety is obtained before, during, and after treatment. Twelve patients were entered into this study during this reporting period.

# **A CLINICAL STUDY OF THE EFFICACY OF CEFTAZIDIME IN THE PARENTERAL THERAPY OF INFECTIONS IN HOSPITALIZED BURN PATIENTS**

## **INTRODUCTION**

Ceftazidime is an extended spectrum cephalosporin antibiotic for parenteral administration. It offers both Gram-positive activity and activity against a wide range of Gram-negative organisms, including bacteria that are resistant to first and second generation cephalosporins and aminoglycosides. Ceftazidime is distinguished by its anti-Pseudomonal activity. Additionally, it demonstrates excellent stability to beta lactamases produced by many clinically important organisms.

Ceftazidime exhibits an excellent pharmacokinetic profile. The antibiotic is rapidly distributed throughout the body following parenteral administration. Ceftazidime is not metabolized; excretion is via glomerular filtration. Protein binding is low. The compound has a half-life of 1.90 h, making it possible to employ the drug on an every 8-12 h schedule.

Ceftazidime has proven to be efficacious in the treatment of nosocomial and community-acquired infections. The compound has been evaluated in worldwide clinical trials in over 5,000 patients with a variety of infection problems including lower respiratory tract, urinary tract, bone and joint, intra-abdominal, gynecologic, skin, and skin structure infections as well as bacterial septicemia and meningitis. Overall, 93% of patients treated in United States trials were clinically cured or improved (cured = 68%, improved = 25%). A bacterial cure (eradication of the initial pathogen) was achieved in 89% of ceftazidime-susceptible organisms isolated in United States clinical studies.

The objective of this study is to evaluate the efficacy of ceftazidime as monotherapy in the treatment of serious infections in burned patients and to compare the efficacy of ceftazidime to antibacterial agents currently used in combination in the treatment of serious infections in burned patients.

## **MATERIALS AND METHODS**

This study will randomize 50 consecutive burned patients requiring the first use of intravenous therapy for bacterial infection. Twenty-five patients will be assigned ceftazidime and 25 patients will be assigned to a combination therapy. Patients randomized to ceftazidime or to a combination that does not include vancomycin that develop a clinical need for the addition of vancomycin will be considered failures of the initial therapy. The assigned treatment will be maintained (plus vancomycin) for 8-14 days. Patients under study who

require surgery will be maintained on the assigned treatment during the perioperative period.

## **MATERIALS AND METHODS**

**Selection of Patients.** Patients who have clinical and/or laboratory indications of bacterial infection are eligible for entry into the study. Intravenous antibiotic therapy must be indicated. Bacteria isolated from the site of infection must be sensitive or presumed sensitive to ceftazidime and a combination therapy prior to randomization. Patients who have a history of allergy or adverse reaction to penicillins, cephalosporins, aminoglycosides, or vancomycin are excluded. Also, patients who have been treated for bacterial infection with intravenous antibiotics (except penicillin) during the current hospitalization are excluded.

**Procedures Prior to Treatment.** A chest roentgenogram and a medical history are obtained within 72 hours prior to the initiation of treatment and a pertinent physical examination is performed. A laboratory profile, to include hematology, standard chemistries, and urinalysis, is obtained.

**Randomization.** Randomization is by a random number chart maintained in the pharmacy.

**Dosage and Administration.** Ceftazidime is administered in a dose of 250, 500, 750, or 1,000 mg 2-4 times daily, with the usual dose being 1,000 mg every 8-12 h. Standard therapy is administered as is currently practiced. The amikacin dose is based on 1.5 mg/kg/day divided into 2-3 equal doses per day given at equal intervals and adjusted as appropriate for renal function. The total daily dose of amikacin does not exceed 1.5 mg/kg/day. Piperacillin is administered in a dose of 3-4 g every 4-6 h not to exceed 24 g/day. Vancomycin is given as 500 mg every 6 h or 1 g every 12 h.

**Procedures During Treatment.** Clinical signs and symptoms of infection are assessed daily and are used as a measure of the efficacy of the study treatment. Serial chest roentgenograms and other procedures are performed as appropriate to assess clinical status. All adverse effects are recorded. Cultures are taken from the site of infection on a daily basis, with the exception of blood cultures which are taken for clinical indications.

**Procedures After Treatment.** The clinical effectiveness of the assigned treatment is documented upon completion or withdrawal of treatment. This record indicates the clinical result of the original treatment and reasons, if any, for withdrawal. Seven to 10 days after completion of the treatment, a laboratory profile, to include hematology, standard chemistries, and urinalysis, and a pertinent physical examination are performed.

### RESULTS

Six of the 12 patients entered into the study died. However, all of these patients had completed a course of therapy and had clinical and microbiological improvement of the treated infection. One patient of the remaining 6 patients failed on combination therapy and improved on ceftazidime. All other patients also had improvement. Several patients randomized to ceftazidime therapy required the addition of vancomycin and therefore must be deemed failures of ceftazidime therapy. There have been no obvious side effects noted as yet and there have been no withdrawals from the study.

### DISCUSSION

Although it is too early at this point to draw statistically significant conclusions, there have been several patients randomized to the ceftazidime group who required the addition of vancomycin. Vancomycin was added when there was lack of improvement as documented either by microbiological or clinical means. Once vancomycin was added, improvements were noted in each patient.

### PRESENTATIONS/PUBLICATIONS

None.

<b>RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY</b>				1 AGENCY ACCESSION DA066969	2 DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR-6(RAR) 438	
3 DATE PREP NUMBER	4 KIND OF SUMMARY	5 SUMMARY TITLE	6 WORK SECURITY	7 REGRADING	8 DISSEM INSTR	9 LEVEL OF SUM A WORK UNIT	
10 NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a PRIMARY	011 20	0011100014	RD	302			
b CONTRIBUTING							
c INTERESTING							
11 TITLE (Precede with Security Classification Code) (U) The Study of Metabolism and Nutritional							
12 SUBJECT AREAS							
01 Nutrition; 02 Medical Research; 03 Microbiology; 04 Pharmacology							
13 START DATE	14 ESTIMATED COMPLETION DATE	15 FUNDING ORGANIZATION	16 PERFORMANCE METHOD				
		DA					
17 CONTRACT GRANT	18 FUNDING CERTIFIED			18 RESOURCES ESTIMATE			
a DATE RECEIVED	b EXPIRATION DATE			c FISCAL YEARS	d PROFESSIONAL WORK YEARS	e FUNDS (In thousands)	
				87	3.5	245	
c CONTRACT GRANT NUMBER	d AMOUNT			88	0.0	0	
f KIND OF AWARD	g SUM TOTAL						
19 RESPONSIBLE DOD ORGANIZATION				20 PERFORMING ORGANIZATION			
a NAME				a NAME			
b ADDRESS (include zip code)				b ADDRESS			
c NAME OF RESPONSIBLE INDIVIDUAL				c NAME OF PRINCIPAL INVESTIGATOR			
d TELEPHONE NUMBER (include area code)				d TELEPHONE NUMBER (include area code)			
e GENERAL USE				f NAME OF ASSOCIATE INVESTIGATOR (if available)			
military/civilian application				g NAME OF ASSOCIATE INVESTIGATOR (if available)			
22 KEY WORDS (Precede EACH with Security Classification Code) (U) Nitrogen Balance; (U) Burn Injury;							
(U) Intensive Pharmacology; (U) Mitochondria; (U) Volunteers; (U) Lab							
23 SUMMARY (Precede text of each with Security Classification Code)							
24 OBJECTIVES (Precede text of each with Security Classification Code)							
25 PROGRESS (Precede text of each with Security Classification Code)							
<p>1. To identify the cellular mechanisms of postburn hypermetabolism and assess thermoregulation in burned soldiers and establish nutritional requirements following thermal injury. A literature search was conducted and experiments initiated.</p> <p>2. To determine if postburn metabolism and its mechanisms have been explained by several experimental animal models. Of these, the most satisfactory is the rat, in which it is possible to study some of the possible different mechanisms of postburn hypermetabolism discretely. On the basis of findings in this model, we were to explore the contribution of muscle activity to hypermetabolism in patients.</p> <p>3. To plan and execute the renovation and modernization of the controlled environmental metabolic room on Ward 14A. Work on the exploration of the role of muscle activity in postburn hypermetabolism will be reinitiated upon completion of the room.</p>							

RESEARCH COMPLETION REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: THE STUDY OF METABOLISM AND NUTRITIONAL EFFECTS  
OF BURN INJURY IN SOLDIERS: Thiamine Levels in  
the Acutely Burned Patient

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 June 1987

INVESTIGATORS

Debra Ann Reilly, MD  
Ronald L. Shippee, PhD, Captain, MS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

# ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: THE STUDY OF METABOLISM AND NUTRITIONAL EFFECTS  
OF BURN INJURY IN SOLDIERS: Thiamine Levels in  
the Acutely Burned Patient

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Jun 87

INVESTIGATORS: Debra Ann Reilly, MD  
Ronald L. Shippee, PhD, Captain, MS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

Nineteen adult patients admitted to the Institute between February and June 1987 with >20% total body surface area burns were studied to determine their thiamine levels during the first month of their hospital course. Early analysis of the data for 15 of these patients reveals an initial drop in their blood thiamine content below normal followed by a rebound to supranormal levels by the end of the study period. Based on this early analysis, thiamine supplementation for this patient population is recommended during the immediate postburn week.

## THIAMINE LEVELS IN THE ACUTELY BURNED PATIENT

### INTRODUCTION

The objective of this study was to determine thiamine levels in patients sustaining severe thermal injury (1-6). Blood samples were taken during the first 4 wk postburn. The medical application was to recommend a supplemental dose of thiamine for this patient population (7).

### MATERIALS AND METHODS

Nineteen patients and 10 controls were entered into the study during this reporting period. All controls were studied once to determine a baseline level of thiamine in a healthy patient population based upon our assay techniques.

Prior to beginning this study, about 60 units of packed red blood cells, which were randomly transfused in the operating room, were tested for their thiamine content relative to their hemoglobin content, age, and blood type.

All burn patients with total body surface area burns >20% were eligible for admission into the study. Patients entered into the study had 1.5 cc of heparinized blood drawn on admission and weekly thereafter for the first month postburn or until expiration. In addition, all transfused units of packed red blood cells to be received by the patient were tested for thiamine content. Weekly charts were kept to record each patient's nutritional and supplemental thiamine intake, other medical problems, amount of skin grafting done, and subjective and objective mental status changes (8).

Sample preparations were separated by centrifugation and the plasma was aspirated off. The packed cells were then washed, lysed, and frozen at -70°C until assayed. After thawing, the samples were prepared for ion pairing reverse phase liquid chromatography and the thiamine elution peak recorded (9-12).

### RESULTS

The randomly sampled units of packed red blood cells were found to have varying levels of both hemoglobin and thiamine present per unit of blood. Therefore, the amount of thiamine transfused into each of our patients could not be assumed, but was measured for each unit of blood received during the study period.

Control subjects were found to have an average hemoglobin content of 14 (similar to the level at which the study patients were kept) and an average thiamine content of 160.



Fifteen of the 19 patients completed 3-4 wk of the study and were found to have a markedly low thiamine blood content upon admission ( $>2SD$  vs. control). By the third week postburn, they then rebounded to above normal levels ( $>2SD$  vs. control) before returning to normal. Serum hemoglobin levels did not vary much during the study period.

#### DISCUSSION

Total thiamine content in the blood of acutely burned patients appears to be markedly low during the initial phase of burn resuscitation. As the patient's wounds heal and are grafted and nutritional intake improves, the serum thiamine rebounds to above the normal average. Further analysis of the data needs to be performed to determine if the burn size, age, and number of packed red blood cell transfusions or nutritional status have any influence on these values. In addition, the patient's subjective responses and mental status should be examined. It does, however, appear that early thiamine supplementation should be recommended for this patient population.

#### PRESENTATIONS/PUBLICATIONS

None.

#### REFERENCES

1. Levenson SM: Ascorbic acid, riboflavin, thiamine, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human. Ann Surg 121:840-856, 1946.
2. Von Bulow M and Stahlschmidt M: Nonalcoholic encephalopathy as a cause of death in 3 surgical patients. Infusion Ther Klin Ernahr 7:276-278, 1980.
3. Rose RC: Intestinal transport of vitamins. J Inherited Metab Dis (Suppl) 8:13-16, 1975.
4. Blair R and Newsome F: Involvement of water-soluble vitamins in disease of swine. J Anim Sci 60:1508-1517, 1985.
5. Van Der Beek EJ: Vitamines and endurance training. Food for running or faddish claim? Sports Med 2:175-197, 1985.
6. Tinker D and Rucker RB: Role of selected nutrients in synthesis, accumulation and chemical modification of connective tissue proteins. Physiol Rev 65:607-657, 1985.
7. Bell SJ and Waytt J: Nutritional guidelines for burned patients. Perspectives in practice. J Am Dietetic Assoc 86:648-653, 1986.

8. Rosenthal MJ and Goodwin JS: Cognitive effects of nutritional deficiency. Adv Nutr Res 7:71-100, 1985.
9. Brin M: Transketolases. In Methods of Enzymatic Analysis. Bergmeyer HU (ed). New York: Verlag Chemie Weinheim, 1974, pp 703-709.
10. Lehninger AL: Biochemistry. New York: Worth Publishers, Inc., 1975, p 338.
11. Sanemore H, Ueki H, and Kawasaki T: Reversed-phase high performance liquid chromatographic analysis of thiamine phosphate esters at subpicomole levels. Analytical Biochemistry 107:451-455, 1980.
12. Kimura M, Fujita T, and Itokawa Y: Liquid-chromatographic determination of the total thiamine content of blood. Clin Chem 28:29-31, 1982.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1. AGENCY ACCESSION	2. DATE OF SUMMARY	REPORT CONTROL SYMBOL
				DAOG6968	87 10 01	DD-DR&B(AR) 636
3. DATE PREV. SUMMARY	4. KIND OF SUMMARY	5. SUMMARY SCTY	6. WORK SECURITY	7. REGRADING	8. DISB'N INSTR'N	9. LEVEL OF SUM A. WORK UNIT
86 10 01	D	U	U		CX	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY	61102A	3M161102BS14	BD	303		
b. CONTRIBUTING						
c. CONTRIBUTING	DA LRRDAP, FY88-01					
11. TITLE (Precede with Security Classification Code)						
(U) Alteration of Host Resistance in Burned Soldiers						
12. SUBJECT AREAS						
06 05 Medicine and Medical Research 06 13 Microbiology 06 15 Pharmacology						
13. START DATE	14. ESTIMATED COMPLETION DATE		15. FUNDING ORGANIZATION	16. PERFORMANCE METHOD		
76 10	99 09		DA	C		
17. CONTRACT/GRANT NO. (MILITARY RELEVANCY CERTIFIED)						
a. DATE EFFECTIVE				b. FISCAL YEARS	c. PROFESSIONAL WORK YEARS	d. FUNDS (In thousands)
a. CONTRACT/GRANT NUMBER				87	5.0	165
c. TYPE				88	5.0	250
e. KIND OF AWARD				f. CUM. TOTAL		
19. RESPONSIBLE DOD ORGANIZATION				20. PERFORMING ORGANIZATION		
a. NAME				a. NAME		
US Army Institute of Surgical Research				US Army Institute of Surgical Research		
b. ADDRESS (include zip code)				b. ADDRESS		
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012		
c. NAME OF RESPONSIBLE INDIVIDUAL				c. NAME OF PRINCIPAL INVESTIGATOR		
FRUITT, B A				MC MANUS, A T		
d. TELEPHONE NUMBER (include area code)				d. TELEPHONE NUMBER (include area code)		
512-221-2720				512-221-3411		
21. GENERAL USE				f. NAME OF ASSOCIATE INVESTIGATOR (if available)		
FINA				g. NAME OF ASSOCIATE INVESTIGATOR (if available)		
MILITARY/CIVILIAN APPLICATION: M						
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Tissue Spreading Factors; (U) Infection; (U) Immunostimulants; (U) Virulence Factors; (U) Plasmids; (U) Antibiotic						
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)						
22. (Continued) Effects; (U) Volunteers; (U) RAI						
23. (U) To define the microbial basis of opportunistic infection in susceptible burned soldiers, identify specific mechanisms of decreased host resistance that are targeted by opportunistic pathogens, and develop and evaluate countermeasures. A literature search was conducted for each protocol initiated.						
24. (U) The high susceptibility of burned rats to experimental infection with <i>Pseudomonas aeruginosa</i> and <i>Proteus mirabilis</i> will be investigated. The effect of <i>in vitro</i> alterations of specific microbial characteristics on infection will be investigated. Specific antimicrobial and immunostimulatory therapies will be examined.						
25. (U) 8601 - 8612. The clinical trial of the parenteral antibiotic ceftazidime as monotherapy in infected burn patients is in progress. Isoelectric-focusing techniques to identify specific and chromosomal beta-lactamase activities of multiply resistant Gram-negative burn patient isolates have been developed. A standard set of known plasmid-mediated beta-lactamase genes has been established. A probe to detect one of the two common plasmid-mediated sulfonamide resistance genes has been developed. The second probe is expected to be finished in the next reporting period.						

ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED  
SOLDIERS

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

INVESTIGATORS

Albert T. McManus, PhD  
Virginia C. English, MS  
Camille L. Denton, MA  
Charles H. Guymon, MS, SGT  
Aldo H. Reyes, SSG  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED SOLDIERS

INSTITUTION: US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: Albert T. McManus, PhD  
Virginia C. English, MS  
Camille L. Denton, MA  
Charles H. Guymon, MS, SGT  
Aldo H. Reyes, SSG  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

The clinical trial and in vitro evaluation of the parenteral antibiotic ceftazidime as monotherapy in infected burn patients is in progress. Twelve patients were entered into the study during this reporting period. Sensitivity of Gram-negative organisms to ceftazidime has remained high (>93%) during the trial. A beta-lactamase capable of inactivating ceftazidime and all other tested cephalosporins has been recovered from several treated patients. The characteristics and spread of this enzyme are being investigated. A proposed topical antimicrobial agent, Alcider<sup>®</sup>, has been evaluated in the standardized *Pseudomonas*-infected burned rat model. This compound was found to have minimal activity when compared to silver sulfadiazine. Evaluation of agar well diffusion technique with in vitro sensitivity to silver sulfadiazine has shown that the agar well diffusion technique can be easily replaced by standardized and much cheaper sulfonamide disc sensitivity testing.

## ALTERATION OF HOST RESISTANCE IN BURNED SOLDIERS

### EXPERIMENTAL PARENTERAL AGENTS

Measurement of in vitro activity against Pseudomonas aeruginosa of the investigational cephalosporin class antibiotic cefsulodin sodium (Abbott-46811) continued during this reporting period. In 264 tested isolates of Pseudomonas aeruginosa, 33 resistant strains were found. A comparison of these results to previous findings is presented in Table 1. This compound, although available in most other areas of the world, remains unlicensed in the United States. The activity of this drug against Pseudomonas aeruginosa is similar to newer and licensed cephalosporins (see below) and the very limited spectrum and limited need of cefsulodin sodium for specific antipseudomonal activity makes it of questionable future value. Testing of this compound, unless specific need arises, will end with this report.

The in vitro activities of newly approved antibiotics are presented in Table 2. A clinical trial of ceftazidime as monotherapy for infected burn patients is in progress. Cefriaxone and aztreonam have not been clinically used to date.

Cross resistance to all tested cephalosporins has been observed. The mechanism of resistance appears to be a newly described beta-lactamase enzyme (1). Examination of resistant strains by isoelectric-focusing techniques has shown them to contain multiple beta-lactamase activities. One activity at an isoelectric point of 6.3 appears to be common among the strains. Investigations into the location (plasmid and/or chromosomal) of the gene responsible for this enzyme are being conducted. The multiply resistant phenotype has been found in 3 enteric Gram-negative species isolated from 7 burn patients.

### EXPERIMENTAL TOPICAL AGENTS

Alcide<sup>R</sup>, a proposed topical antimicrobial agent, has been tested for antipseudomonal activity in the standard infected, burned rat model. The compound was tested at 4 concentrations and treatment was once per day for 10 days. Initial treatment was started 24 h after burning and inoculation with Pseudomonas aeruginosa (Strain 59-1244). Silver sulfadiazine, an effective burn topical, was used as a reference for positive therapeutic activity. Burned and infected animals without antimicrobial treatment were used as expected mortality controls. The results of this study are presented in Table 3.

Five-percent mafenide acetate was examined for in vitro activity against Pseudomonas aeruginosa isolated from 32 burn patients. Agar dilution minimal inhibitory concentration (MIC) assays were done on 79 strains. The mean MIC was 0.2987 g/100

TABLE 1. Cefsulodin Sodium Activity Against Burn Patient Pseudomonas aeruginosa

	Fiscal Year 1982	Fiscal Year 1983	Fiscal Year 1984	Fiscal Year 1985	Fiscal Year 1986	Fiscal Year 1987
Resistant	143 (17.9)	49 (12.1)	36 (7.8)	59 (10.3)	48 (9.7)	33 (14.3)
Sensitive	655	355	463	571	444	231

( ) = Percent resistant.

TABLE 2. Activity of Experimental Antibiotics for Fiscal Year 1987

	Ceftazidime <sup>a</sup>	Ceftriaxone <sup>a</sup>	Aztreonam <sup>b</sup>
Resistant	80 (6.7%)	167 (14.4%)	81 (7.1%)
Sensitive	1,106	1,163	1,051

<sup>a</sup>Against all flora except oxacillin-resistant Staphylococcus aureus.

<sup>b</sup>Against Gram-negative aerobic flora.

( ) = Percent resistant.

ml. The median MIC was 0.319 g/100 ml. Data comparing fiscal years 1986 and 1987 are presented in Table 4.

#### SEROLOGIC TYPES OF *Pseudomonas aeruginosa* ISOLATED FROM BURN PATIENTS

*Pseudomonas aeruginosa* isolates from 26 patients were serotyped using the Difco International Typing Sera™ set and autoclaved bacterial suspensions. Stains were selected on the basis of having a distinct antibiotic sensitivity pattern for each patient. A total of 147 strains were typed. Data are presented as the total number of patients with each serotype and the total number of isolates per serotype in Figure 1. Serotypes 09 and 11 were the predominant types identified.

#### EFFECT OF SULFONAMIDE ACTIVITY ON AGAR WELL DIFFUSION MEASUREMENTS OF SILVER SULFADIAZINE

The effect of sulfonamide activity on agar well diffusion inhibition zones of silver sulfadiazine was examined by plasmid transfer. Clinical isolates with known transferrable sulfonamide resistance were mated to separate clones of *Escherichia coli* k12 c600. Matings were done on agar and selection was for transfer of sulfonamide resistance to naladixic acid resistance c600 hosts. Plasmid from 33 strains were successfully transferred. Strains of c600 with a transferred plasmid were then tested against the same parent c600 without the plasmid. Strains were examined for zones of inhibition against 1% silver sulfadiazine, the silver salt of the sulfadiazine analog benzenesulfonamidopyrimidine and standard sulfonamide disc (250 mg). The effect of transfer of sulfonamide resistance plasmids on silver sulfadiazine zones is presented in Figure 2. The average inhibition zone without the



TABLE 3. Examination of Alcide<sup>R</sup> in Pseudomonas aeruginosa-Infected Rats

	Untreated	Control	ClX	C2X	C3X	C4X	Silver Sulfadiazine
First Study	7/8	6/8	4/7	5/8	2/8	4/8	0/8
Second Study	8/8	8/8	8/8	8/8	7/8	5/8	2/8
TOTAL	15/16	14/16	12/15	13/16	9/16	9/16	2/16
Mortality (%)	94%	88%	80%	81%	56%*	56%*	13%

\*Less effective than silver sulfadiazine ( $P < 0.023$ , Fisher exact test).

C = Concentration.




FIGURE 1. Number of patients with each serotype and isolates per serotype.

TABLE 4. Minimal Inhibitory Concentration for Pseudomonas aeruginosa Strains to Mafenide Acetate

Mafenide Acetate Concentration (g/100 ml)	Number of Strains Fiscal Year 1986	Number of Strains Fiscal Year 1987
0.019	6	1
0.039	9	5
0.078	28	12
0.156	47	21
0.312	83	21
0.625	15	19
TOTAL NUMBER OF STRAINS	189	79

plasmid was changed from a mean zone of 24.9 mm to a mean zone of 17.3 mm ( $P < 0.001$ ). The activity of the same strains against the activity of silver as silver benzenesulfonamidopyrimidine is presented in Figure 3. There was no significant change between plasmid-containing (15.93 mm) and plasmid-free (15.81 mm) strains of c600. The transfer of sulfonamide activity alone was responsible for the significant change in silver sulfadiazine agar well diffusion. Figure 4 shows the control study in which the sulfonamide-sensitive parent strains were converted to sulfonamide resistance using disc technique.




FIGURE 2. Effect of sulfonamide plasmids on silver sulfadiazine diffusion zones.




FIGURE 3. Effect of sulfonamide plasmids on silver diffusion zones.




FIGURE 4. Effect of sulfonamide plasmids on sulfadiazine diffusion zones.

ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED  
SOLDIERS: Characterization of Biochemical  
Indicators of Infection in the Thermally  
Injured

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1985 - 30 September 1987

INVESTIGATORS

David G. Burleson, PhD, Lieutenant Colonel, MS  
Avery A. Johnson, BS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED  
SOLDIERS: Characterization of Biochemical  
Indicators of Infection in the Thermally  
Injured

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: David G. Burleson, PhD, Lieutenant Colonel, MS  
Avery A. Johnson, BS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

We have previously described factors found in perchloric acid (PCA) filtrates of the blood of burned-infected rats. One of these factors has a maximum emission at 420 nm at 355 nm excitation (355ex/420em). This factor was subsequently found in the blood of many burned patients. The factor consists of several fluorescent substances that can be resolved by high-pressure liquid chromatography (HPLC). We have analyzed the level of one of the fluorescent components that has an identical HPLC retention time to neopterin. The factor is chromatographically and spectrally similar to neopterin, yet its identity has not been verified by a separate chemical technique. The concentration of the compound quantitated by HPLC was found to be highly correlated to the level of 355ex/420em fluorescence found in many patient blood samples. This suggests that the HPLC-identified substances contribute significantly to the fluorescence measured in the PCA filtrates and that the conditions that lead to the appearance of these factors in the blood of burned patients lead to the appearance of these HPLC-identified substances as well.



# CHARACTERIZATION OF BIOCHEMICAL INDICATORS OF INFECTION IN THE THERMALLY INJURED

## INTRODUCTION

Infection continues to be a serious complication in severely burned patients and contributes heavily to mortality. Sepsis can be difficult to diagnose in a timely manner in severe trauma. The increase in white blood cell count and fever induced by burn injury hamper the detection of sepsis and make objective diagnosis more difficult. Abnormal levels of hormones (1,2), acute phase proteins in serum (3,4), and fluorescent substances (5,6) in blood and plasma are associated with the presence of inflammation and/or infection in human burn patients and animal burn models. The presence of these substances in blood and plasma likely reflect the metabolic response that the stress of trauma and infection place on the host.

A specific measure of pathogens is desirable, but the wide range of possible microbes that would have to be detected at the low levels present in blood early after infection limit the applicability of microbe-specific biochemical indicators. A biochemical measurement of specific products of the immune system produced in response to invading organisms would provide a means of differentiating the metabolic response induced by trauma from the response induced by activation of the immune system. If this test could be detected by biochemical means, it could be performed in less than an hour and be timely enough to alert the clinician to sepsis in a more timely and objective manner than currently possible with standard microbiology techniques.

We are attempting to find clinically useful indicators to use as an adjunct to standard microbiological methods of assessing the presence of sepsis (5-7). In this report, we describe further characterization of the nature of the previously reported 355ex/420em fluorescent substances found in the blood of burn victims.

## MATERIALS AND METHODS

**Measurement of Fluorescent Indicators in Blood.** One ml of anticoagulated blood or plasma was mixed with 4 ml of cold (4°C) PCA (0.8 M). After incubating for 10 min, the mixture was centrifuged at 4°C for 10 min at 3000 g. The supernatant was recentrifuged at 20000 g for 30 min. The clear supernatant was transferred to another tube and fluorescence was then measured using an Aminco Bowman spectrofluorometer at (355ex/420em). The fluorometer was standardized by using a calibration standard (fluorescence intensity block).

**HPLC Determination of the 355ex/420em Factor in Serum.** Serum (100  $\mu$ l) was deproteinized by incubating at 100°C in an oil bath for 20 min after the addition of 200  $\mu$ l of 0.2 M potassium phosphate buffer (pH 4.5). The mixture was then centrifuged at 20000 g for 20 min and the supernatant was injected directly on the HPLC. HPLC was performed on an Hewlett-Packard liquid chromatograph (Model 1090) with a Biophase ODS reverse phase, 4.6 X 250 mm column (Bioanalytical Systems). The mobile phase consisted of 0.05 M ammonium acetate at a pH of 7.0. The column temperature was maintained at 45°C and the flow rate was 1.0 ml/min. The HPLC was equipped with a Kratos fluorescence detector (Model 980) with a 25  $\mu$ l flow cell. The excitation monochromometer was set at 350 nm and the emission cutoff filter was at 389 nm. The retention time for standard pterins (Sigma Chemical) were determined using 10  $\mu$ l of a standard solution of pterins (10 ng/ml). The amount of each fluorescent substance present was measured on a Hewlett-Packard integrator (Model 3392A).

**Mass Spectral Analysis of the 355ex/420em Factor.** Mass spectral analysis of neopterin was attempted by derivatization of purified standard material (Sigma Chemical) to make it volatile enough for gas chromatography separation and introduction into the mass spectrometer. The mass spectral analysis was attempted on a Hewlett Packard Model 5985. The gas-liquid chromatography column was either a packed column with particles coated with nonpolar silicone as a liquid phase or a 15 m-fused silica capillary column with a nonpolar bonded phase. The gas phase consisted of helium at a flow rate appropriate for the column being used.

## RESULTS

**Determination of the 355ex/420em Substance in Patient Samples.** The conditions under which the fluorescence of the 355ex/420em factor are measured in the PCA filtrates (0.7M PCA, pH <1) and after separation by HPLC (NH<sub>3</sub> acetate buffer, pH 7.4) are quite different. Since the chemical environment can greatly effect fluorescence intensity of a substance, it was not known whether the fluorescence of the HPLC-purified components of the 355ex/420em factor contributed significantly to the fluorescence measured in the PCA filtrates.

A number of samples were analyzed to determine if the level of the fluorescent material with a neopterin HPLC retention time was correlated with the level of fluorescence in the PCA filtrates. The relative amount of material found by HPLC, using neopterin as a standard, was determined by integration of the HPLC peak in randomly selected patient samples. This result was plotted against the log of the fluorescence, which corresponds to concentration, of the same unpurified filtrates at 355ex/420em. Figure 1 depicts the correlation of the neopterin-like substance to the concentration of 355ex/420em factors in blood and plasma. The correlation coefficient ( $r^2$ )




FIGURE 1. Correlation of the amount of neopterin-like substance determined by HPLC with the amount 355ex/420em fluorescence in the PCA filtrate. Neopterin-like substance was determined by comparing the integrated peak area of fluorescence for the unknown sample to the peak area for the fluorescence determined for a purified neopterin standard. The concentrations determined for the neopterin-like substance by HPLC were compared to the fluorescence measured in the original PCA filtrates.

was  $>0.8$  for both blood and plasma. This suggests that the pterin-like substances contribute significantly to the fluorescence of the 355ex/420em factor and are induced by the same sequence of events that cause the factor to be elevated.

The level of neopterin (peak area) determined by HPLC in patient samples was compared with fluorescence of the samples at 355ex/420em. The level of neopterin was plotted along with fluorescence as a function of postburn day. The plots obtained for 3 different patients are shown in Figure 2. Perusal of the figures show that, in general, the trend of 355ex/420em fluorescence was similar to the level of neopterin determined by HPLC for the same day. This is further evidence that a portion of the fluorescence at 355ex/420em is due to neopterin.






FIGURE 2. Comparison of the level of neopterin-like substance determined by HPLC to the level of fluorescence in PCA filtrates. Fluorescence in serial patient samples were determined after PCA protein precipitation for 3 patients. A portion of whole blood from the sample was deproteinized and the amount of neopterin-like substance was determined by HPLC. Both determinations were then plotted for that patient vs. postburn day. HPLC peak area (ng/ml), log fluorescence in PCA filtrates (arbitrary units).

derivatives. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis. Several attempts to measure neopterin by GC-MS and thermospray mass spectrometry had met with limited success. The limited vapor pressure of neopterin made detection by direct insertion probe impractical, so many other attempts were made to synthesize a derivative that would have sufficient volatility for GC-MS analysis. Bis-trimethylsilylacetamide, bis-trimethylsilyl-trifluoroacetamide, tri-methylchlorosilane, N-trimethylsilylimidazole, hexamethyldisilane, and hexamethylchlorosilane were used in many combinations and under multiple reaction conditions to find the conditions that would result in a sufficiently volatile derivative of standard neopterin to allow analysis by GC-MS. No suitable combination was found. Bis-trimethylsilylacetamide and pyridine gave some initial success, but could not be repeated consistently.

With the acquisition of a thermospray HPLC-mass spectrometry instrument, we hope to be able to purify sufficient quantities of the neopterin-like material to verify its chemical composition without the necessity of making volatile derivatives. Direct analysis of the material that elutes from the HPLC column should be possible.

#### DISCUSSION

We have separated four components that are consistently found in extracts of patient serum that have highly fluorescent PCA filtrates. These substances have fluorescent spectral characteristics similar to nucleotide derivatives such as the pterins. Three of the components copurify with and behave chromatographically similar to pterins. We have not yet established chemical identity with any of the commonly found pterin derivatives with which they have been compared.

It is difficult to accurately determine how much of the fluorescence seen in the original PCA supernatant extracts from patient serum can be accounted for by these four chromatographically separated substances. Fluorescence is highly dependent on chemical structure as well as environmental factors such as pH. Since the pH of the detector chamber is approximately 7.4 and the fluorescent factors were originally measured in concentrated PCA solution, it is not possible to quantitatively compare the fluorescence. We cannot assume that all of the fluorescent substances present in the supernatant extracts are detectable under the chromatographic conditions employed.

Several attempts have been made to derivatize the material and obtain ionization fragmentation patterns by GC-MS, which is the most sensitive method of determination of chemical structure available. Suitable derivatives have not yet been attained.

biochemical characterization may not be possible on the small amount of material of limited purity that we have obtained to date. Future attempts at identification of these fluorescent substances will be attempted after collection and purification of milligram quantities of these substances.

#### PRESENTATIONS/PUBLICATIONS

None.

#### REFERENCES

1. Becker RA, Vaughan GM, Goodwin CW Jr, et al: Interactions of thyroid hormones and catecholamines in severely burned patients. Rev Infect Dis 5:S908-S913, 1983.
2. Wilmore DW: Hormonal responses and their effect on metabolism. Surg Clin North Am 56:999-1018, 1976.
3. Pepys MB and Baltz ML: Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141-212, 1983.
4. Burleson DG, Lin KD, and Powanda MC: Indicators of infection in burned patients. In Proceedings of the Sixteenth Annual Meeting of the American Burn Association, p 57.
5. Powanda MC, Dubois J, Villarreal Y, et al: Detection of potential biochemical indicators of infection in the burned rat. J Lab Clin Med 97:672-679, 1981.
6. Powanda MC, Dubois J, and Villarreal Y: Monitoring and modification of the metabolic and physiologic alterations associated with thermal injury in burned soldiers. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1981, pp 341-352.
7. Lin KD, Burleson DG, and Powanda MC: Characterization of biochemical indicators of infection in the thermally injured. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1984, pp 200-208.

ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED  
SOLDIERS: Studies on the Role that Outer  
Membrane Proteins Play in the Susceptibility of  
Pseudomonas aeruginosa (PA) to Imipenem

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

INVESTIGATORS

Robert G. Eagon, PhD\*  
Albert T. McManus, PhD  
Basil A. Pruitt, Jr., MD, Colonel, MC

\*Participant, US Army Summer Faculty  
Research and Engineering Program  
Department of Microbiology  
University of Georgia  
Athens, Georgia 30602

## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED SOLDIERS: Studies on the Role that Outer Membrane Proteins Play in the Susceptibility of Pseudomonas aeruginosa (PA) to Imipenem

INSTITUTION: US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: Robert G. Eagon, PhD  
Albert T. McManus, PhD  
Basil A. Pruitt, Jr., MD, Colonel, MC

Outer membrane proteins approximating the molecular weights of proteins D1 and D2 were observed in wild-type, prototrophic PA irrespective of the growth medium, i.e., whether glucose, succinate, or casamino acids served as the carbon and energy sources. This is in contrast to previous reports that outer membrane protein D1 in PA was glucose-inducible and succinate-repressible. The significance of outer membrane protein D1 is that it is considered to function as a diffusion channel through the outer membrane of PA by the beta-lactam antibiotic, imipenem, which is considered to account for the susceptibility of PA to imipenem.

In an imipenem-resistant clinical isolate of PA, however, outer membrane proteins with molecular weights approximating that of outer membrane proteins D1 and D2 were repressed by growth on casamino acids but not by growth on succinate. Moreover, well-defined mutants of PA blocked in glucose catabolism, glucose transmembrane transport, or glucose periplasmic binding protein showed wild-type susceptibility to imipenem. That is, outer membrane protein D1 synthesis would have been expected to be repressed in these mutants if outer membrane protein D1 were genetically regulated similarly to systems that control glucose utilization. Thus, the data suggested that the acquisition of imipenem resistance in PA involved genetic factors other than those which are involved in glucose transport and glucose catabolism and in the synthesis of outer membrane protein D1.



NO-N212-178

US ARMY INSTITUTE OF SURGICAL RESEARCH ANNUAL RESEARCH

PROGRESS REPORT FOR FISCAL YEAR 1987(U) ARMY INST OF


SURGICAL RESEARCH FORT SAM HOUSTON TX B A PRUITT


UNCLASSIFIED

01 OCT 87

F/G 6/5

NL





STUDIES ON THE ROLE THAT OUTER MEMBRANE PROTEINS  
PLAY IN THE SUSCEPTIBILITY OF Pseudomonas  
aeruginosa (PA) TO IMIPENEM

INTRODUCTION

Imipenem is a broad spectrum, beta-lactam-type antibiotic that is especially effective against PA. This is surprising since PA is inherently resistant to a large variety of antibiotics, especially most beta-lactam antibiotics. According to current concepts, the outer membrane of PA acts as a diffusion barrier against antibiotics, thus preventing the antibiotics from reaching their physiological targets (1-4).

Hydrophilic solutes in general are considered to diffuse through specific proteins in the Gram-negative bacterial outer membrane which form water-filled diffusion channels. The trivial term, porin, has been coined for such proteins. The outer membrane of Escherichia coli, which has been intensively studied, has two major porins, OmpF and OmpC, with diameters of 1.2 and 1.1 nm, respectively (4). The major porin of PA, protein F, however, has a diameter of 2.0 nm. Thus, it would be expected that the outer membrane of PA would be more permeable than that of Escherichia coli. Such is not the case. Instead, even though PA has about  $3 \times 10^5$  copies of protein F in its outer membrane, <1% of the porins are considered to be in an open, functional state (1-4). This, then, is considered to account for the highly impermeable nature of the outer membrane of PA and, as a consequence, its intrinsic resistance to antimicrobial agents.

Imipenem is effective against PA because it is considered to be able to diffuse through outer membrane protein D1 in addition to outer membrane protein F. This supposition is based on recent observations that imipenem-resistant isolates of PA have reduced amounts of an outer membrane protein whose molecular weight approximates that of outer membrane protein D1 (5,6).

Evidence has been presented that PA outer membrane protein D1 is glucose inducible (7,8) and that it may function as a more or less specific diffusion channel for glucose and related sugars. Thus, outer membrane protein D1 may be physiologically analogous to the lamB gene product in Escherichia coli which functions as a specific diffusion channel for maltose and maltodextrin.

Glucose is catabolized in PA by the Entner-Doudoroff pathway, which is an inducible system. Moreover, glucose transport in PA is a shock-sensitive system, meaning that a periplasmic glucose binding protein is involved in addition to a specific glucose transport protein in the cell membrane. Both of the latter two proteins are also glucose inducible.

Organic acids appear to be the preferred energy source for PA and not carbohydrates. Succinate, for example, acts as a catabolite repressor of the glucose catabolic enzymes and transport proteins in PA (9).

Considerable information is available on the position of the genes and on the genetic regulatory factors for the transport and catabolism of glucose and related compounds in PA (9). Thus, the purpose of the studies described herein was to determine whether the synthesis of outer membrane protein D1 was genetically regulated similarly to that of the carbohydrate catabolic enzymes, transport proteins, and binding proteins in PA and to provide further information on the presumed role of outer membrane protein D1 as a diffusion channel for imipenem.

#### MATERIALS AND METHODS

**Organisms.** The strains of PA and their descriptions used in these studies are shown in Table 1.

**Media.** The organisms were grown in either Mueller-Hinton (MH) medium or in the chemically defined basal salts medium (EPBS) previously described (10) and supplemented, in final concentration, with 20 mM glucose (Glc), 20 mM sodium succinate (Suc), or 0.5% casamino acids (CA). As required, these media were solidified with 1.5% agar-agar (in final concentration).

**Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC).** MIC determinations were normally carried out by the Kirby-Bauer standard disk diffusion overlay technique. In some instances, however, the tube dilution technique was used to determine MIC and MBC. The chemotherapeutic agents used included amikacin (AM), gentamicin (GM), mezlocillin (MZ), piperacillin (PIP), tobramycin (NN), ticarcillin (TIC), moxalactam (MOX), cefotaxime (CTX), cefoperazone (CEP), cefsulodin (CEF), sulfadiazine (SD), azlocillin (AZ), kanamycin (K), chloramphenicol (C), tetracycline (TE), colistin (CL), netilmicin (NET), imipenem (IMP), norfloxacin (NOR), aztreonam (ATM), ticarcillin/clavulanate (TIM), ceftazidime (CAZ), ceftriaxone (CRO), and carbenicillin (CB).

**Preparation of Outer Membranes of PA and Extraction of Outer Membrane Proteins.** Prototrophic, wild-type PA (Strain PA01(PVP)) and an imipenem-resistant clinical isolate (Strain 87-05-11-004) were used in these studies. The cells were grown overnight in EPBS-Glc, EPBS-Suc, and EPBS-CA, harvested by centrifuging, washed once in EPBS, and harvested again by centrifuging. The cells were ruptured by sonicating as follows: 1 g wet weight of the cell pellets was suspended in 8.5 ml of EPBS minus the  $(\text{NH}_4)_2\text{SO}_4$  component. Then, 0.5 ml of a mixture of DNase and RNase  $2(1\text{ mg/ml each})$  was added. The cell suspension was then placed in an ice bath and sonicated for 6 repetitions of 20 sec followed by 40 sec of cooling.

TABLE 1. Strains of *Pseudomonas aeruginosa* Used

Strain	Genotype/Phenotype	Derivative/Source
PA01(PVP)	Prototroph	From Phibbs' Collection
PFB311		PFB57; glc <sup>-</sup> (Spontaneous Revertant)
PFB331	glcT-4	PFB311; glc <sup>-</sup> (EMS Mutagenesis)
PFB360	glcT-2	PFB311; glc <sup>-</sup> (EMS Mutagenesis)
PFB362	glcB1	PFB311; glc <sup>-</sup> (EMS Mutagenesis)
PFB363	glcT-3	PFB311; glc <sup>-</sup> (EMS Mutagenesis)
A10	glcT	PFB311; glc <sup>-</sup> (EMS Mutagenesis)
MB723	trp gdh Tglc	See Reference 12
PA01(HN)	Prototroph	From Nikaido's Collection
87-05-15-004	Imipenem	Clinical Isolate (From McManus' Collection)
87-05-11-004	Imipenem	Clinical Isolate (From McManus' Collection)
1244 (ATCC 27317)	"Standard Virulent Strain"	Clinical Isolate (From McManus' Collection)
ATCC 27853	"Standard Strain"	American Type Culture Collection

Strains PA01(PVP), PFB311, PFB331, PFB360, PFB362, PFB363, A10, and MB723 were generously provided by Dr. Paul V. Phibbs, Jr., although Strain MB723 was originally acquired by Dr. Phibbs from another laboratory (12).

PFB311 is a spontaneous revertant of PFB57, i.e., glc<sup>-</sup> to glc<sup>+</sup>. For a description of PFB57, see reference 13.

Strains PFB331, PFB360, PFB362, PFB363, and A10 were developed by mutagenizing PFB311 with ethylmethanesulfonate (EMS). The parental strain, PFB311, was glc<sup>+</sup> (phosphorylative pathway only), mannitol transport negative, glucose and gluconate dehydrogenase negative, gluconate transport negative, gluconokinase negative, and 2-ketogluconate negative.

PFB362 is suspected of having an inactive glucose periplasmic binding protein, whereas PFB363 has been reported to be glucose periplasmic binding protein deficient.

A10 is glucose transport negative but the mutation is leaky.

PFB360 is also a leaky mutant.

MB723 is a tryptophane auxotroph, glucose dehydrogenase negative and glucose transport negative.

Strains 87-05-15-004 and 87-05-11-004 are imipenem-resistant clinical isolates from burn wound tissue.

Strain 1244 (ATCC 27317) was a clinical isolate, also originally from burn wound tissue, which is widely used in a control sense as the "standard virulent strain."

ATCC 27853 is a standard strain of PA from the American Type Culture Collection which is also widely used for control purposes.

Whole cells and cellular debris were removed by centrifuging at 4°C for 20 min at 7000 x g. Cell envelopes were then sedimented from the supernatant by centrifuging at 4°C for 45 min at 100000 x g. The cell envelopes were suspended in 10 ml of water and sedimented again at the same centrifugal force and time. Next, the cell envelopes were suspended in 0.15 ml of water and an equal volume of 1% sodium N-laurylsarcosine was added to selectively solubilize the cytoplasmic membrane (13). The suspensions were incubated at ambient temperature for 20 min. Outer membranes were collected by centrifuging at 4°C for 45 min at 100000 x g, washed once in 2.5 ml of water, and collected again by centrifuging in the same manner. This was essentially the same procedure used by others to prepare outer membranes from Gram-negative bacteria (14).

The outer membranes were then suspended in 0.1 ml of a solubilization reduction mixture of the following composition: 0.5 M tris(hydroxymethyl)aminomethane (Tris)-HCL, pH 6.8, 12.5 ml; 10% sodium dodecyl sulfate (SDS), 20 ml; mercaptoethanol, 5 ml; glycerol, 10 ml; and bromphenol blue to 0.001% (final concentration). The suspension was then placed in a boiling water bath for 3 min.

**Electrophoresis.** The outer membrane proteins were separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) using 14% acrylamide (final concentration) in the separating gel. Electrophoresis was run for 9 h at 25-30 mA.

Molecular weight standards (Bio-Rad Laboratories, Richmond, CA) were: phosphorylase B, 97,400; bovine serum albumin, 66,200; ovalbumin, 42,699; carbonic anhydrase, 31,000; soybean trypsin inhibitor, 21,500; and lysozyme, 14,400.

## RESULTS

**Susceptibility of Various PA Strains to Imipenem.** Susceptibility of the various strains of PA to imipenem when MH, EPBS-Glc, EPBS-Suc, and EPBS-CA were used both as the growth media and as the susceptibility test media is shown in Table 2. When MH medium, which is the accepted antibiotic susceptibility test medium, was used, only two clinical isolates (Strains 87-05-11-004 and 87-05-15-004) were found to be resistant.

The diameters of the zones of inhibition on the other three media were, with two exceptions, wider than those on MH medium for the various antibiotics. Nevertheless, the diameters of the zones of inhibition by imipenem were most narrow for the imipenem-resistant clinical isolates (Strains 87-05-11-004 and 87-05-15-004). Thus, it was concluded that the imipenem resistance patterns did not vary irrespective of what media were used for the growth and susceptibility test media. However, when zones of inhibition noted for media other than MH medium were compared, the evidence suggested that the clinical

TABLE 2. Susceptibility of the Various Strains of PA by Imipenem on MH, EPBS-Glc, EPBS-Suc, and EPBS-CA Media Determined by the Kirby-Bauer Disc Differentiation Overlay Technique

PA Strain	Diameter (mm) of Zones of Inhibition			
	MH	EPBS-Glc	EPBS-Suc	EPBS-CA
PA01(PVP)	28.0 (S)	33.4	31.0	23.8
PFB311	28.4 (S)	35.8	32.6	27.0
PFB331	29.4 (S)	NG	32.6	27.0
PFB360	23.6 (S)	NG	30.0	30.4
PFB362	25.4 (S)	NG	32.0	26.4
PFB363	26.4 (S)	NG	NG	28.4
A10	30.0 (S)	NG	38.4	34.0
MB723	27.0 (S)	NG	NG	NG
PA01(HN)	28.0 (S)	33.0	31.4	28.6
87-05-15-004	11.0 (R)	18.2	20.4	17.0
87-05-11-004	12.0 (R)	18.6	17.6	16.0
1244 (ATCC 27317)	26.6 (S)	33.8	26.0	28.8
ATCC 27853	25.0 (S)	34.6	32.6	28.4

NG = no growth, S = sensitive, R = resistant.

isolates were somewhat more resistant to imipenem when EPBS-CA was used as the growth and test medium.

**MIC and MBC Values.** The MIC and MBC values were determined by the tube dilution method using EPBS-Glc and EPBS-CA as the test media for PA Strains PA01(PVP), ATCC 27853, 87-05-11-004, and 87-05-15-004. The results in Table 3 show that the MIC values were the same on both media for the wild-type organisms (Strains PA01(PVP) and ATCC 27853), but the MBC was higher for Strain ATCC 27853 on EPBS-Glc as compared to EPBS-CA while Strain PA01(PVP) showed no difference. Strain 87-05-11-004, however, had higher values for both the MIC and MBC in EPBS-CA

TABLE 3. MIC and MBC Values of Imipenem ( $\mu\text{g/ml}$ ) for Four Strains of PA on EPBS-Glc and EPBS-CA Media Determined by the Tube Dilution Method

PA Strain	EPBS-Glc		EPBS-CA	
	MIC	MBC	MIC	MBC
PA01(PVP)	<2	<2	<2	<2
87-05-15-004	<2	4	4	4
87-05-11-004	<2	4	6	8
ATCC 27853	<2	4	<2	<2

medium than in EPBS-Glc medium. Strain 87-05-15-004 had a higher MIC value in EPBS-CA than in EPBS-Glc, but the MBC values were the same for both media.

**SDS-PAGE of Outer Membrane Proteins.** The results of SDS-PAGE of outer membrane proteins from PA Strains PA01(PVP) and 87-05-11-004 when grown on EPBS-Glc, EPBS-Suc, and EPBS-CA are shown in Figure 1. No differences in the profile of outer membrane proteins of PA Strain PA01(PVP) were observed irrespective of the medium in which the organism was grown (Fig 1, Lanes 1-3).

PA Strain 87-05-11-004, on the other hand, had two outer membrane proteins missing when grown on EPBS-CA (Fig 1, Lane 6) as compared to cells grown on EPBS-Glc and EPBS-Suc (Fig 1, Lanes 4 and 5). These outer membrane proteins had molecular weights of approximately 47,000 and 52,000. As mentioned above, these outer membrane proteins were present in cells grown on EPBS-Glc and EPBS-Suc. Interestingly, the 47,000-dalton outer membrane protein separated into two bands, suggesting that it was a heat-modifiable protein. Regrettably, the photograph and its reproduction in Figure 1 is of such low quality that this cannot be clearly seen.

**Zones of Inhibition with Aqueous 0.5% Casamino Acids Medium.** Although not a planned series of studies for the research problem that was undertaken as described herein, certain results were obtained inadvertently that should be mentioned. In one series of studies, the basal salts were omitted from the media with casamino acids as the carbon and energy sources. Instead, a 0.5% aqueous solution of casamino acids was used, solidified with 1.5% agar-agar as appropriate. The basal salts that normally would have been incorporated into an EPBS-based medium are mono- and dibasic potassium phosphate, ammonium sulfate, and magnesium sulfate.






FIGURE 1. SDS-PAGE of outer membrane proteins of PA Strain PA01(PVP) grown on EPBS-Glc (Lane 1), EPBS-Suc (Lane 2), and EPBS-CA (Lane 3), and of PA Strain 87-05-11-004 grown on EPBS-Glc (Lane 4), EPBS-Suc (Lane 5), and EPBS-CA (Lane 6). Lane 7 shows molecular weight standards.

When the various strains of PA were grown and tested on 0.5% aqueous casamino acids media, unexpected results were observed as compared to those obtained on EPBS-CA media (Table 4). Notably, the diameters of the zones of inhibition for the various antibiotics seen on 0.5% aqueous casamino acids were greater as compared to those seen on EPBS-CA. In many cases, organisms that would have been judged to have been susceptible to certain antibiotics on EPBS-CA appeared instead to be resistant when 0.5% aqueous casamino acids were used. In other cases, the reverse was observed.

Finally, when these results were compared to those obtained on MH medium, the approved antibiotic test assay medium, it was seen that results obtained from the use of both EPBS-CA and 0.5% aqueous casamino acids differed substantially from those seen when MH medium was used (Table 5).

The results shown in Tables 4 and 5 are too complex for further discussion. Instead, they are presented here to

TABLE 4. Comparison of the Inhibition of PA Strains by Antimicrobials on Casamino Acids Media With and Without the Addition of Basal Salts

Antibiotic	PA Strain	Diameter (mm) of zones of inhibition <i>P. aeruginosa</i> strain										ATCC 27853
		PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	PA01 (HN)	
AN	18.6 (17.6)	20.4 (16.0)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CH	16.6 (17.6)	20.4 (16.0)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
NP	20.4 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
PIP	29.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
NN	22.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
TTC	19.4 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CTX	18.4 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CEP	21.4 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CEF	23.0 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
SD	19.4 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
AZ	24.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
K	20.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
C	20.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
TE	24.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CL	12.0 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
NEI	19.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
IPH	23.8 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
NOR	32.0 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
ATM	21.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
THM	21.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CAZ	26.6 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CRO	0 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)
CB	14.0 (17.6)	21.0 (16.4)	22.4 (16.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	22.4 (17.6)	20.6 (16.6)

( ) = Zones of inhibition when PA strains were grown in an aqueous 0.5% solution of casamino acids and then antibiotic inhibition determined on the same medium solidified with 1.5% agar-agar.  
 ND = Not done.  
 NG = No growth.



dramatically illustrate the importance of environmental factors in antibiotic susceptibility testing and to raise questions about the response of infectious microorganisms in the infected tissue environment of the host as compared to that under laboratory conditions. The results shown in Tables 4 and 5, therefore, should be carefully studied by those workers interested in susceptibility testing.

### DISCUSSION

Outer membrane protein D1 of PA has been reported to be a glucose-inducible protein and to be repressed when the cells were grown on succinate (7,8). If true, outer membrane protein D1 in PA would be genetically similar to the glucose catabolic enzymes, glucose transport protein(s), and glucose periplasmic binding protein in PA, all of which are glucose-inducible and succinate-repressible (9). We did not find this to be the case. Instead, outer membrane proteins of molecular weights approximating that of outer membrane proteins D1 and D2 were formed in wild-type PA Strain PA01(PVP) irrespective of the carbon and energy sources in which it was grown, i.e., whether glucose, succinate, or casamino acids were the carbon and energy sources. Moreover, there was no perceptible change in imipenem susceptibility of wild-type PA strains PA01(PVP) and ATCC 27853 irrespective of the carbon and energy sources on which they were grown. This is important because, according to current concepts, imipenem is considered to be especially effective against PA because it is able to permeate the outer membrane through outer membrane protein/porin D1 which, as mentioned herein, has been reported to be glucose-inducible and repressed by growth on succinate or casamino acids (5-8).

The imipenem resistant clinical isolate of PA Strain 27-05-11-004 responded differently than the wild-type laboratory strains. Two outer membrane proteins of approximate molecular weights of 47,000 and 52,000 were not observed in cells grown on EPBS-CA medium. This is in agreement with reports by others that outer membrane protein D1 is repressed by growth on casamino acids (5-8). However, in contrast to reports by others (7,8), growth on succinate did not repress the formation of these outer membrane proteins. The clinical imipenem-resistant isolates, however, were more resistant to imipenem when grown on casamino acids, suggesting a role for outer membrane proteins D1/D2 as diffusion channels for imipenem as reported by others (5,6).

The data indicate, therefore, that there was a basic difference between wild-type strains of PA as compared to imipenem-resistant clinical isolates. Namely, outer membrane proteins of molecular weights similar to that of proteins D1/D2 were repressed in the imipenem-resistant isolates by growth on casamino acids, but not in the wild-type strains. However, growth on succinate did not repress these outer membrane

proteins in either an imipenem-resistant isolate or in a wild-type strain.

Several well-defined mutants of PA blocked in glucose transport or in glucose catabolism were not resistant to imipenem. Instead, they showed wild-type susceptibility to imipenem. It would have been expected that these mutants would be lacking in outer membrane protein D1 if the synthesis of this protein was regulated similarly to that of the glucose catabolic enzymes, of the glucose cell membrane transport protein, and of the glucose periplasmic binding protein. Our data strongly suggest, however, that such was not the case.

Finally, the imipenem-resistant clinical isolates of PA used in these studies appeared to differ substantially from the wild-type, prototrophic strains in the synthesis and thus in genetic regulatory factors of the two outer membrane proteins whose molecular weights approximated that of outer membrane proteins D1 and D2 of PA.

#### PRESENTATIONS/PUBLICATIONS

None.

#### REFERENCES

1. Eagon RG: The resistance characteristics of *Pseudomonas*. Developments in Industrial Microbiology 25:337-348, 1984.
2. Hancock RE: Alterations in outer membrane permeability. Annu Rev Microbiol 38:237-264, 1984.
3. Hancock RE: Role of porins in outer membrane permeability. J Bacteriol 169:929-933, 1987.
4. Nikaido H and Vaara M: Molecular basis of bacterial outer membrane permeability. Microbiol Rev 49:1-32, 1985.
5. Buscher K-H, Cullmann W, Dick W, and Opferkuch W: Imipenem resistance in *Pseudomonas aeruginosa* resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 31:703-708, 1987.
6. Quinn JP, Dudek EJ, DiVincenzo CA, et al: Emergence of resistance to imipenem during therapy for *Pseudomonas aeruginosa* infections. J Infect Dis 154:289-294, 1986.
7. Hancock RE and Carey AM: Outer membrane of *Pseudomonas aeruginosa*: heat-2-mercaptoethanol-modifiable proteins. J Bacteriol 140:902-910, 1979.

8. Hancock REW and Carey AM: Protein-D1 - a glucose-inducible, pore-forming protein from the outer membrane of Pseudomonas-aeruginosa. FEMS Microbiology Letters 8:105-109, 1980.
9. Lessie TG and Phibbs PV Jr: Alternative pathways of carbohydrate utilization in pseudomonads. Annu Rev Microbiol 38:359-388, 1984.
10. Eagon RG and Phibbs PV Jr: Kinetics of transport of glucose, fructose, and mannitol by Pseudomonas aeruginosa. Can J Biochem 49:1031-1041, 1971.
11. Stinson MW, Cohen MA, and Merrick JM: Purification and properties of the periplasmic glucose-binding protein of Pseudomonas aeruginosa. J Bacteriol 131:672-681, 1977.
12. Guymon LF and Eagon RG: Transport of glucose, gluconate, and methyl alpha-D-glucoside by Pseudomonas aeruginosa. J Bacteriol 117:1261-1269, 1974.
13. Filip C, Fletcher G, Wulff JL, et al: Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate. J Bacteriol 115:717-722, 1973.
14. Field LH, Headley VL, Payne SM, and Berry LJ: Influence of iron on growth, morphology, outer membrane protein composition, and synthesis of siderophores in Campylobacter jejuni. Infect Immun 54:126-132, 1986.

## RESEARCH COMPLETION REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED  
SOLDIERS: Therapy with IgG and T4 in Burn  
Patients

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

### INVESTIGATORS

Anne E. Missavage, MD, Major, MC  
George M. Vaughan, MD, Lieutenant Colonel, MC  
Albert T. McManus, PhD  
David G. Burleson, PhD, Major, MS  
William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC  
Arthur D. Mason, Jr., MD

## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ALTERATION OF HOST RESISTANCE IN BURNED  
SOLDIERS: Therapy with IgG and T4 in Burn  
Patients

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: Anne E. Missavage, MD, Major, MC  
George M. Vaughan, MD, Lieutenant Colonel, MC  
Albert T. McManus, PhD  
David G. Burleson, PhD, Major, MS  
William F. McManus, MD, Colonel, MC  
Basil A. Pruitt, Jr., MD, Colonel, MC  
Arthur D. Mason, Jr., MD

The possible prophylactic effects of exogenously administered IgG were evaluated in a cohort of 69 seriously burned patients. Treated patients were given 500 mg/kg twice a week starting 2-5 days postburn. Patients were treated for a minimum of 2 wk or until death or wound coverage. Control patients were resuscitated under the same protocol but did not receive IgG. Group assignment was by randomization of admissions having initial predicted survival probabilities between 20 and 80%. The resulting groups were similar in total burn, full-thickness burn, presence of inhalation injury, age, sex, and pretreatment serum IgG levels. Infections and mortality were recorded during the 60 days following injury. At 60 days postburn, 64 infections had occurred in 26 treated patients and 7 in control patients. Final mortality was 11 treated patients and 9 control patients. No significant improvement in mortality or reduction in infections could be attributed to the use of intravenous gamma globulin.



## THERAPY WITH IgG AND T4 IN BURN PATIENTS

### INTRODUCTION

In thermally injured subjects, relentless sepsis remains a major problem despite the availability of potent antibiotics and major advances in the areas of fluid therapy, nutritional support, and burn wound management. Profound suppression of humoral and cellular immune responsiveness and of neutrophil function represent characteristic defects in the defense mechanisms of burn patients. This state of acquired immune deficiency in burn patients is somewhat akin to the depressed immune status of patients with primary immune deficiency syndromes and manifests itself as deficiency in the cell-mediated and humoral components of immunity; patients in both groups are susceptible to infection (1,2). For two decades, IgG replacement in patients with immune deficiency syndromes has been recognized as the mainstay of prophylaxis and has distinctly reduced the incidence of infection in these individuals. In burn patients, the lack of a protective skin barrier and the use of invasive monitoring enhance the risk of colonization of deeper tissues with a wide variety of organisms. Associated defects in the immune defenses may further aid the evolution of infectious processes. This study proposed immunomodulation of burned patients by IgG replacement during the first 4 wk postburn when concentrations of endogenous IgG in these subjects were subnormal and they were prone to systemic infection.

### MATERIALS AND METHODS

This unblinded, randomized study evaluated the efficacy of exogenously administered IgG and T4 for prophylaxis of infection in burn patients. Adult patients were offered admission to the study if, for that particular patient's age, the total burn size was such that the probability of death was between 20 and 80%, based on previous logistic regressions over a large population of burn patients receiving about the same general care as our patients were expected to receive.

**Inclusion Criteria.** Burn patients of either sex >18 yr of age with a probability of mortality between 20 to 80% admitted to this Institute during the first 5 days postburn were considered eligible for this study.

**Exclusion Criteria.** Patients under the age of 18, females of childbearing age with a positive pregnancy test, patients with <20% or >80% chance of mortality (based on age and total burn size), and those admitted to this Institute more than 5 days postburn were not eligible for this study.

**Design.** Each patient was randomized into the IgG treatment group (those who receive IgG) or the IgG control group (those

who do not receive IgG). This protocol originally included a thyroid hormone replacement component for selected randomized hypothyroid patients. However, because of a very low accretion due to a lack of patients meeting the inclusion criteria, this component was discontinued. IgG therapy (500 mg/kg IV infused over 4 hr twice weekly for 2 wk) began between the second and fifth postburn days. IgG administration was advanced to the immediate postoperative period for patients undergoing surgery.

**Hormonal, Biochemical, and Immunological Monitoring.** From the time of initial randomization, blood samples were obtained twice weekly (just before the IgG infusion in the group receiving IgG) for hormonal, biochemical, and immunological monitoring. Indices of cellular and humoral immunity, bacteriologic and virologic surveillance, and hormonal responses were examined twice weekly over a 4-wk period. However, patients with persistently abnormal findings often required further investigation beyond 4 wk.

**Cellular and humoral immunity.** Indices of immune responsiveness included measurements of T-cells and their subsets and B-cells and their subsets by flow cytometry using the immunofluorescence technique, polyclonal lymphocyte activation by standard mitogens, and measurements of total and differential leukocyte count as well as chemiluminescence.

**Bacteriologic and virologic surveillance.** Surveillance for infectious agents included bacteriologic (blood, urine, and sputum cultures) and virologic (urine and throat washings for cytomegalovirus culture and antibody titers) tests. Blood cultures were drawn only when clinically indicated.

**Hormonal responses.** Hormonal response testing included catechols, steroids, renin-angiotensin-aldosterone, vasopressin, and thyroid hormones (T<sub>4</sub>, T<sub>3</sub>, rT<sub>3</sub>, TSH, T<sub>3</sub>U).

Immunoglobulins were analyzed by nephelometry (8). A fluorescence-activated cell sorter was employed to separate various lymphocyte subpopulations (9) and monoclonal cells (10). Chemiluminescence was measured as previously described (11). Bacteriologic and viral isolation was performed by standard methods. Hormones were measured by RIA with standard kits (thyroid hormones, cortisol, aldosterone, PRA) and by procedures developed at this Institute (angiotensin I and II).

## RESULTS

A comparison of demographic characteristics of treated and control patients is presented in Table 1. The randomization resulted in two comparable groups. Measurement of serum IgG prior to treatment, or within the first 5 days postburn for the control group, showed mean values of  $421.2 \pm 33.8$  and  $382.4 \pm 38.6$  mg/dl, respectively. A value of 800 mg/dl is considered the lower limit of the normal range for adults.

TABLE 1. General Information

	Treatment Group	Control Group
Number of Patients	35	34
Sex (Male/Female)	27/8	31/3
Age (Mean Yr)	43	44
Total Burn Size (Mean %)	45	47
3° Burn Size (Mean %)	22	22
Inhalation Injury (Cases)	18	20
Survivors	18	19
Nonsurvivors	11	9

The distribution of the weekly mean maximum serum IgG values are presented in Figure 1. Treated patients had IgG values within normal limits by the first week postburn and control patients had synthesized IgG to within normal limits by the second week postburn.

A comparison of infections that occurred within the first 30 days is presented in Table 2. A comparison at 60 days is presented in Table 3. No differences in the number of sites or infections were noted. As shown in Figure 2, the types of organisms causing infections were also similar between the two groups.

Mortality data are presented in Table 4. As can be seen, no differences in mortality between the groups were observed. No reduction in infection or mortality could be attributed to the use of intravenous gamma globulin.

#### DISCUSSION

Overwhelming sepsis significantly contributes to the mortality of patients with extensive burns (12). A multitude of perturbations encountered in the immunologic defenses of burn patients point to the immunosuppressive nature of burn injury. Burn-induced changes in the humoral and cellular responses include hypogammaglobulinemia (13), reduction in the complement levels (14), depressed serum opsonic activity (15), decreased granulocyte chemotaxis (16), anergy to recall antigens (17), prolonged survival of skin allograft (18), depressed response in autologous mixed lymphocyte culture, and decreased OKT4/OKT8 ratio (19). In the past, encouraged by the favorable




FIGURE 1. Maximum weekly IgG concentration.

TABLE 2. Comparison of Infections Observed in Treatment and Control Patients at the End of 30 Days' Hospitalization (Infections/Patients)

	Treatment Group	Control Group
Pneumonia	22/20	22/21
Bacteremia	11/11	12/11
Urinary Tract Infection	4/4	4/4
Cellulitis	7/7	7/7
Burn Wound Invasion	1/1	3/3
Other	3/3	4/4
<b>TOTAL NUMBER OF INFECTIONS</b>	<b>48</b>	<b>52</b>

TABLE 3. Comparison of Infections Observed in Treatment and Control Patients at the End of 60 Days' Hospitalization (Infections/Patients)

	Treatment Group	Control Group
Pneumonia	27/20	29/31
Bacteremia	15/12	20/15
Urinary Tract Infection	8/7	6/5
Cellulitis	8/7	8/8
Burn Wound Invasion	3/3	3/3
Other	3/3	4/4
<b>TOTAL NUMBER OF INFECTIONS</b>	<b>64</b>	<b>70</b>




FIGURE 2A. Organisms causing infections (control group).




FIGURE 2B. Organisms causing infections (treatment group).

TABLE 4. Comparison of Mortality Between Treated and Control Patients (Dead/Alive)

	Treatment Group	Control Group
30 Days	6/29	6/28
60 Days	10/25	7/27
<b>TOTAL DEATHS</b>	<b>11/24</b>	<b>9/25</b>

experience observed in patients with immune deficiency syndromes (2), two clinical trials in burn patients (20,21) employed IgG for prophylaxis of infection with apparently contradictory results. IgG administered in sufficient amounts in the early postburn period was credited with improved survival in children (20). However, in adult patients, IgG therapy in relatively small doses administered during a variable postburn period failed to show any beneficial effects (21). During the past, clinical trials of IgG in burn patients has been impeded on two counts, by nonexistence of a suitable IgG preparation for intravenous use and by a lack of information about the kinetics of infused IgG in burn patients. Currently available IgG preparations are completely devoid of the vasomotor and other side effects reported with older products. This has been achieved by the modification of IgG through a process of reduction and alkylation (Gammimune<sup>®</sup>, Cutter Biological) and by reduction alone (IGIV, pH 4.25, Cutter Biological). This latter preparation, however, preserves more than 90% of the IgG molecule in its native monomer form. In recent kinetic studies, we have demonstrated that twice weekly IgG infusions given in a dose of 500 mg/kg are sufficient to normalize serum IgG concentration in burn patients (22). Within 48 hours of thermal injury, serum IgG is at its lowest concentration, and thereafter gradually returns to normal over a 3- to 4-wk period (12). Based on this state of knowledge, it was reasonable to test whether immunomodulation of burn victims with IgG would aid in reduction of infection and thus improve survival in these immunocompromised individuals. For therapeutic interventions aimed at prophylaxis, it was imperative that such therapy be instituted during the period of extreme vulnerability which precedes clinical manifestations of established sepsis. For this reason, patients in this study received IgG therapy during the early postresuscitation period when concentrations of their endogenous IgG were subnormal. This study attempted to characterize modifications produced in burn-induced immunologic and endocrine responses and their correlation with subsequent development of sepsis in the study population.

## PRESENTATIONS/PUBLICATIONS

None.

## REFERENCES

1. Arturson G, Hogman CF, Johansson SGO, and Killander L: Changes in immunoglobulin levels in severely burned patients. Lancet 1:546-548, 1969.
2. Buckley RH: Immunoglobulin replacement therapy: indications and contraindications for use and variable IgG levels achieved. Alving BM (ed). In Immunoglobulins: Characteristics and Uses of Intravenous Preparations. Washington, DC: United States Government Printing Office, 1980, pp 3-8.
3. Becker RA, Vaughan GM, Ziegler MG, et al: Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med 10:870-875, 1982.
4. Slag MF, Morley JE, Elson MK, et al: Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 245:43-45, 1981.
5. Kaptein EM, Weiner JM, Robinson WJ, et al: Relationship of altered thyroid hormone indices to survival in nonthyroidal illnesses. Clin Endocrinol 16:565-574, 1982.
6. Vaughan GM, Mason AD Jr, McManus WF, and Pruitt BA Jr: Alterations of Mental Status and Thyroid Hormones after Thermal Injury. J Clin Endocrinol and Metab 60:1221-1225.
7. Obregon MJ, Roelfsema F, Morreale de Escobar G, et al: Exchange of triiodothyronine derived from thyroxine with circulating triiodothyronine as studied in the rat. Clin Endocrinol 10:305-315, 1979.
8. Killingsworth LM and Savory J: Manual nephelometric methods for immunochemical determination of immunoglobulin IgG, IgA, and IgM in human serum. Clin Chem 18:335-339, 1972.
9. Herzenberg LA and Herzenberg LA: Analysis and separation using the fluorescence activated cell sorter (FACS). Weir DM (ed). In Handbook of Experimental Immunology. Oxford: Blackwell Scientific Publications, 1978, pp 22.1-22.21.
10. Goldstein G, Lifter J, and Mittler R: Immunoregulatory changes in human disease detected by monoclonal antibodies to T lymphocytes. McMichael AJ (ed). In Clinical Medicine. London: Academic Press, 1982, pp 39-70.



11. Allen RC and Pruitt BA Jr: Humoral-phagocyte axis of immune defense in burn patients. Chemoluminigenic probing. Arch Surg 117-133-140, 1982.
12. Sevitt S: A review of the complications of burns, their origin and importance for illness and death. J Trauma 19:358-369, 1979.
13. Munster AM, Hoagland HC, and Pruitt BA Jr: The effect of thermal injury on serum immunoglobulins. Ann Surg 172:965-969, 1970.
14. Fjellstrom KE and Arturson G: Changes in the human complement system following burn trauma. Acta Path Microbiol Scand 59:257-270, 1963.
15. Bjornson AB and Alexander JW: Alterations of serum opsonins in patients with severe thermal injury. J Lab Clin Med 83:372-382, 1974.
16. Warden GD, Mason AD Jr, and Pruitt BA Jr: Evaluation of leukocyte chemotaxis in vitro in thermally injured patients. J Clin Invest 54:1001-1004, 1974.
17. Casson P, Solowey AC, Converse JM, et al: Delayed hypersensitivity status of burned patients. Surg Forum 17:268-270, 1966.
18. Ninnemann JL, Fisher JC, and Frank HA: Prolonged survival of human skin allografts following thermal injury. Transplantation 25:69-72, 1978.
19. Antonacci AC, Calvano SE, Reaves LE, et al: Restoration of autologous mixed lymphocyte responses in burn patients following in vitro addition of interleukin-2: analysis of responder cell populations with monoclonal antibodies. Surg Forum 34:108-110, 1983.
20. Klefalides NA, Arana JA, Bazan A, et al: Role of infection in mortality from severe burns. New Engl J Med 267:317-323, 1962.
21. Stone HH, Graber CD, Martin JD Jr, and Kolb L: Evaluation of gammaglobulin for prophylaxis against burn sepsis. Surgery 58:810, 1965.
22. Shirani KZ, Vaughan GM, McManus AT, et al: Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies. Am J Med 76:175-180, 1984.

23. Canonico PG, McManus AT, and Powanda MC: Biochemistry and function of the neutrophil in infected and traumatized hosts. Dingle JT, Jacques PJ, and Shaw IH (eds). In Lysosomes in Applied Biology and Therapeutics. Amsterdam: North-Holland Publishing Company, 1979, pp 287-326.
24. Bisset SK and Alexander WD: The effect of intravenous injections of triiodothyroacetic acid and l-triiodothyronine on the oxygen consumption of circulating human leucocytes. Quart J Exp Physiol 46:50-53, 1961.
25. Klebanoff SJ and Clark RA: The metabolic burst. In The Neutrophil: Function and Clinical Disorders. Amsterdam: North-Holland Publishing Company, 1978, pp 283-408.
26. Becker RA, Vaughan GM, Goodwin CW Jr, et al: Interactions of thyroid hormones and catecholamines in severely burned patients. Rev Inf Dis 5(S5):S908-S913, 1983.

<b>RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY</b>				1 AGENCY ACCESSION DAOG1842	2 DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR&B(AR) 636	
3. DATE PREV SUM'RY 86 10 01	4. KIND OF SUMMARY D	5. SUMMARY SCTY U	6. WORK SECURITY U	7. REGRADING	8. DISB'N INSTR'N CX	9. LEVEL OF SUM A WORK UNIT	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a. PRIMARY	61102A	3M161102BS14	BD	304			
b. CONTRIBUTING							
c. CONTRIBUTING	DA LRRDAP	FY88-01					
11. TITLE (Precede with Security Classification Code) (U) Role of Thyroid Hormones in Burn Pathophysiology							
12. SUBJECT AREAS 06 05 Medicine and Medical Research 06 01 Biochemistry							
13. START DATE 79 08	14. ESTIMATED COMPLETION DATE 99 09	15. FUNDING ORGANIZATION DA	16. PERFORMANCE METHOD C				
17. CONTRACT/GRANT RELEVANCY CERTIFIED							
a. DATE EFFECTIVE	EXPIRATION	FISCAL YEARS	a. PROFESSIONAL WORKYEARS	b. FUNDS (In thousands)			
b. CONTRACT/GRANT NUMBER			87	1.2	78		
c. TYPE	d. AMOUNT	98		1.2	82		
e. KIND OF AWARD	f. CUM. TOTAL						
19. RESPONSIBLE DOD ORGANIZATION				20. PERFORMING ORGANIZATION			
a. NAME US Army Institute of Surgical Research				a. NAME US Army Institute of Surgical Research			
b. ADDRESS (include zip code) Fort Sam Houston San Antonio, Texas 78234-5012				b. ADDRESS Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL PRUITT, B A				c. NAME OF PRINCIPAL INVESTIGATOR VAUGHAN, J M			
d. TELEPHONE NUMBER (include area code) 512-221-2720				d. TELEPHONE NUMBER (include area code) 512-221-5416			
21. GENERAL USE FINA MILITARY/CIVILIAN APPLICATION M				f. NAME OF ASSOCIATE INVESTIGATOR (if available)			
				g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22. KEYWORDS (Precede EACH with Security Classification Code) (U) L-Triiodothyronine; (U) Therapy; (U) Deiodinase; (U) Hypothyroidism; (U) Thyroxine; (U) Volunteers;							
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code) 22. (Continued) (U) Lab Animals: (U) Rats; (U) Hamsters; (U) RAIL  23. (U) To assess the abnormalities of thyroid function to improve survival in burned soldiers. A literature search was conducted.  24. (U) To characterize pituitary-thyroid feedback setting in a rat burn model.  25. (U) 3610 - 9709. Studies of burn patients reported previously suggested that relative inadequacy of thyroid-stimulating hormone (TSH) secretion may occur as a reflection of an altered feedback setting. To assess this possibility, male adult Sprague-Dawley rats with full-thickness 50% scald burns received a continuous subcutaneous thyroxine (T4) infusion via osmotic pumps at one of two dose levels (or no T4) for 6 days prior to sampling on the postburn day 8. Thyroidectomized rats (as controls) received the same T4 treatment, which raised the low serum T4 in burned and thyroidectomized rats to or above normal (dose-related). Among dose groups, serum T4 means in thyroidectomized rats encompassed the range of the mean T4 in burned rats. For a given serum T4 (including that in the normal range where triiodothyronine (T3) was not different between burned and thyroidectomized rats), TSH was markedly lower in burned rats than in thyroidectomized rats (P<0.001). In another rat study (no T4 treatment), serum T4 was depressed in burned rats (vs. sham-burned rats) by 24 h postburn. Hormone values in sham-burned and normal rats were similar. At							

CONTINUATION OF DD FORM 1498 FOR "ROLE OF THYROID HORMONES IN  
BURN PATHOPHYSIOLOGY"

48 h, T4 exhibited a partial return toward normal (though still depressed), only to regress further to very low levels by postburn days 7 and 14. Serum T3 remained depressed in burned rats at all time points. Whereas TSH was able to respond in a qualitatively normal fashion by 24 h, this elevation above normal was lost by 48 h. TSH fell to depressed levels thereafter in a pattern parallel with T4. The major resetting of TSH control in burned rats was evident only after the previously reported time of appearance (by 48 h) of ectopic supraependymal neurons on the floor of the third ventricle seen by scanning electron microscopy of the medial basal hypothalamus. Relative TSH deficiency occurs in burn injury and is associated with augmented negative feedback, allowing even low levels of thyronines to restrict elevation of serum TSH. This may reflect involvement of the central nervous system.

## ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ROLE OF THYROID HORMONES IN BURN  
PATHOPHYSIOLOGY: Control of Thyrotropin (TSH)  
After Burn Injury

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

### INVESTIGATORS

George M. Vaughan, MD, Lieutenant Colonel, MC  
Khan Z. Shirani, MD, Lieutenant Colonel, MC  
Mary K. Vaughan, PhD\*  
Sandy H. Coggins  
David E. Scott, PhD, Colonel, USAR\*\*  
Basil A. Pruitt, Jr., MD, Colonel, MC

\*Department of Cellular and Structural Biology  
The University of Texas Health Science Center  
San Antonio, Texas 78284-7877

\*\*Department of Anatomy and Cell Biology  
Eastern Virginia Medical School  
Norfolk, Virginia 23501

## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: ROLE OF THYROID HORMONES IN BURN  
PATHOPHYSIOLOGY: Control of Thyrotropin (TSH)  
After Burn Injury

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: George M. Vaughan, MD, Lieutenant Colonel, MC  
Khan Z. Shirani, MD, Lieutenant Colonel, MC  
Mary K. Vaughan, PhD\*  
Sandy H. Coggins  
David E. Scott, PhD, Colonel, USAR\*\*  
Basil A. Pruitt, Jr., MD, Colonel, MC

Previous studies in burned humans identified a relative inadequacy of TSH secretion, which might be viewed functionally as an altered control setting for negative feedback. To assess this possibility, male adult Sprague-Dawley rats with a 50% full-thickness scald burn (BURN) received a continuous subcutaneous thyroxine (T4) infusion via osmotic pumps at one of two dose levels (or no T4) for 6 days prior to sampling on postburn day 8. Thyroidectomized (THYREX) rats received the same T4 treatment, which raised the low T4 in BURN and in THYREX to or above normal (dose related). High TSH in THYREX and low normal mean TSH in BURN (without subcutaneous T4) were both lowered by T4 (dose related). Among dose groups, serum T4 means in THYREX encompassed the range of mean T4 in BURN. For a given serum T4 (including that in the normal range where triiodothyronine (T3) was not different between BURN and THYREX), TSH was markedly lower in BURN than in THYREX ( $P < 0.001$ ). In another rat study (no T4 treatment), serum free thyroxine index (FT4I) was depressed in BURN (vs. sham-burn) by 24 h postburn. At 48 h, FT4I exhibited a partial return toward normal (though still depressed), only to regress further to very low levels by days 7 and 14. Serum T3 remained depressed in BURN at all time points. Whereas TSH was able to respond in a qualitatively normal fashion by 24 h, this TSH elevation above normal was lost by 48 h. TSH fell (to depressed levels) thereafter in a pattern parallel with FT4I. The major resetting of TSH control in BURN was evident only after the appearance of ectopic supraependymal neurons on the floor of the third ventricle noted at and after 48 h on scanning electron microscopy of the medial basal hypothalamus.

Relative TSH deficiency occurs in burn injury, associated with augmented negative feedback, allowing even low levels of

thyronines to restrict elevation of serum TSH. In rats, this correlates in time with morphologic changes in the hypothalamus, suggesting involvement of the central nervous system.

## CONTROL OF THYROTROPIN (TSH) AFTER BURN INJURY

### INTRODUCTION

Though circulating thyroxine (T4) and triiodothyronine (T3) may be depressed in patients with burns or other nonthyroidal illness, and more severely depressed in nonsurvivors, the behavior of serum TSH is not well characterized. With use of a highly sensitive and specific two-site immunoradiometric assay, we previously were able to identify an abnormality of the serum TSH pattern in severely burned patients (1). Though mean T4 and T3 and their free concentrations were depressed already by postburn days (PBD) 2-3, mean TSH was in the normal range and rose only to the upper normal limit in survivors as T4 and T3 gradually returned to normal. However, all these hormones fell progressively in nonsurvivors. While the data were compatible with augmented peripheral thyronine disposal, a TSH deficiency was also indicated by the falling TSH in nonsurvivors and by the many normal values of TSH in the first week in survivors despite low free T4 and T3. If there were no abnormality of TSH secretion, one would expect a marked rise in serum TSH when thyronines are low and providing less negative feedback. Relative inadequacy of TSH secretion, less marked in survivors, might be viewed functionally as an altered control setting for negative feedback. This hypothesis was tested in the present studies.

### MATERIALS AND METHODS

For the first study, adult male Sprague-Dawley rats were given a full-thickness scald burn (BURN) according to a standardized procedure (including hair clipping in the dorsal and ventral areas to be burned) under sodium pentobarbital anesthesia (2). The burn covered 50% of the total body surface area. Since burning is known to produce low serum T4, other rats for comparison were thyroidectomized (THYREX) under similar anesthesia (but not burned) and maintained with 0.9% calcium chloride in the drinking water. All other rats were given tap water. All rats ate rodent chow ad libitum. A group of 5 controls received no treatment (CON) and served to indicate the normal values of thyroid hormones. Both the BURN and THYREX rats were divided into 3 subgroups (5 rats each), receiving, respectively, no infusion (T4 INF = 0), T4 infusion at 1.1  $\mu$ g/100 g/day (T4 INF = 1), or T4 infusion at 11.0  $\mu$ g/100 g/day (T4 INF = 2). Rats received T4 as a continuous infusion from osmotic minipumps implanted subcutaneously under sodium pentobarbital anesthesia, which remained in the dorsal neck region for 6 days up to the time of sacrifice and sampling at postburn day 8 or post-thyroidectomy day 12. At this time, rats were anesthetized with sodium pentobarbital, opened ventrally, and exsanguinated by central venipuncture for assay of T4, T3, and TSH.




For the second study, rats were scalded (BURN) as for the first study, except that the burn size was 60% of the total body surface area, and other rats received anesthesia and clipping but no burn (SHAM). For this study, there were no T4 infusions, no thyroidectomized groups, and BURN and SHAM rats were sacrificed by guillotine in groups of 5 rats at 6 h, 24 h, 48 h, 7 days, and 14 days after burn. CON (9 rats) received no procedure except sacrifice at various times along with the groups of BURN and SHAM rats. Trunk serum was saved for analysis of T4, T3, in vitro radiotracer T3 uptake from serum onto charcoal (T3U), and TSH. The medial basal hypothalami were prepared for scanning electron microscopy. Those results, together with thyroid hormone values, were reported previously (3). However, the crucial TSH values were not then available, and herein they are presented along with an estimate of the bioavailable T4. Thus, a cohesive interpretation of central control of the thyroid axis is now possible from this study.

During both studies, the rats were sampled at 0800-0900 h (except for one group 6 h later after burning at 0800 h in the second study). Thyroid hormones and T3U were measured with RIA kits from Diagnostic Products. TSH was measured by RIA, with the antibody and standard supplied by the National Institute of Arthritis and Metabolic Diseases (Bethesda, MD), with sample volumes of 200  $\mu$ l. The free T4 index (FT4I), the product of T4 and the T3U, is a measure of the circulating T4 available to tissues. Data were analyzed on the VAX 11/780 with the BMDP software package from the University of California (Los Angeles, CA) (4). In the first study, for a given T4 INF, group intercomparisons were made by Bonferroni-corrected t-tests, and a given hormonal variable versus T4 INF was tested for rectilinear correlation within BURN or THYREX. In the second study, an hormonal variable at a given postburn time was compared by Bonferroni-corrected t-test (BURN vs. CON).

## RESULTS

Figure 1 shows that infusion of T4 for 6 days can replace low circulating T4 after BURN or THYREX in a dose-related fashion. T3 was not fully normalized. TSH was depressed by T4 infusion in both BURN and THYREX in a dose-related fashion. However, as also shown in Figure 2 with TSH as a function of T4, TSH was much lower in BURN than in THYREX for a given T4 value. Of particular importance, neither T4 nor T3 were statistically different between THYREX after T4 INF = 1 and BURN after T4 INF = 2, and this mean T4 (5  $\mu$ g/dl) was nearly identical to that of CON. Nevertheless, at this normal T4 level, TSH in BURN was markedly below TSH in CON and in THYREX.

Figure 3 shows that T4 is depressed already by 6 h postburn, and such a rapid fall probably results from accelerated disposal of T4, perhaps due partly to extravascular shifts of circulating constituents diluted by the 30 ml (0.15 M



**FIGURE 1.** Circulating thyroid axis hormones (mean  $\pm$  SE) in rats of the first study at 12 days after thyroidectomy (THYREX) or 8 days after a full-thickness burn (BURN) of 50% of the total body surface area ( $n = 5/\text{group}$ ). One group had no treatment and are represented by the box with a vertical extent of the mean  $\pm$  2 SD. In THYREX and BURN groups, T4 was infused (INF) in saline from implanted osmotic pumps at one of two concentrations (1 = 1.1  $\mu$ g/100 g/day; 2 = 11  $\mu$ g/100 g/day) or pumps were not implanted (T4 INF = 0). Pumps were present for 6 days up to the time of sampling for rats with implanted pumps (T4 INF = 1 or 2). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  vs. controls. † $P < 0.01$ , †† $P < 0.001$  vs. BURN. LD, least detectable TSH. T4, T3, and TSH (THYREX) and T4 and TSH (BURN) correlated significantly ( $P < 0.05$  or better) with T4 INF (0-2), negatively for TSH and positively for T4 and T3. T3 did not change with T4 INF in BURN.




FIGURE 2. Data from Figure 1 relating TSH and T<sub>4</sub> (mean  $\pm$  SE). The T<sub>4</sub> infusion number (0-2) appears next to the symbols. THYREX, thyroidectomized; CON, controls. \* $P < 0.05$ , \*\* $P < 0.01$ , vs. CON for groups with similar T<sub>4</sub> means. T<sub>3</sub> means did not differ among THYREX and burn groups with T<sub>4</sub> INF of 1 or 2, but T<sub>3</sub>, both in THYREX (INF 1) and in BURN (INF 2), was lower than the mean T<sub>3</sub> in CON (see Fig 1). Thus, the comparison between BURN and THYREX indicates that for equivalent levels of T<sub>4</sub>, TSH is lower in BURN than in THYREX (equivalent T<sub>3</sub>) or in CON (in spite of higher T<sub>3</sub> in CON). Thus, negative feedback of T<sub>4</sub> on TSH secretion appears reset at a lower setpoint (stronger effect) for TSH after burn injury than in the normal pituitary-thyroid axis (THYREX).




FIGURE 3. Serum FT4I and TSH (mean  $\pm$  SE) in controls (CON), sham-burned (SHAM), and 60% total body surface area full-thickness burned (BURN) rats at various postburn days (PBD) in study 2. There were 5 rats/group. Enough serum from only 2 BURN rats was available for TSH determination at PBD 0.25 (6 h). \*\* $P < 0.01$ , \*\*\* $P < 0.001$  vs. CON. The qualitatively normal TSH elevation in response to low FT4I in burns at PBD 1 is not seen on PBD 2, and TSH becomes depressed at PBD 7 and 14 despite FT4I approaching the level seen on PBD 1. The resetting of TSH secretion to lower levels on PBD 2 in BURN was accompanied by appearance of ectopically placed supraependymal neurons above the medial basal hypothalamus present only on PBD 2, 7, and 14.

sodium chloride) resuscitation injection given intraperitoneally just before the ventral burn plus any imbibed water. Such a mechanism for the initial fall of T4 (and T3) has yet to be documented. The fall of T4 was greater by 24 h, when TSH became elevated, perhaps producing a secondary rise in FT4I noted at 48 h. By 48 h, TSH had fallen to normal and subsequently fell further in parallel with a fall of T4 and FT4I. Ectopic supraependymal neurons were seen in the third cerebral ventricle just above the medial basal hypothalamus only in BURN beginning only at 48 h.

### DISCUSSION

The lower TSH concentration in BURN (PBD 8) for a given altered circulating T4 level compared with that for THYREX (Fig 2) suggests that burn injury alters the feedback setting for T4 control of TSH secretion. The range of T4 means in THYREX encompassed that in BURN. The known approximately 35% elevation of the T4 dialyzable fraction in BURN rats at this time point would not have elevated even free T4 concentration of the BURN rats without T4 infusion to that in CON, and FT4I and free T4 are depressed at PBD 8 and 14 (5). Thus, even without T4 infusion, TSH is dramatically lower in BURN than it should be as indicated by TSH in THYREX for an equivalent T4 or for any other THYREX T4 in the range exhibited in BURN groups.

In low-T4-nonthyroidal illness, the FT4I appears to represent a better index of the concentration of circulating T4 available to cells than does the free T4 concentration by dialysis (6). The time course of thyroid hormone changes after a large burn injury (Fig 3) indicates that FT4I (and T4, not shown) fall by 6 h, perhaps as a result of accelerated peripheral disposal, though the precise disposal factors altered are not yet clarified; and that after a secondary small rise of FT4I (and T4, not shown) but still below normal at 48 h, they fall again further over about 2 wk. T3 (not shown) is low at all time points (3). TSH is able to rise in a qualitatively normal fashion by 24 h. However, after this, by 48 h, this elevation of TSH is lost. This indicates that by 48 h, the major resetting of the control of TSH (no longer able to respond to low T4 and T3, as if the negative feedback effect of thyronines is exaggerated) has taken place. The temporal coincidence of this event with the appearance of ectopic supraependymal neurons above the hypothalamus suggests that it is associated with a change in CNS function. The most likely change would seem to be a possible reduction of hypothalamic support of pituitary thyrotrophs normally exerted by secretion of TSH-releasing hormone (TRH). Such a deficiency of TRH could explain what would appear as overly effective negative feedback by thyronines on TSH secretion.

### PRESENTATIONS/PUBLICATIONS

**Vaughan GM:** Central nervous system effects of injury. Presented at the Fourth Annual Army Regional Meeting of the American College of Physicians, San Francisco, California, 23-26 October 1987.

**Vaughan GM:** Control of thyrotropin after burn injury. Presented at the 40th Anniversary Symposium sponsored by the US Army Institute of Surgical Research, San Antonio, Texas, 25-27 October 1987.

**Scott DE, Vaughan GM, and Pruitt BA Jr:** Hypothalamic neuroendocrine correlates of cutaneous burn injury in the rat. I. Scanning electron microscopy. Brain Res Bull 17:367-378, 1986.

### REFERENCES

1. Vaughan GM, Becker RA, Shirani KZ, et al: Two patterns of thyrotrophin alteration and lack of change in thyronine binding globulin. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1986. San Antonio: US Government Printing Office (in press).
2. Walker HL and Mason AD Jr: A standard animal burn. J Trauma 8:1049-1051, 1968.
3. Vaughan GM, Scott DE, and Pruitt BA Jr: Thyroid hormones as neurotransmitters or neuromodulators. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1985. San Antonio: US Government Printing Office, 1986, pp 354-378.
4. Dixon WJ (ed): BMDP Statistical Software. Berkeley: University of California Press, 1983.
5. Shirani KZ, Vaughan GM, Pruitt BA Jr, et al: Reduced serum T<sub>4</sub> and T<sub>3</sub> and their altered serum binding after burn injury in rats. J Trauma 25:953-958, 1985.
6. Sarne DH and Refetoff S: Measurement of thyroxine uptake from serum by cultured human hepatocytes as an index of thyroid status: reduced thyroxine uptake from serum of patients with nonthyroidal illness. J Clin Endocrinol Metab 61:1046-1052, 1985.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL
				DA311508	87 10 01	DD-DR&E(AR) 836
3. DATE PREV SUMMARY	4. KIND OF SUMMARY	5. SUMMARY SCTY	6. WORK SECURITY	7. REGRADING	8. DISR N INSTR N	9. LEVEL OF SUM A WORK UNIT
86 10 01	D	U	U		CX	
10. NO CODES	PROGRAM ELEMENT	PROJECT NUMBFR	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY	61102A	3M161102BS14	BD	305		
b. CONTRIBUTING						
c. CONTRIBUTING	DA LRRDAP, FY88-01					
11. TITLE (Precede with Security Classification Code) (U) Inequality of VA/O Ratios Following Smoke Inhalation Injury and the Effect of Angiotensin Analogues						
12. SUBJECT AREAS						
06 05 Medicine and Medical Research 06 04 Anatomy and Physiology						
13. START DATE	14. ESTIMATED COMPLETION DATE	15. FUNDING ORGANIZATION	16. PERFORMANCE METHOD			
86 10		DA	C			
17. CONTRACT GRANT MILITARY RELEVANCY CERTIFIED				18. RESOURCES ESTIMATE		
a. DATE EFFECTIVE	APPROXIMATE EXPIRATION DATE	FISCAL YEARS	a. PROFESSIONAL WORK YEARS	b. FUNDS (in thousands)		
b. CONTRACT GRANT NUMBER						
c. TYPE	d. AMOUNT	87	2.0	65		
e. KIND OF AWARD	f. CUM. TOTAL	88	2.0	68		
19. RESPONSIBLE DOD ORGANIZATION		20. PERFORMING ORGANIZATION				
a. NAME		a. NAME				
US Army Institute of Surgical Research		US Army Institute of Surgical Research				
b. ADDRESS (include zip code)		b. ADDRESS				
Fort Sam Houston		Fort Sam Houston				
San Antonio, Texas 78234-5012		San Antonio, Texas 78234-5012				
c. NAME OF RESPONSIBLE INDIVIDUAL		c. NAME OF PRINCIPAL INVESTIGATOR				
PRUITT, B A		IKEUCHI, H				
d. TELEPHONE NUMBER (include area code)		d. TELEPHONE NUMBER (include area code)				
512-221-2720		512-221-7832				
21. GENERAL USE		f. NAME OF ASSOCIATE INVESTIGATOR (if available)				
FINA		SAKANO, Tsutomu				
MILITARY/CIVILIAN APPLICATION M		g. NAME OF ASSOCIATE INVESTIGATOR (if available)				
		MASON, A D				
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Inhalation Injury; (U) Cardiac Output; (U) Indicator Dilution; (U) Ventilation-Perfusion Ratio; (U) Cobra Venom;						
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)						
22. (U) Lab Animals: (U) Sheep; (U) RAI1						
23. (U) To evaluate the effect of smoke inhalation on pulmonary ventilation and perfusion. To study the effects of positive end-expiratory pressure and oxygen on pulmonary ventilation-perfusion ratio. To study the role of the complement system in the respiratory insufficiency following smoke inhalation. A literature search was conducted.						
24. (U) Ventilation-perfusion ratios will be measured utilizing the six-inert gas technique. These pulmonary variables will be correlated with standard cardiopulmonary variables before and after the introduction of inhalation injury and subsequent treatment with different types and volumes of resuscitation fluid. Lung and prefemoral lymph will be collected and a specific gravity method for estimation of extravascular lung water volume will be used to assess the pathophysiologic mechanisms of pulmonary edema formation after smoke inhalation. A platelet-activating factor antagonist will be used to estimate the role of platelet-activating factors in edema formation following smoke inhalation.						
25. (U) 8610 - 3709. Ventilation-perfusion alterations following smoke inhalation injury have been established. Techniques for collecting lung and prefemoral lymph have been developed and studies of a specific gravity method for estimating extravascular lung water volume have been initiated.						

DD FORM 1498  
83 MAR

EDITION OF MAR 68 IS OBSOLETE.

• USGPO 1986-491-003/50329

**ANNUAL RESEARCH PROGRESS REPORT**

**PROJECT NUMBER:** 3M161102BS14-00, BASIC RESEARCH

**PROJECT TITLE:** INEQUALITY OF VA/Q RATIOS FOLLOWING SMOKE  
INHALATION INJURY AND THE EFFECT OF ANGIOTENSIN  
ANALOGUES: Effects of Positive End-Expiratory  
Pressure (PEEP) and Oxygen on  
Ventilation-Perfusion (VA/Q) Distribution After  
Smoke Inhalation Injury

**US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012**

**1 October 1986 - 30 September 1987**

**INVESTIGATORS**

Takeshi Shimazu, MD  
Hisashi Ikeuchi, MD  
Gene B. Hubbard, DVM, MS, Lieutenant Colonel, VC  
Avery A. Johnson, Jr., BS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC



## ABSTRACT

PROJECT NUMBER: 3M161102BS14-00, BASIC RESEARCH

PROJECT TITLE: INEQUALITY OF VA/Q RATIOS FOLLOWING SMOKE INHALATION INJURY AND EFFECTS OF ANGIOTENSIN ANALOGUES: Effects of Positive End-Expiratory Pressure (PEEP) and Oxygen on Ventilation-Perfusion (VA/Q) Distribution After Smoke Inhalation Injury

INSTITUTION: US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: Takeshi Shimazu, MD  
Hisashi Ikeuchi, MD  
Gene B. Hubbard, DVM, Lieutenant Colonel, VC  
Avery A. Johnson, Jr., BS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

To evaluate respiratory management after smoke inhalation injury, effects of PEEP alone (Part I) and oxygen with or without PEEP (Part II) on cardiopulmonary function and VA/Q ratio were studied. In Part I, various severities of smoke inhalation injury were produced in 15 sheep and the effects of 10 cmH<sub>2</sub>O PEEP were evaluated under general anesthesia using mechanical ventilation with an FI<sub>O</sub><sub>2</sub> of 0.21 either 12 or 72 h after smoke exposure. There were no significant differences, at 12 or 72 h, in the effects of PEEP; PEEP increased dead space ventilation but did not improve PaO<sub>2</sub> on the whole, and exerted no significant effect on the shunt (VA/Q=0) or low (0<VA/Q<0.1) VA/Q compartments. In Part II, 12 sheep received severe smoke inhalation injury. Baseline measurements were made at 24 h using mechanical ventilation and an FI<sub>O</sub><sub>2</sub> of 0.21 without PEEP. Six sheep were then ventilated with 100% oxygen without PEEP and the remaining six with 100% oxygen with 10 cmH<sub>2</sub>O PEEP and a second set of measurements was made 30 min later. Oxygen alone converted the low VA/Q compartment into the true shunt and the average PaO<sub>2</sub> rose minimally from 54.3 to 101 torr. This change was not completely prevented by 10 cmH<sub>2</sub>O PEEP; three sheep (responders) showed PaO<sub>2</sub> above 300 torr during treatment while the remaining three (nonresponders) had a PaO<sub>2</sub> below 150 torr. Mechanical obstruction of the major bronchi by pseudomembrane was more prominent in the nonresponders and resulted in diffuse atelectasis.

Part I thus showed unfavorable short-term effects of PEEP after smoke inhalation injury, suggesting that PEEP

overinflated alveoli that were already open rather than opening collapsed alveoli. Part II showed that PEEP can not totally prevent oxygen atelectasis and suggests that bronchoscopic removal of the pseudomembranes from major bronchi may be crucial to successful oxygen therapy with PEEP after smoke inhalation injury.

**EFFECTS OF POSITIVE END-EXPIRATORY PRESSURE (PEEP)  
AND OXYGEN ON VENTILATION-PERFUSION (VA/Q) DISTRIBUTION  
AFTER SMOKE INHALATION INJURY**

**INTRODUCTION**

Although smoke inhalation injury is one of the primary determinants of mortality following smoke inhalation injury, the pathophysiologic mechanism of such injury is not yet clear. Treatment of the injury remains controversial, especially in regard to the use of steroids and anti-inflammatory agents. On the other hand, higher concentrations of oxygen and PEEP are well accepted as treatment for hypoxic patients after smoke inhalation, although there have been few studies of the cardiopulmonary effects of oxygen and PEEP in inhalation injury (1-3).

We have developed a dose-responsive model of smoke inhalation injury in which we have investigated pathophysiologic alterations in cardiopulmonary function, including VA/Q ratio, and demonstrated development of a low VA/Q ( $0 < VA/Q < 0.1$ ) compartment as hypoxia progressed (4-6). In the present study, we have evaluated respiratory management of smoke inhalation injury in terms of acute effects of PEEP and oxygen on cardiopulmonary indices.

**MATERIALS AND METHODS**

**Animals.** Thirty-one neutered male sheep weighing 26-40 kg were used in this study. In Part I, various severities of smoke inhalation injury were produced in 15 sheep; 4 uninjured sheep were studied as controls. In Part II, severe smoke inhalation injury was produced in 12 sheep.

**Smoke Exposure.** Smoke was generated by burning 10 disposable underpads in a smoke generator. The smoke was equilibrated at room temperature to avoid thermal injury of the airway and contained 10-14% oxygen, 3-8% carbon dioxide, and 0.7-2.2% carbon monoxide and other combustion products, but no cyanide. Smoke inhalation injury was produced under general anesthesia (methohexital sodium, 9 mg/kg) as previously described (4). Severity of injury was controlled by changing the duration of exposure to the smoke.

**Study Design.** In Part I, 8 sheep were studied at 12 h and 7 at 72 h after smoke exposure. The animals were anesthetized (alpha-chloralose, 0.05 g/kg), paralyzed (pancuronium bromide, 0.03-0.04 mg/kg), and ventilated mechanically with an  $FIO_2$  of 0.21, tidal volume of 15 ml/kg, and respiratory rate of 12/min. Arterial, central venous, peripheral venous, and Swan-Ganz (7F, American Edward Laboratories, Irvine CA) catheters and an esophageal balloon were inserted. After a 2-h stabilization period, initial measurements were made at  $FIO_2$  of 0.21 without

PEEP. Then 10 cmH<sub>2</sub>O of PEEP was applied for 30 min and a second set of measurements were made with an FIO<sub>2</sub> of 0.21 and 10 cmH<sub>2</sub>O PEEP.

In part II, the sheep were reanesthetized 24 h after smoke exposure, catheterized as in Part I, and baseline cardiopulmonary measurements were made using mechanical ventilation and an FIO<sub>2</sub> of 0.21 without PEEP. Then 6 sheep were ventilated with 100% oxygen without PEEP (Group A) and the remaining 6 with 100% oxygen and 10 cmH<sub>2</sub>O PEEP (Group B). A second set of measurements were made after 30 min of treatment.

**Monitoring.** Central venous pressure (CVP), pulmonary artery pressure, and systemic artery pressure were monitored continuously. Pulmonary capillary wedge pressure (PCWP), cardiac output, arterial and venous blood gasses were measured every 30 min after catheter placement. Respiratory indices were monitored with a pneumotachograph for flow rate and tidal volume and a differential transducer for transpulmonary pressure. VA/Q ratio was measured by the multiple inert gas elimination technique (MIGET) using a Hewlett-Packard Model 5985 GC-MS (5,7-9). All animals were sacrificed at the end of studies and tissues were obtained for histological evaluation.

**Statistical Analyses.** Comparisons between the two groups before treatment was made by Student's t-test (Table 1). Effects of treatment were evaluated by paired t-test within each group, and differences induced by treatment was compared between the groups by t-test (Tables 1 and 2, Figs 1 and 2). Fractional blood flows to the four major compartments were compared using multivariate analysis (Figs 3 and 4).

## RESULTS

**Part I.** Figure 1 shows the PaO<sub>2</sub> before and after application of 10 cmH<sub>2</sub>O PEEP in each group. There were no significant changes in PaO<sub>2</sub> in any group. Other cardiopulmonary changes are summarized in Table 1. Since there were no significant differences in response to PEEP, measurements at 12 and 72 h were combined for the smoke-exposed group. In controls, significant changes included increases of PCWP and MPAP and decreases in LVSW index. In the smoke-exposed group, however, increases in PaCO<sub>2</sub>, CVP, PCWP, MPAP, and dead space were significant.

Mean fractional blood flows to the four major compartments, i.e., shunt (VA/Q=0), low VA/Q compartment (0<VA/Q<0.1), normal VA/Q compartment (0.1<VA/Q<10), and high VA/Q compartment (10<VA/Q), are shown in Figure 3. To emphasize the severity-related alterations in VA/Q distribution, the smoke-exposed animals were subdivided into those with PaO<sub>2</sub> above 65 torr and below 65 torr. Before the application of PEEP, blood flow to the normal VA/Q compartment decreased as hypoxia became more severe, while blood flow to the low VA/Q

TABLE 1. Changes in Cardiopulmonary Indices (Mean  $\pm$  SL)

	Oxygen Only (Group A)		Oxygen + PEEP (Group B)	
	Pretherapy	Posttherapy	Pretherapy	Posttherapy
PaCO <sub>2</sub> (torr)	40.1 $\pm$ 5.5	45.2 $\pm$ 8.1*	42.9 $\pm$ 2.2	48.7 $\pm$ 4.8**
CVP (cmH <sub>2</sub> O)	1.3 $\pm$ 1.5	2.0 $\pm$ 2.1	1.4 $\pm$ 1.7	6.3 $\pm$ 5.4
PCWP (torr)	6.8 $\pm$ 3.5	6.0 $\pm$ 2.4	8.5 $\pm$ 4.2	12.3 $\pm$ 4.0**
MPAP (torr)	17.6 $\pm$ 4.7	17.0 $\pm$ 2.4*	21.6 $\pm$ 3.6	22.3 $\pm$ 3.2**
Cardiac index (l/min/m <sup>2</sup> )	4.7 $\pm$ 1.1	4.3 $\pm$ 0.9	5.3 $\pm$ 1.7	4.8 $\pm$ 1.5*
LVSW index (g m/m <sup>2</sup> )	36.7 $\pm$ 10.5	38.2 $\pm$ 8.9	49.8 $\pm$ 15.3	49.4 $\pm$ 19.1
Compliance (ml/cmH <sub>2</sub> O)	64 $\pm$ 24	62 $\pm$ 19	75 $\pm$ 28	82 $\pm$ 27
Resistance (cmH <sub>2</sub> O sec/l)	38.5 $\pm$ 16.5	41.3 $\pm$ 10.5	27.5 $\pm$ 9.1	26.0 $\pm$ 5.2
Peak inspiratory pressure (cmH <sub>2</sub> O)	13.8 $\pm$ 4.4	14.5 $\pm$ 3.2	10.5 $\pm$ 3.4	15.4 $\pm$ 2.8
Dead space (% minute ventilation)	42.6 $\pm$ 8.5	45.7 $\pm$ 11.7	39.7 $\pm$ 5.2	68.1 $\pm$ 12.7**

\*P &lt; 0.05, \*\*P &lt; 0.01, paired t-test.

TABLE 2. Changes in Cardiopulmonary Indices by PEEP (Mean  $\pm$ SD)

	Control Group (n=4)		Smoke-Exposed Group (n=15)	
	Pre-PEEP	Post-PEEP	Pre-PEEP	Post-PEEP
PaCO <sub>2</sub> (torr)	30.1 $\pm$ 5.2	30.2 $\pm$ 5.4	34.9 $\pm$ 7.4	36.8 $\pm$ 7.6*
CVP (cmH <sub>2</sub> O)	0.3 $\pm$ 1.3	2.5 $\pm$ 3.4	1.7 $\pm$ 2.9	5.0 $\pm$ 3.2**
PCWP (torr)	4.3 $\pm$ 1.7	8.8 $\pm$ 1.3*	6.1 $\pm$ 3.5	10.9 $\pm$ 3.1**
MPAP (torr)	12.0 $\pm$ 4.1	15.8 $\pm$ 3.5*	18.5 $\pm$ 6.9	24.1 $\pm$ 4.9**
Cardiac index (l/min/m <sup>2</sup> )	3.9 $\pm$ 0.8	3.1 $\pm$ 0.5	4.5 $\pm$ 1.2	4.2 $\pm$ 1.0
LVS index (g m/m <sup>2</sup> )	38.5 $\pm$ 6.9	30.9 $\pm$ 7.7*	44.1 $\pm$ 11.2	39.6 $\pm$ 9.4
Compliance (ml/cmH <sub>2</sub> O)	135 $\pm$ 37	150 $\pm$ 56	108 $\pm$ 47	95 $\pm$ 38
Resistance (cmH <sub>2</sub> O sec/l)	14.8 $\pm$ 2.5	14.2 $\pm$ 3.9	26.9 $\pm$ 15.0	29.0 $\pm$ 13.5
Peak inspiratory pressure (cmH <sub>2</sub> O)	6.4 $\pm$ 1.2	8.1 $\pm$ 1.4	10.1 $\pm$ 4.8	13.6 $\pm$ 4.2
Dead space (% minute ventilation)	34.2 $\pm$ 10.3	33.1 $\pm$ 11.5	32.6 $\pm$ 6.0	38.1 $\pm$ 5.2**

\*p &lt; 0.05, \*\*p &lt; 0.01, paired t-test.




FIGURE 1.  $PaO_2$  changes induced by PEEP in the 3 groups. There was no statistically significant change in any group.

compartment increased reciprocally (Fig 3A). There were no significant changes in the shunt and high VA/Q compartment. Figure 3B represents fractional blood flow after PEEP. A similar severity-related pattern was observed, but no significant change were induced by PEEP in the mean fractional blood flow in any group.

Although there was no significant change as a group in the fractional blood flow, PEEP improved  $PaO_2$  substantially in some animals and worsened in others. Figure 5 illustrates VA/Q changes in a "successful" PEEP. In that case, the typical low VA/Q compartment decreased markedly with PEEP, resulting in improved  $PaO_2$  from 67 to 75 torr. There was also a substantial decrease in  $\dot{V}_E$  cardiac output and increase in dead space. An





FIGURE 2.  $PaO_2$  changes by oxygen with or without PEEP. Because of the diversity in response to PEEP, the change was not statistically significant, although some animals (responders) showed substantial increase in  $PaO_2$  during treatment.


example of "unsuccessful" PEEP is shown in Figure 6. Before application of PEEP, typical low VA/Q compartment and shunt were observed. The low VA/Q area, however, did not change with the institution of PEEP, while the true shunt increased considerably from 5.1 to 23.5% cardiac output. Consequently,  $PaO_2$  decreased from 66 to 56 torr, but there was minimal change in  $PaCO_2$ , dead space, or cardiac output.

Part II. Changes of  $PaO_2$  in the two groups are shown in Figure 2. Before administration of oxygen with (Group B) or






**FIGURE 3.** Fractional blood flow to the 4 major compartments before (top panel) and after (bottom panel) application of PEEP. Blood flow to the normal VA/Q compartment decreased as the extent of hypoxia increased and blood flow to the low VA/Q compartment increased reciprocally. There was no significant change in the shunt and high VA/Q compartments. PEEP did not exert significant effect as a group in any of the 3 groups. See text for detail.





**FIGURE 4.** Fractional blood flow to the 4 major compartments before (top panel) and after (bottom panel) treatment by oxygen with or without PEEP. There was no significant difference between the two groups in any fraction. PEEP recruited blood flow from the low VA/Q compartment to the shunt. There was no significant difference in the response to oxygen between the two, although central peak to the normal VA/Q compartment was broadened more in the oxygen alone group.



**FIGURE 5.** Ventilation-perfusion change of a successful PEEP treatment. Typical low  $\dot{V}_A/\dot{Q}$  compartment was reduced substantially with improvement of  $\text{PaO}_2$ . Decrease in cardiac output and increase in dead space was also noted. See text for detail.

without PEEP (Group A), there were no significant differences in any of the cardiopulmonary indices between the two groups. In Group A,  $\text{PaO}_2$  rose from  $54.3 \pm 7.3$  torr to  $100.5 \pm 31.4$  torr during treatment, while in Group B,  $\text{PaO}_2$  changed from  $56.8 \pm 7.3$  torr to  $238.9 \pm 142.1$  torr. These changes as a group were not significantly different because of the large variability within



**FIGURE 6.** Ventilation-perfusion change of an unsuccessful PEEP treatment. PEEP did not reduce blood flow to the low VA/Q compartment, but blood flow to the shunt increased significantly, leading to a 10-torr fall in PaO<sub>2</sub>.

Group B. Changes in other cardiopulmonary indices are summarized in Table 2. In Group B, significant changes were observed in PaCO<sub>2</sub>, PCWP, cardiac index, peak inspiratory pressure, and dead space, while only PaCO<sub>2</sub> increased

significantly in Group A. Differences (post- vs. prevalues) induced by the treatment were compared between the two groups and the increases in PCWP, peak inspiratory pressure, and dead space were significantly greater in Group B. Fractional blood flows to the four major compartments are shown in Figure 4. Before treatment, there was no significant difference between Group A (oxygen alone, open bars) and Group B (oxygen + PEEP, shaded bars) (Fig 4A). After 30 min of treatment, blood flow to the low VA/Q area decreased and blood flow to the shunt increased considerably (Fig 4B). However, there was no significant difference in blood flow to any of the four compartments between the two groups before or after treatment. The relationship between increased shunt flow and decreased blood flow to the low VA/Q compartment is plotted in Figure 7. The abscissa (X) represents change in the blood flow to the low VA/Q segment and the ordinate (Y) represents change in the flow to the shunt. Changes are shown as % cardiac output since only minimal change was induced in cardiac output by treatment. The regression for all the animals (n=12) was  $Y = 9.7 - 0.74X$  ( $r=0.54$ ,  $P<0.05$ ). Typical VA/Q changes in Group B are illustrated in Figure 8. Low VA/Q units were totally converted into true shunt (oxygen atelectasis) and the normal VA/Q compartment became wider. Such changes were not completely prevented by institution of 10 cmH<sub>2</sub>O PEEP.

#### DISCUSSION

Smoke inhalation injury is a sequence of progressive deterioration in cardiopulmonary function, which manifests itself by 6 h after injury and reaches a peak by 72 h, after which superimposed infection alters the pathophysiology (4,10,11). In Part I, we have studied the effects of PEEP at an early phase of inhalation injury without significant infection (12 and 72 h) with FIO<sub>2</sub> maintained at 0.21. There were several adverse effects which, although they are common in other disease conditions as well, we must consider in applying PEEP to smoke inhalation injury (12). First, slight suppression of LVSW was observed in uninjured controls; this was not significant in the smoke-exposed group. Dead space ventilation, and consequently PaCO<sub>2</sub>, increased significantly in the smoke-exposed group, but not in the control group. These results suggest that PEEP overinflated alveoli that were already open, rather than opening collapsed alveoli. Previous studies of PEEP in smoke inhalation injury showed improved PaO<sub>2</sub> by PEEP with spontaneous ventilation (CPAP) at 2 h after inhalation and improved survival with PEEP and mechanical ventilation during the first 72 h (2,3). In the present study, we did not observe any consistent effect of PEEP on PaO<sub>2</sub>, making improvement in survival unlikely. This absence of effect might be attributable to the fact that we did not optimize PEEP for each animal and applied PEEP for only 30 min. However, 10 cmH<sub>2</sub>O PEEP would be a common initial clinical level and optimal PEEP is a controversial and poorly defined concept. The acute effects of PEEP were the focus of this part of the





FIGURE 7. Relationship between decreased blood flow to the low VA/Q compartment and increased blood flow to the shunt. Changes in the blood flow to the low VA/Q compartment (abscissa) and to the shunt (ordinate) are expressed as % cardiac output. Regression line for the overall points was  $Y = 9.7 - 0.74X$  ( $r=0.54$ ,  $P<0.05$ ). Shaded area represents mean  $\pm$ SE. There was no significant difference between the two groups.

study; we did not study long-term effects or the effects of high PEEP with oxygen concentrations.

The effects of PEEP with 100% oxygen were studied in Part II. Smoke inhalation injury produces various degrees of partial alveoli collapse due to lung edema, increased secretion, inflammatory cell infiltration, and sloughing of the



**FIGURE 8.** Ventilation-perfusion alteration induced by 100% oxygen without PEEP. Low  $\dot{V}_A/\dot{Q}$  area was completely converted to the shunt and the central peak ( $\dot{V}_A/\dot{Q}$  near 1) was broadened by oxygen, which explained very limited increase in  $\text{PaO}_2$  by pure oxygen.

airway mucosa. These hypoventilated aveoli are susceptible to oxygen and easily collapse (oxygen atelectasis) (13). Under such condition, the acute effects of PEEP might be different. In severe smoke inhalation injury, pure oxygen without PEEP converted the low  $\dot{V}_A/\dot{Q}$  compartments into true shunt by 30 min, with broadening of the central peak ( $\dot{V}_A/\dot{Q}$  ratio near one);  $\text{PaO}_2$

increased minimally during treatment from 54 to 101 torr (Figs 4 and 8). This result is compatible with the theory of absorption atelectasis (13). PEEP did not prevent such change completely, but was effective in some (responders, Fig 2), raising  $\text{PaO}_2$  above 300 torr. There was, however, no statistically significant predictor of responders. Because of the diversity in response to PEEP, there was no significant difference in mean  $\text{PaO}_2$  or VA/Q distribution after treatment between the two groups (Fig 4B). At autopsy, mechanical obstruction of the major bronchi by pseudomembranes was more prominent in the nonresponders and resulted in diffuse atelectasis. Although there are reports that oxygen without PEEP does not increase true shunt in ARDS with low VA/Q, oxygen therapy without PEEP in smoke inhalation injury could do harm. (14,15). Hart et al have reported treatment of smoke inhalation with hyperbaric oxygen, but they addressed carbon monoxide poisoning or cyanide poisoning associated with smoke inhalation (16). The indication for hyperbaric oxygen may be limited to the early postinjury period, and in using such treatment, one must consider the possibility of detrimental respiratory sequelae.

In conclusion, immediate adverse effects of PEEP, including increased dead space and  $\text{PaCO}_2$ , must be considered when PEEP is used in smoke inhalation injury. In this study, oxygen converted the low VA/Q compartment into true shunt (alveolar collapse), and this was not completely prevented by PEEP and was more prominent when major bronchi were mechanically obstructed with pseudomembrane. Bronchoscopic removal of such pseudomembranes from major bronchi is probably crucial to successful oxygen therapy with PEEP after smoke inhalation injury.

#### PRESENTATIONS

Shimazu T: Effects of PEEP on ventilation-perfusion ratios following smoke inhalation injury in a sheep model. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 2 May 1987.

#### PUBLICATIONS

Shimazu TS, Ikeuchi H, Johnson AA, Hubbard GB, Mason AD Jr, and Pruitt BA Jr: Effects of PEEP on ventilation-perfusion ratios following smoke inhalation injury in a sheep model. In Proceedings of the Nineteenth Annual Meeting of the American Burn Association (Abstract 155), 1987.

Shimazu TS, Yukioka T, Hubbard GB, Langlinais PC, Mason AD Jr, and Pruitt BA Jr: A dose-responsive model of smoke inhalation injury: severity-related alteration in cardiopulmonary function. Ann Surg 206(1):89-98, July 1987.



## REFERENCES

1. Horovitz JH: Diagnostic tools for use in smoke inhalation. J Trauma 21:717-719, 1981.
2. Davies LK, Poulton TJ, and Modell JH: Continuous positive airway pressure is beneficial in treatment of smoke inhalation. Crit Care Med 11:726-729, 1983.
3. Herndon DN, Adams T Jr, Traber LD, and Traber DL: Inhalation injury and positive pressure ventilation in a sheep model. Circ Shock 12:107-113, 1984.
4. Shimazu T, Yukioka T, Hubbard GB, et al: A dose-responsive model of smoke inhalation injury: severity-related alteration in cardiopulmonary function. Ann Surg 206:89-98, 1987.
5. Shimazu T, Yukioka T, Hubbard GB, et al: Inequality of VA/Q ratio following smoke inhalation injury and effects of angiotensin analogues. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1985. San Antonio: US Government Printing Office, 1987, pp 428-444.
6. Shimazu T, Johnson AA Jr, Hubbard GB, et al: Inequality of VA/Q ratio following smoke inhalation injury and effects of angiotensin analogues: time course of VA/Q alterations following smoke inhalation injury in a sheep model. In US Army Institute of Surgical Research Annual Research Progress Report for Fiscal Year 1986 (in press).
7. Wagner PD, Saltzman HA, and West JB: Measurement of continuous distributions of venation-perfusion ratios: theory. J Appl Physiol 36:588-599, 1974.
8. Wagner PD, Naumann PF, and Laravuso RB: Simultaneous measurement of eight foreign gases in blood by gas chromatography. J Appl Physiol 36:600-605, 1974.
9. Shimazu T, Yukioka T, Johnson AA Jr, et al: Multiple inert gas measurement with a gas chromatography mass spectrometer at trace level: application for a gas chromatography-mass spectrometer to the multiple inert gas elimination technique. (Submitted for publication).
10. Burke JF: The sequence of events following smoke inhalation. J Trauma 21:721-722, 1981.
11. Esrig BC, Stephenson SF, and Fulton RL: Role of pulmonary infection in the pathogenesis of smoke inhalation. Surg Forum 26:204-206, 1975.

12. Nunn JF: Applied Respiratory Physiology. 3d ed. London: Butterworth, 1987, pp 417-419.
13. Dantzker DR, Wagner PD, and West JB: Instability of lung units with low VA/Q ratios during O<sub>2</sub> breathing. J Appl Physiol 38: 886-895, 1975.
14. Lampron N, Lemaire F, Teisseire B, et al: Mechanical ventilation with 100% oxygen does not increase intrapulmonary shunt in patients with severe bacterial pneumonia. Am Rev Respir Dis 131:409-413, 1985.
15. Lemaire F, Matamis D, Lampron N, et al: Intrapulmonary shunt is not increased by 100% oxygen ventilation in acute respiratory failure. Bull Eur Physiopathol Respir 21:251-256, 1985.
16. Hart GB, Strauss MB, Lennon PA, and Whitcraft DD 3d: Treatment of smoke inhalation by hyperbaric oxygen. J Emerg Med 3:211-215, 1985.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL	
				DA311499	87 10 01	DD-DRABTARI 636	
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCTY	6 WORK SECURITY	7 REGRADING	8 DISB N INSTR N	9 LEVEL OF SUM A WORK UNIT	
86 10 01	D	U	U		CX		
10 NO. CODES		PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a PRIMARY		1102A	3M161102BS14	BD	306		
b CONTRIBUTING							
c CONTRIBUTING		DA ERDAP, FY88-01					
11 TITLE (Precede with Security Classification Code) (U) Preliminary Studies on Zinc Homeostatic Control and Immunocompetence in a Burned Animal Model							
12 SUBJECT AREAS							
06 01 Biochemistry 6 13 Microbiology							
13 START DATE		14 ESTIMATED COMPLETION DATE		15 FUNDING ORGANIZATION		16 PERFORMANCE METHOD	
86 10		88 09		DA		C	
17 CONTRACT GRANT				18 RELEVANCY CERTIFIED			
a DATE EFFECTIVE		b EXPIRATION DATE		c FISCAL YEARS		d PROFESSIONAL WORK YEARS	
86 10		88 09		87		88	
19 CONTRACT GRANT NUMBER				20 RESOURCES ESTIMATE			
a TYPE				b AMOUNT		c FUNDS (In thousands)	
b KIND OF AWARD				c CUM TOTAL		d	
87				1.8		55	
88				1.8		50	
19 RESPONSIBLE DOD ORGANIZATION				20 PERFORMING ORGANIZATION			
a NAME				a NAME			
US Army Institute of Surgical Research				US Army Institute of Surgical Research			
b ADDRESS (include zip code)				b ADDRESS			
Fort Sam Houston				Fort Sam Houston			
San Antonio, Texas 78234-5012				San Antonio, Texas 78234-5012			
c NAME OF RESPONSIBLE INDIVIDUAL				c NAME OF PRINCIPAL INVESTIGATOR			
PRUITT, B A				SHIPPEE, R L			
d TELEPHONE NUMBER (include area code)				d TELEPHONE NUMBER (include area code)			
512-221-2720				512-221-7138			
21 GENERAL USE				e NAME OF ASSOCIATE INVESTIGATOR (if available)			
FIMA				f NAME OF ASSOCIATE INVESTIGATOR (if available)			
MILITARY CIVILIAN APPLICATION M							
22 KEYWORDS (Precede with Security Classification Code) (U) Thermal Injury; (U) Zinc Homeostasis; (U) Immunocompetence; (U) Lab Animals; (U) Rats; (U) RAB							
23 TECHNICAL OBJECTIVE 24 APPROACH 25 PROGRESS (Precede text of each with Security Classification Code)							
<p>23. (U) The main objective of this research is to determine the changes in zinc metabolism caused by burn and infection in a murine model. The study is designed to study the effect of injury on physiological control mechanisms at the whole body, organ, and molecular levels. Information obtained from these studies will be provide a better understanding of the postinjury changes in the metabolism of this important trace element and the role of these changes in septic complications, ultimately leading to the development of optimal supplementation of zinc in burned humans. A literature search was conducted.</p> <p>24. (U) A semi-purified, zinc-deficient (40.5 ppm) diet was fed to adult rats. The effect of zinc nutriture was studied by subcutaneously injecting either saline or 1 mg Zn/kg to create a zinc-deficient or zinc-sufficient status, respectively. The zinc-deficient and sufficient groups were further divided into nonburn and burn groups. The burn groups received a 30% total body surface scald burn.</p> <p>25. (U) 8610 - 8709. Previous studies with this model have shown that no significant increases in endogenous fecal and urine excretion were detected during the first 10 days postburn. Burn injury and burn injury plus zinc deficiency caused a decrease in total peripheral blood T-cells. However, the burn zinc-deficient animals showed an increase in T-suppressor cell populations and an increase in T-suppressor cell populations while the burn zinc-sufficient animals were comparable with the</p>							

DD FORM 1498  
23 MAR

EDITION OF MAR 68 IS OBSOLETE

GPO 1988-441-003/50324

CONTINUATION OF DD FORM 1498 FOR "PRELIMINARY STUDIES ON ZINC HOMEOSTATIC CONTROL AND IMMUNOCOMPETENCE IN A BURNED ANIMAL MODEL"

control/zinc-sufficient and control/zinc-deficient animals. Recent studies have used this model to determine the effect of zinc nutriture and burn injury on antibody response in the rat. This study has shown that there is an increase in antibody response due to burn injury in the zinc-sufficient animals. This response was suppressed in the burn/zinc-deficient rats. This study demonstrated a modulating effect of zinc nutriture on various aspects of the immunological system after burn injury.

<b>RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY</b>				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL	
					87 10 01	DD-DRA (IAR) 636	
3 DATE REV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCTY	6 WORK SECURITY	7 REGRADING	8 DISB'N INSTR'N	9 LEVEL OF SUM A WORK UNIT	
NONE	A	U	U		CX		
10 NO CODES		PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a PRIMARY		01102A	3M161102BS14	BD	307		
b CONTRIBUTING NO							
c CONTRIBUTING		DA LKRDAP, FY88-01					
11 TITLE Precede with Security Classification Code (U) Evaluation of Serum Visceral Protein Levels as Indicators of Nitrogen Balance in Thermally Injured Patients							
12 SUBJECT AREAS							
16 15 Medicine and Medical Research 16 04 Anatomy and Physiology							
13 START DATE		14 ESTIMATED COMPLETION DATE		15 FUNDING ORGANIZATION		16 PERFORMANCE METHOD	
87 12		89 09		DA		C	
17 CONTRACT GRANT				18 RELEVANCY CERTIFIED			
a DATE EFFECTIVE		b EXPIRATION DATE		c FISCAL YEARS		d PROFESSIONAL WORK YEARS	
87 12		89 09		87 88		0 0.5	
b CONTRACT GRANT NUMBER				e FUNDS (in thousands)			
				0 30			
c TYPE		d AMOUNT		e CUM TOTAL			
87		0.0		88		0.5	
19 RESPONSIBLE DCD ORGANIZATION				20 PERFORMING ORGANIZATION			
a NAME				a NAME			
US Army Institute of Surgical Research				US Army Institute of Surgical Research			
b ADDRESS (include zip code)				b ADDRESS			
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012			
c NAME OF RESPONSIBLE INDIVIDUAL				c NAME OF PRINCIPAL INVESTIGATOR			
BRUITT, B A				CARLSON, D			
d TELEPHONE NUMBER (include area code)				d TELEPHONE NUMBER (include area code)			
512-221-2720				512-221-6532			
21 GENERAL USE				f NAME OF ASSOCIATE INVESTIGATOR (if available)			
FINA				CIOFFI, W G			
MILITARY/CIVILIAN APPLICATION M				g NAME OF ASSOCIATE INVESTIGATOR (if available)			
22 KEYWORDS Precede EACH with Security Classification Code (U) Nitrogen Balance; (U) Serum Visceral Protein; (U) Albumin; (U) Transferrin; (U) Retinol-Binding Protein;							
23 TECHNICAL SUBJECTS 24 APPROACH 25 PROGRESS Precede text of each with Security Classification Code							
23. (Continued) (U) Volunteers; (U) RAIF.							
24. (U) The purpose of this study is to assess whether albumin, pre-albumin, transferrin, or retinol-binding protein can be used indicators of nitrogen balance in burned soldiers. A literature search was conducted.							
25. (U) Baseline serum visceral protein levels will be measured on postburn day 3 following stabilization of the patient's fluid status. Serum levels will be repeated every 3 days until postburn day 30. Changes from baseline level will be correlated with nitrogen balance.							
26. (U) 8610 - 8709. This project was approved as a minimal risk protocol by the US Army Institute of Surgical Research Human Use Committee on 11 September 1987.							

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1. AGENCY ACCESSION	2. DATE OF SUMMARY	REPORT CONTROL SYMBOL
				DA312335	87 10 01	DD-DR&BIAR) 636
3. DATE PREV. SUMMARY	4. KIND OF SUMMARY	5. SUMMARY SCTY	6. WORK SECURITY	7. REGRADING	8. DISB'N INSTR'N	9. LEVEL OF SUM A. WORK UNIT
87 01 14	D	U	U		CX	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY	61101A	3A161101A91C	00	075		
b. CONTRIBUTING						
c. CONTRIBUTING	NONE					
11. TITLE (Precede with Security Classification Code) (U) Effect of Growth Factors on the Healing of Partial-Thickness Scald Wounds in the Guinea Pig						
12. SUBJECT AREAS						
06 05 Medicine and Medical Research 06 04 Anatomy and Physiology						
13. START DATE	14. ESTIMATED COMPLETION DATE		15. FUNDING ORGANIZATION	16. PERFORMANCE METHOD		
87 01	89 09		DA	C		
17. CONTRACT GRANT NUMBER				18. RELEVANCY CERTIFIED		
a. DATE EFFECTIVE				b. EXPIRATION DATE		
b. CONTRACT GRANT NUMBER				c. RESOURCES ESTIMATE		
				FISCAL YEARS		
c. TYPE				a. PROFESSIONAL WORK YEARS		
d. AMOUNT				b. FUNDS (In thousands)		
e. KIND OF AWARD				f. CUM/TOTAL		
				87 0.2 3		
				88 0.2 5		
19. RESPONSIBLE DOD ORGANIZATION				20. PERFORMING ORGANIZATION		
a. NAME				a. NAME		
US Army Institute of Surgical Research				US Army Institute of Surgical Institute		
b. ADDRESS (include zip code)				b. ADDRESS		
Fort Sam Houston				Fort Sam Houston		
San Antonio, Texas 78234-5012				San Antonio, Texas 78234-5012		
c. NAME OF RESPONSIBLE INDIVIDUAL				c. NAME OF PRINCIPAL INVESTIGATOR		
FRUITT, B A				CIOFFI, W G		
d. TELEPHONE NUMBER (include area code)				d. TELEPHONE NUMBER (include area code)		
512-221-2720				512-221-4440		
21. GENERAL USE				f. NAME OF ASSOCIATE INVESTIGATOR (if available)		
FINA				g. NAME OF ASSOCIATE INVESTIGATOR (if available)		
MILITARY/CIVILIAN APPLICATION: M						
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Epidermal Growth Factor; (U) Fibroblast Growth Factor; (U) Platelet-Derived Growth Factor; (U) Epithelization;						
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)						
22. (Continued) (U) Thermal Injury; (U) Lab Animals: (U) Guinea Pigs; (U) ILIR; (U) RAI						
23. (U) Epidermal growth factor (EGF), initially isolated from the submaxillary gland of mice and subsequently identified in human urine, has been shown to increase the rate of endothelial and epithelial proliferation. Fibroblast growth factor (FGF), originally noted for its mitogenic effect on fibroblast, has recently been found to have potent angiogenic properties. Platelet-derived growth factor (PDGF) appears to have a variety of properties, one of which is stimulation of epithelization. The purpose of this study is to determine whether these three growth factors can enhance burn epithelization in a partial-thickness burn wound in guinea pigs. A literature search was conducted.						
24. (U) Male guinea pigs weighing 440-500 g will receive a deep partial-thickness burn. The burn wound edges will be tattooed. Four groups of 40 animals each will be studied. Group I will serve as control, Group II will receive EGF, Group III will receive FGF, and Group IV will receive PDGF. Group I animals will receive 0.5 cc of lanolin cream applied to the burn wound twice daily. Groups II, III, and IV will receive 0.5 cc of EGF, FGF, and PDGF, respectively, in a lanolin cream applied twice daily to the burn wound. Wounds will be measured daily for assessment of contraction. On postburn days 5 and 10, 5 animals in each group will be sacrificed and 15 animals in each group will be sacrificed on postburn days						

DD FORM 1498  
83 MAR

EDITION OF MAR 68 IS OBSOLETE.

• USGPO 1986-491-003/50329

CONTINUATION OF DD FORM 1498 FOR "EFFECT OF GROWTH FACTORS ON THE HEALING OF PARTIAL-THICKNESS SCALD WOUNDS IN THE GUINEA PIG"

20 and 30. At the time of sacrifice, the extent of healing by contraction will be assessed utilizing a planimeter and the extent of reepithelization will be assessed histologically.

25. 8610 - 8709. (U) This project was approved by the US Army Institute of Surgical Research Animal Care and Use Committee on 14 January 1987. Progress on this study has been delayed. First, the Amgen Corporation has been unable to supply a stable form of either FGF or PDGF in a lanolin cream. The Amgen Corporation is currently trying to derive a stable formulation of both compounds. Secondly, the animal care facilities at this Institute are currently unable to handle a large number of animals due to renovation. The renovation of the facilities is expected to be completed by 1 October 1987. When these problems are solved, the project will begin.

<b>RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY</b>				1. AGENCY ACCESSION DA311488	2. DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR&S(AR) 636	
3. DATE PREV SUMMARY 86 10 01	4. KIND OF SUMMARY D	5. SUMMARY SCTY U	6. WORK SECURITY U	7. REGRADING	8. DISB'N INSTR'N CX	9. LEVEL OF SUM A. WORK UNIT	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a. PRIMARY	61101A	3A161101A91C	00	076			
b. CONTRIBUTING							
c. CONTRIBUTING	NONE						
11. TITLE (Precede with Security Classification Code) (U) Cellular Host Defense Function After Thermal Injury: Assessment by Flow Cytometry of Peripheral Blood Cells							
12. SUBJECT AREAS 06 01 Biochemistry 06 05 Medicine and Medical Research							
13. START DATE 86 05	14. ESTIMATED COMPLETION DATE 90 09	15. FUNDING ORGANIZATION DA	16. PERFORMANCE METHOD C				
17. CONTRACT GRANT NUMBER a. DATE EFFECTIVE APR 87 b. FISCAL YEARS c. PROFESSIONAL WORK YEARS d. FUNDS (In thousands)							
18. RELEVANCY CERTIFIED				18. RESOURCES ESTIMATE			
c. TYPE				87	0.4	35	
d. AMOUNT				88	1.5	50	
e. KIND OF AWARD				f. CUM. TOTAL			
19. RESPONSIBLE DOD ORGANIZATION				20. PERFORMING ORGANIZATION			
a. NAME US Army Institute of Surgical Research				a. NAME US Army Institute of Surgical Research			
b. ADDRESS (include zip code) Fort Sam Houston San Antonio, Texas 78234-5012				b. ADDRESS Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL PRUITT, B A				c. NAME OF PRINCIPAL INVESTIGATOR BURLESON, D G			
d. TELEPHONE NUMBER (include area code) 512-221-2720				d. TELEPHONE NUMBER (include area code) 512-221-7138			
21. GENERAL USE FINA MILITARY/CIVILIAN APPLICATION: M				f. NAME OF ASSOCIATE INVESTIGATOR (if available) MASON, A D g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Flow Cytometry; (U) Lymphocyte Subpopulations; (U) Burn Injury; (U) Infection; (U) Immunocompetence;							
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)							
22. (U) Volunteers; (U) ILIR; (U) RAI							
23. (U) The objectives of this study are to develop methods to analyze the complex leukocyte mixtures seen in the blood of burn patients, to quantitate the changes in cell morphology and function that occur, and to correlate those findings with the clinical outcome of the patient. The ultimate goal is to develop tests for effective diagnosis of infection susceptibility and evaluation of the effectiveness of new treatment modalities. A literature search was conducted.							
24. (U) The development of techniques for assessing immune status of burn patients will focus on the evaluation of lymphocyte subpopulations composition and function. The resolving power of the flow cytometer will be used to differentiate the lymphocyte subpopulations. Five measurements will be made on each cell simultaneously, consisting of two light scatter measurements or physical properties and three subpopulation or functional markers. The multiparameter analysis will be correlated with patient mortality and morbidity and compared to parameters measured on control subjects. Abnormal lymphocyte subset composition or function that correlates with patient outcome will be analyzed in more detail for efficacy as a clinical diagnostic tool and as a probe to determine how the abnormality is related to the defect in host defense.							



CONTINUATION OF DD FORM 1498 FOR "CELLULAR HOST DEFENSE  
FUNCTION AFTER THERMAL INJURY: ASSESSMENT BY FLOW CYTOMETRY OF  
PERIPHERAL BLOOD CELLS"

25. (U) 8610 - 8709. Detecting surface markers for relatively small populations has been particularly difficult because of contaminating blood leukocytes. A panel of monoclonal reagents was surveyed to find one marker with specificity to immature granulocytes and monocytes in patient lymphocyte preparations. One reagent was found with a strong specificity against monocyte antigen and a weak affinity for myelocytic cells. A scatter discriminates between the contaminating cells and the cells of interest. Data has been collected on 66 patients and is now undergoing detailed analysis. Preliminary analysis of the data indicates there is a general decrease (10-30%) in the T lymphocyte subpopulations in burn patients as compared to unburned controls. The proportion of B lymphocytes, NK cells, and monocytes were unchanged, indicating there was an increase in the proportion of cells with no distinguishable antigens in the blood of burn patients and this proportion of "null" cells was higher in those patients who did not survive their injury. Further, patients who died had significantly decreased (10-35%) proportions of T lymphocyte subpopulations as compared to those who survived. The proportion of lymphocytes of the "suppressor" subset were depressed (35%) even more than those of the "helper" subset (24%) as compared to the subsets in surviving patients.

**ANNUAL RESEARCH PROGRESS REPORT**

**PROJECT NUMBER:** 3A161101A91C-00, IN-HOUSE LABORATORY  
INDEPENDENT RESEARCH

**PROJECT TITLE:** CELLULAR HOST DEFENSE FUNCTION AFTER THERMAL  
INJURY: ASSESSMENT BY FLOW CYTOMETRY OF  
PERIPHERAL BLOOD CELLS

**US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5017**

**1 October 1986 - 30 September 1987**

**INVESTIGATORS**

David G. Burleson, PhD, Lieutenant Colonel, MS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

## ABSTRACT

**PROJECT NUMBER:** 3A161101A91C-00, IN-HOUSE LABORATORY  
INDEPENDENT RESEARCH

**PROJECT TITLE:** CELLULAR HOST DEFENSE FUNCTION AFTER THERMAL  
INJURY: ASSESSMENT BY FLOW CYTOMETRY OF  
PERIPHERAL BLOOD CELLS

**INSTITUTION:** US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

**PERIOD COVERED IN THIS REPORT:** 1 Oct 86 through 30 Sep 87

**INVESTIGATORS:** David G. Burleson, PhD, Lieutenant Colonel, MS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

Changes in lymphocyte phenotype that may be related to the defect in host resistance in burned patients were measured by flow cytometry. Purified lymphocyte preparations from 33 burn patients and 33 controls were analyzed for T lymphocyte and non-T lymphocyte subpopulation antigens. The proportion of all subpopulations of T lymphocytes (Leu-4, Leu-2, and Leu-3) were decreased in burn patients as compared to controls. The decrease in T lymphocyte subpopulations caused an increase in the proportion of B cells, but the proportion of all other non-T cell subpopulations was unchanged. Absolute numbers of circulating T lymphocytes were also decreased in burn patients as compared to controls, while absolute numbers of non-T cells remained unchanged. The proportion of T lymphocyte subpopulations in those patients who died were decreased further than in the patients who survived their injury. There were no differences between non-T cell subpopulations in the survivors and nonsurvivors. When viewed as a function of postburn day, subpopulations of helper and suppressor lymphocytes were decreased soon after injury. The subpopulations continued to decrease for those patients who died and gradually returned to normal for those patients who recovered. The ratio of helper lymphocytes to suppressor lymphocytes did not differ for controls, patients who died, or patients who survived.

## CELLULAR HOST DEFENSE FUNCTION AFTER THERMAL INJURY: ASSESSMENT BY FLOW CYTOMETRY OF PERIPHERAL BLOOD CELLS

Changes in function and phenotype of circulating leukocytes may be related to the defect in host resistance underlying the increased susceptibility of burn patients to opportunistic infection. Among the changes frequently reported in burn patients are decreased cell-mediated immune reactions, expressed as a reduced capacity to reject allogeneic skin grafts (1-3), and impaired response to delayed hypersensitivity antigens (4). The component of the host defense system responsible for cell-mediated immunity responses are T lymphocytes. The relationship between depression of T cell function and susceptibility to opportunistic infection remains unclear.

We have investigated the phenotype of circulating lymphocyte subpopulations after burn injury and compared them to unburned controls. The proportion of both of the major subpopulations of T lymphocytes are decreased in burn patients soon after injury and remain decreased for several weeks after injury. Absolute numbers of non-T cells remained at levels comparable to unburned controls. Further, patients that died had a greater decrease in the proportion of their T cell subpopulations than those who lived. The absolute number of non-T cell subpopulations was unchanged between the two groups, but the proportion of B cells in the lymphocyte preparations increased as the T lymphocytes decreased.

### MATERIALS AND METHODS

Lymphocyte subpopulations were measured in 33 burn patients and 33 unburned controls. All patients in this study were admitted during the first 5 days postinjury and had expected mortalities between 20 and 90%. The average burn size was 44.5% and average age 43.4 yr. The expected mortality for the group, based on previous experience at this Institute, was 50.9%. Peripheral blood samples were obtained twice weekly for up to 8 wk postburn for assessment of cell number, cell subpopulations, and morphology. The controls were sampled at random for comparison.

Fresh whole blood was diluted 1:3 with HBSS (Gibco Laboratories, Life Technologies, Inc.) containing 5 mg of EDTA and 1 g bovine serum albumin (BSA) per liter. Lymphocytes were purified by adding a layer of 8 ml diluted whole blood over 4 ml of Ficoll-Hypaque (Pharmacia Fine Chemicals, Inc.). The gradients were centrifuged for 30 min at 450 g at 15°C. Cells were harvested from the Ficoll-Hypaque interface and washed 3X with HBSS. Slides for differential analysis were made by placing cells ( $5 \times 10^5$  in 0.5 ml) in a cytocentrifuge (Shandon), spun at 400 rpm for 4 min, stained with Wright's stain, and evaluated to determine the purity of the cell

suspension. The remaining cells were suspended in 1 ml HBSS and 2 ml of a lysing solution (4.15 g  $\text{NH}_4\text{Cl}$ , 0.5 g  $\text{KHCO}_3$ , and 0.185 g  $(\text{NH}_4)_2\text{EDTA/L}$ ) to lyse any contaminating red blood cells. After a 15-min incubation, the lysed cell suspension was underlaid with a cushion of 0.8 ml of fetal bovine serum and centrifuged for 10 min at 200 g at 15°C.

The cells were resuspended in HBSS at a concentration of  $1 \times 10^7$  cells/ml and 25  $\mu\text{l}$  of the cell suspension was added to a sample tube for staining with monoclonal antibody. The cells were stained with up to 3 monoclonal antibodies in a sequential fashion. An unstained monoclonal antibody was added, the cells were incubated for 15 min at 5°C and washed with HBSS. Goat anti-mouse IgG (Fab2' fragments, 25  $\mu\text{l}$  diluted 1:40 with HBSS) labelled with Texas Red was added, incubated for 15 min, and the cells washed. Normal mouse serum (5  $\mu\text{l}$ ) was added to prevent cross-reaction of primary conjugated monoclonal antibodies with the goat anti-mouse Texas Red. Monoclonal antibodies labelled with phycoerythrin and with fluorescein (Becton-Dickinson, Inc.) were added and the cell suspensions were washed twice and fixed by adding 400  $\mu\text{l}$  of 2% paraformaldehyde and HBSS.

Cells were analyzed on either a FACS 400 flow cytometer modified by the addition of a third analysis channel and a Consort 40 data analysis system (Becton-Dickinson, Inc.) or a Coulter EPICS model 753 flow cytometer (Coulter Electronics, EPICS Division). Data analysis was performed by a student's t-test using program P7D from BMDP(UCLA) on a VAX 11-780 computer (DEC).

## RESULTS

The changes in the number and morphology of circulating leukocytes following thermal injury are quite dramatic. Shortly after injury, burn patients become leukocytotic and lymphopenic (5). Most of the cells are granulocytes, many being immature or otherwise abnormal. This combined leukocytosis and lymphopenia make separation of lymphocytes for analysis difficult. Ficoll-Hypaque density gradients separate PMN and RBC from lymphocytes by density, the heavier PMN and RBC settling to the bottom of the tube while the less dense mononuclear cells staying at the blood:gradient interface. In normals, this results in a preparation containing about 90% lymphocytes. In burn patients, however, abnormal PMN with densities similar to lymphocytes significantly contaminate the lymphocyte preparation.

Measurement of immune function or cell phenotype requires a pure cell population on which to make measurements. Obtaining pure lymphocyte populations from burn patients would involve physical or antibody panning separation techniques in addition to density gradient separation. Every purification procedure has the potential to introduce artifacts in subsequent

measurements. To avoid this problem and the artifacts that might be introduced by extensive physical separation techniques, we used flow cytometry to measure lymphocyte subpopulations. Flow cytometry examines cells individually in a sequential fashion so that each cell can be analyzed independently of all the other cells in the preparation. Lymphocytes can be distinguished from monocytes and PMN by measuring light scatter intensity at forward and 90° angles. Lymphocyte subpopulations were resolved by the addition of subset specific monoclonal antibodies bound to fluorescent dyes and determining the proportion of the lymphocytes binding the monoclonal antibody marker.

A summary of the results of the proportions of T lymphocyte subpopulations determined in peripheral blood from burn patients and controls is shown in Figure 1. The proportion of T cells (as measured by the Pan-T cell markers, Leu-1, Leu-4 and Leu-5) as well as the helper and suppressor/cytotoxic subsets (Leu-3 and Leu-2, respectively) were reduced in burn patients. The proportion of positive lymphocytes in the samples does not relate directly to the number of positive cells in the circulation since the lymphocytes are concentrated in the Ficoll-Hypaque purification. To represent these subpopulations as the absolute numbers of cells per unit of whole blood, it is assumed that the cells isolated from the gradient are a true representation of those in the circulation. The peripheral blood concentration of a subpopulation of cells is then given by.

$$\frac{\text{Positive Cells}}{\text{nl Whole Blood}} = \text{WBC} \times \frac{\% \text{ Lymphs}}{100} \times \frac{\% \text{ Positive}}{100}$$

where WBC is the whole WBC in cells/nl and % lymph is the percentage of lymphocytes determined from the whole blood differential and % positive is the percent positive cells passing through the "lymphocyte" light scatter gate. The comparison between control and burn patients after this transformation is shown in Figure 2. The difference in T cell subpopulations between the two groups was even greater than when compared as percent positive. The concentration of all the T lymphocyte subpopulations measured in whole blood were significantly decreased in the burn patients as compared to controls.

Several other lymphocyte markers were also tested, Leu-12 (B cells) and Leu-M3 (monocytes), which mark exclusively non-T cells, and Leu-11 (NK cells), Leu-7 (large granular lymphocytes), and Leu-15 (complement III receptor), which have a limited cross-reactivity with some T cells. As shown in Figure 3, there was a decrease only in the proportion of B lymphocytes. All the other non-T subpopulations were unchanged from the percent positive levels found in controls. There was no difference in any of the non-T cell subpopulations when the absolute number of positive cells per nl of whole blood were




FIGURE 1. T lymphocyte subpopulations from the blood of burned patients and controls. Values shown are mean % positive cells  $\pm$ SEM of controls and burn patients. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .




FIGURE 2. T lymphocyte subpopulations from the blood of burned patients and controls. Values shown are mean positive cells/nl of whole blood  $\pm$ SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .






FIGURE 3. Non-T cell subpopulations from the blood of burned patients and controls. Values shown are mean % positive cells  $\pm$ SEM of controls and burn patients. \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ .

compared for patients and controls (Fig 4). Since the proportion of T lymphocytes decreased sharply and the proportion of non T cells remained relatively constant, there must have been an increase in "null" cells having none of the common antigens that were tested.

The patients were further divided into two groups based on mortality. Patients who died had decreased T cell subpopulations as compared to those who lived as shown in Figure 5. Survivors had decreased T lymphocytes as compared to unburned controls, but the nonsurvivors had greater decreases in these subpopulations. There was no difference in non-T cell subpopulations between survivors and nonsurvivors (Fig 6).

The data were analyzed with respect to the change in T lymphocyte subpopulations over time. Figure 7 shows the data depicted as percent Leu-2 positive cells with respect to postburn day for survivors and nonsurvivors. The mean for the surviving patients is plotted along with the mean for the nonsurvivors up to postburn day 30. Both survivors and nonsurvivors had decreased suppressor/cytotoxic T subpopulations soon after burn injury. The mean for nonsurvivors was less than that for survivors after the first few days postburn. The mean for nonsurviving patients continued to decrease with increasing postburn day, while that for survivors increased after the third wk postburn. A similar pattern is depicted in Figure 8 for the helper (Leu-3 positive) T cell subpopulation, although the differences between survivors and nonsurvivors was not as great as for the suppressor/cytotoxic subpopulation.

The ratio of the percent positive helper T lymphocytes (Leu-3 positives) and the percent suppressor/cytotoxic T lymphocytes (Leu-2) positives was also determined and the ratios for survivors, nonsurvivors, and unburned controls are compared in Table 1. There was no significant difference between the helper/suppressor ratio for any of the three groups. Although the helper subpopulations were decreased in

TABLE 1. Helper/Suppressor Ratios (Mean  $\pm$  SD)

Comparison	Control Patients		Burn Patients		P Value
	Number	Average	Number	Average	
Control vs. Burn	289	2.07 $\pm$ 1.69	286	2.09 $\pm$ 1.59	NS
	Survivors		Nonsurvivors		P Value
	Number	Average	Number	Average	
Lived vs. Died	251	1.97 $\pm$ 1.54	35	2.92 $\pm$ 1.77	.0043




FIGURE 4. Non-T cell subpopulations from the blood of burned patients and controls. Values shown are mean positive cells/nl of whole blood  $\pm$ SEM of controls and burn patients. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .




FIGURE 5. Comparison of T lymphocyte subpopulations for survivors and nonsurvivors. Values shown are mean % positive cells  $\pm$  SEM of each group. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .




FIGURE 6. Comparison of non-T cell subpopulations for survivors and nonsurvivors. Values shown are mean  $\pm$  SEM of each group. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .




FIGURE 7. Comparison of Leu-2 & positive cells for survivors and nonsurvivors as a function of postburn day. Values shown are moving mean & positive values for 7 days past the postburn day indicated  $\pm$ SEM. The control mean values SEM for Leu-2 & positive are shown as a background bar.




FIGURE 8. Comparison of Leu-3 & positive cells for survivors and nonsurvivors as a function of postburn day. Values shown are moving mean & positive values for 7 days past the postburn day indicated  $\pm$ SEM. The control mean values SEM for Leu-3 & positive are shown as a background bar.

the burned groups, the suppressor subpopulations were decreased by a similar amount and the mean ratios did not change.

### DISCUSSION

The relative proportion of helper to suppressor cells (termed the helper/suppressor ratio) has been used as a measure of immunosuppression. Antonacci and coworkers at Cornell (6) as well as McIrvine and coworkers in Boston (7) have reported a decreased helper/suppressor ratio in burn patients as compared to normal controls, and the ratio could be related to mortality in one study (7). We have demonstrated no difference in the helper suppressor ratio between burn patients and unburned controls. Further, there was no difference in ratio between surviving and nonsurviving patients. The reasons for the difference between the results of those studies and the present study are not known. One of the studies was done by fluorescence microscopy rather than flow cytometry. Both studies were done on substantially smaller patient populations than the present study. The reason for the change in the ratio in the other two studies was a selective decrease in helper cells as compared to the cells of the suppressor/cytotoxic subpopulation, whereas in our study there was a substantial decrease in both subpopulations.

We observed a selective decrease in all major T lymphocyte subpopulations in burn patients and a greater decrease in nonsurviving than in surviving patients. As a result, there was an increased proportion of cells of unknown phenotype or "null" cells. It is possible that the decreased cell-mediated immunity and increased infection susceptibility of the burn patients are related to the decreased numbers of T cells in the circulation. The decrease in the number of T cells may decrease the number of functional effectors (helper, helper/inducer, or cytotoxic lymphocytes) able to respond to an infection challenge.

The nature of the "null" cells is unknown but several possibilities exist, i.e., they could be "activated" cells that have shed their normal antigens, nonlymphoid cells contaminating the sample because they were not eliminated from analysis by the light scatter "lymphocyte window," immature cells that have not developed detectable markers, or cells of currently undefined specificity and function. Whatever their phenotype, they may represent active "suppressors" of the host response or merely cells of limited function that cannot respond appropriately. Although it is important to enumerate the cells of each subset, information about cell function may be more critical to evaluating host defense. Our future efforts will endeavour to measure cell function as well as cell phenotype.



### PRESENTATIONS/PUBLICATIONS

Burleson DG: A system for batch processing positive calculations from multiparameter flow cytometry list mode data. Presented at the Second Annual Coulter Users Meeting and Immunology Symposium, San Francisco, California, 2-5 December 1986.

Burleson DG: Anti-LeuM3 as an adjunct to accurately identify minor lymphocyte subpopulations in burn patients. Presented at the Conference on Immune Consequences of Thermal Traumatic Injuries, Snowbird, Utah, 20-24 January 1987.

### REFERENCES

1. Polk HC: Prolongation of xenograft survival in patients with Pseudomonas sepsis: a clarification. Surg Forum 19:514-515, 1968.
2. Kay GD: Prolonged survival of a skin homograft in a patient with very extensive burns. Ann NY Acad Sci 64:767-774, 1957.
3. Ninnemann JL, Fisher JC, and Frank HA: Prolonged survival of human skin allografts following thermal injury. Transplantation 25:69-72, 1978.
4. Wolfe JHN, Wu AVO, O'Connor NE, et al: Anergy, immunosuppressive serum, and impaired lymphocyte blastogenesis in burn patients. Arch Surg 117:1266-1271, 1982.
5. Sevitt S: Changes in white cells, platelets, and clotting factors. In: Burns: Pathology and Therapeutic Applications. London: Butterworth, 1957, pp 220-228.
6. Antonacci AC, Reaves LE, Calvano SE, et al: Flow cytometric analysis of lymphocyte subpopulations after thermal injury in human beings. Surg Gynecol Obstet 159:1-8, 1984.
7. McIrvine AJ, O'Mahony JB, Saporoschetz I, et al: Depressed immune function in burn patients: use of monoclonal antibodies and functional assays to define the role of suppressor cells. Ann Surg 196:297-304, 1982.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL
				DA311489	87 10 01	DD-DR&B(AR) 636
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SET	6 WORK SECURITY	7 REGRADING	8 D.S.B.N INSTR N	9 LEVEL OF SUM A WORK UNIT
					CX	
10 NO CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
1. PRIMARY	0110A	DA311489101010	00	077		
2. CONTRIBUTING						
3. CONTRIBUTING						
11 TITLE (Precede with Security Classification Code.) (U) A Study of Biochemical Changes in the Cellular Environment of Tissue of the in vivo Partial-Thickness Rat Burn Wound						
12 SUBJECT AREAS						
13. 15. Chemistry 16. 04 Anatomy and Physiology						
13 START DATE	14 EST MATED COMPLETION DATE	15 FUNDING ORGANIZATION	16 PERFORMANCE METHOD			
87 09	89 09	DA	C			
17 CONTRACT GRANT/AGENCY RELEVANCY CERTIFIED						
18 DATE EFFECTIVE	19 EXPIRATION DATE	20 FISCAL YEARS	21 PROFESSIONAL WORK YEARS	22 FUNDS (in thousands)		
23 CONTRACT GRANT NUMBER		24 TYPE	25 AMOUNT	26 KIND OF AWARD		
			87	0.7		
			88	1.0		
				30		
				50		
27 RESPONSIBLE DOD ORGANIZATION				28 PERFORMING ORGANIZATION		
a. NAME				a. NAME		
US Army Institute of Surgical Research				US Army Institute of Surgical Research		
b. ADDRESS (include ZIP code)				b. ADDRESS		
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012		
c. NAME OF RESPONSIBLE INDIVIDUAL				c. NAME OF PRINCIPAL INVESTIGATOR		
BROWN, W L				BROWN, W L		
d. TELEPHONE NUMBER (include area code)				d. TELEPHONE NUMBER (include area code)		
512-221-4652				512-221-4652		
29 GENERAL USE				f. NAME OF ASSOCIATE INVESTIGATOR (if available)		
FINA				MASON, A D		
MILITARY/CIVILIAN APPLICATION				g. NAME OF ASSOCIATE INVESTIGATOR (if available)		
M						
23 KEYWORDS (Precede EACH with Security Classification Code) (U) Burn Wound Metabolism; (U) Edema; (U) Burn Injury; (U) Lab Animals; (U) Rats; (U) ILIR; (U) RAIL						
24 TECHNICAL OBJECTIVE 24 APPROACH 25 PROGRESS (Precede text of each with Security Classification Code)						
<p>23. (U) The purpose of study study is to determine biochemical and metabolic changes that occur in the in vivo partial-thickness rat burn wound during the early postburn period which might be deleterious to recovery of function in cells in which thermal injury was potentially reversible. Cellular injury due to short episodes of ischemia in heart, liver, muscle, and brain is reversible but becomes irreversible when ischemia and local tissue acidosis is prolonged. If this same sequence of events is found to occur in the in vivo rat burn wound, it may be possible to block or reverse the metabolic changes and limit the progression in the size and degree of injury in wounds of burned soldiers. A literature search was conducted.</p> <p>24. (U) Microelectrodes will be used to measure changes in extracellular potassium ion content and in pH and/or carbon dioxide partial pressure at various sites in the in vivo burn wound. Samples from sites adjacent to the microelectrodes will be taken to measure selected metabolites using enzymatic methods. Cells and subcellular organelles will be isolated by centrifugation in self-generating gradients or Percoll for measurement of changes in cellular function with time postburn.</p> <p>25. (U) 3610 - 3709. Wet and dry weights of 20% total body surface area sham wounds and partial-thickness burn wounds of 180-200 g rats were measured at intervals from 1 to 48 h postburn. The water content of the burn wound increased at the same rate and in the same volume as had</p>						

DD FORM 1498  
10 MAR

EDITION OF MAR 68 IS OBSOLETE

CONTINUATION OF DD FORM 1498 FOR "A STUDY OF BIOCHEMICAL CHANGES IN THE CELLULAR ENVIRONMENT OF TISSUE OF THE in vivo PARTIAL-THICKNESS RAT BURN WOUND"

previously been observed in full-thickness 20% total body surface area scald burn wounds during the first 6 to 9 h postburn. Afterwards, however, during the period in which the full-thickness burns exhibited a further increase in the rate of water accumulation, the partial-thickness burn wound water content gradually decreased from a peak of 6.5 to 7 ml excess water to approximately 1 ml excess water at 48 h postburn. Sham wound water content was approximately 5 g throughout the 48-h period.

Tissue pH was measured in sham and burn wounds at times from 1 to 48 h postburn. Needle pH microelectrodes and glass reference microelectrodes were inserted through a slit in the wound tissue to the depth of the panniculus carnosus. Tissue pH was recorded when the pH meter indicated stable electrode readings. The pH of the sham wound tissue ranged from 7.44 to 7.13 over the 48-h postburn period. The pH of burn wounds decreased from 7.41 at 1 h postburn to a low of 6.76 at 12 h postburn; from 18 to 48 h postburn, the burn wound pH was approximately 6.9.

Some measurements of tissue carbon dioxide partial pressure were made at the same sites using a combination carbon dioxide microelectrode. In the occluded artery ischemic heart model, it has been shown that the decrease in tissue pH and the increase in tissue carbon dioxide partial pressure correlate very well. However, in the burn wounds in which pH had decreased, measured carbon dioxide partial pressure was lower than in sham wounds, indicating that the decrease in pH was due to the presence of acidic compounds other than carbon dioxide. More analyses will have to be performed to determine if these changes are statistically significant. When that has been completed, samples will be taken from wounds to measure selected metabolites using enzymatic methods. Subsequently, if indicated, cells will be isolated to determine whether changes in cellular function occur with time postburn.

ANNUAL RESEARCH PROGRESS REPORT

PROJECT NUMBER: 3A161101A91C-C0, IN-HOUSE LABORATORY  
INDEPENDENT RESEARCH

PROJECT TITLE: A STUDY OF BIOCHEMICAL CHANGES IN THE CELLULAR  
ENVIRONMENT OF TISSUE OF THE in vivo  
PARTIAL-THICKNESS RAT BURN WOUND

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

1 October 1986 - 30 September 1987

INVESTIGATORS

Wanda L. Brown, MS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

# ABSTRACT

PROJECT NUMBER: 3A161101A91C-00, IN-HOUSE LABORATORY  
INDEPENDENT RESEARCH

PROJECT TITLE: A STUDY OF BIOCHEMICAL CHANGES IN THE CELLULAR  
ENVIRONMENT OF TISSUE OF THE in vivo  
PARTIAL-THICKNESS RAT BURN WOUND

INSTITUTION: US Army Institute of Surgical Research, Fort Sam  
Houston, San Antonio, Texas 78234-5012

PERIOD COVERED IN THIS REPORT: 1 Oct 86 through 30 Sep 87

INVESTIGATORS: Wanda L. Brown, MS  
Arthur D. Mason, Jr., MD  
Basil A. Pruitt, Jr., MD, Colonel, MC

Sprague-Dawley rats weighing 180-200 g were anesthetized and subjected to a 20% total body surface area sham or partial-thickness dorsal scald burns. Microelectrodes were used to measure the pH, and in some cases, the  $pCO_2$  of the wounds. Burn wound pH was within control limits<sup>2</sup> at 1 h postburn (PB) but then decreased to its lowest value of 6.76 at 6 h PB. It did not return to the sham control range until 24 h PB. Burn wound  $pCO_2$  was lower than that of sham wounds during the period of decreased pH, in contrast to findings in ischemic heart. Mean water content of the partial-thickness burn wound increased rapidly and attained its maximum value at 18 h PB when burn wounds contained 7.8 ml more water than sham wounds. The water content then decreased slowly but the wounds still contained 3.6 ml excess water at 72 h PB. Burn wound dry weights were greater than sham wound dry weights at each time measured.

# A STUDY OF BIOCHEMICAL CHANGES IN THE CELLULAR ENVIRONMENT OF TISSUE OF THE in vivo PARTIAL-THICKNESS RAT BURN WOUND

## INTRODUCTION

The progressive increase in the depth of irreversibly injured tissue of burn wounds during the first 24-48 h postburn (PB) has been attributed to ischemia (1), but the sequence of metabolic and biochemical changes which occur in vivo in the burn wound have not been well characterized. However, the changes that occur in other ischemic organs have been well documented (2-4). These include a rapid depletion of glycogen and high energy phosphate compounds, an accumulation of lactate, carbon dioxide, NADH, and protons from other metabolic processes, and, ultimately, a cessation of all energy-dependent functions. Since the changes that occur are similar to heart, brain, liver, kidney, and muscle, it is possible that they may also occur in vivo in the burn wound during the early PB period, although they may differ in time and extent because of the relative contribution of different pathways for energy production in a particular organ. Our purpose in this study is to determine the changes that occur in vivo in the burn wound during the early PB period using the information about changes which occur in other ischemic organs as a guide.

## MATERIALS AND METHODS

Young Sprague-Dawley rats weighing from 180-200 g were anesthetized with alpha-chloralose (5.5 mg/100 g, IP). The hair on the dorsum was clipped and the rats were placed in a protective mold which limited the area to be burned to 20% of the total body surface area. Immersion of the exposed area in water at 80°C for 8 sec produced a partial-thickness burn. Sham control rats were anesthetized, clipped, and placed in the same protective mold and an area on the dorsum equal to that of the burn area was outlined in ink. Rats were housed in individual cages and permitted access to food and water ad libitum. No parenteral fluids were administered. The rats were reanesthetized prior to measurements.

**Microelectrode Measurements.** The pH of sham and partial-thickness burn wounds of rats were measured at intervals from 1-72 h PB using an MI-408 needle pH microelectrode and an MI-401 microreference electrode with glass barrel inserted through a slit in the skin into the wound tissue. The microelectrode pairs were connected through an Orion Model 607 Electrode Switchbox to an Orion Model EA 9040 microprocessor-controlled IonAnalyzer which was equipped with a Model GLP printer. In some cases, the  $pCO_2$  of the wound tissue was measured using an MI-720 microcarbon<sup>2</sup> dioxide electrode. Microelectrodes were obtained from Microelectrodes, Inc. (Londonderry, NH). Tissue pH and  $pCO_2$  were recorded when the IonAnalyzer indicated stable electrode readings.

**Measurement of Water Content and Dry Weight of Wounds.** The total area of the 20% total body surface area sham or partial-thickness burn wound was rapidly excised to the depth of the fascia, immediately weighed, and dried to constant weight at 70°C. Water content was determined from the difference in the wet and dry weight of the wound tissue.

### RESULTS

The pH of sham wounds ranged from 7.07 to 7.17 from 1-72 h PB (Fig. 1). The pH of the partial-thickness burn wound was within the sham control range at 1 h PB but decreased to its lowest value of 6.76 at 6 h PB. The burn wound pH increased slowly to 6.92 at 18 h PB and was within control range from 24-72 h PB.

In contrast to findings reported for ischemic heart (5),  $pCO_2$  of the burn wounds decreased rather than increasing during the period in which wound pH was lower than control values, indicating that the decrease in pH of burn wounds was due to other acidic compounds.




FIGURE 1. pH of Sham Control and Partial-Thickness Burn Wounds from 1-72 h PB.

The mean water content of the sham wounds was 4.6 ml (Fig. 2). At 1 h PB, the burn wounds contained 3.6 ml more water than sham wounds. At 3 h PB, they contained 4.6 ml more water. From 6-12 h PB, burn wounds contained approximately 7 ml more water than sham wounds and increased to a maximum of 7.8 ml excess water at 18 h PB before decreasing slowly to 3.6 ml excess water at 72 h PB.




FIGURE 2. Total Water Content of Sham Control and Partial-Thickness Burn Wounds from 1-72 h PB.

The dry weights of the burn wounds were greater than that of the equivalent sham wounds at each time measured (Fig. 3).

We are currently testing methods for separating epidermal and dermal cells of tissue from sham control and partial-thickness burn wounds to be used in studies to determine changes in cellular function.

#### PRESENTATIONS/PUBLICATIONS

None.






FIGURE 3. Dry Weights of Sham Control and Partial-Thickness Burn Wounds from 1-72 h PB.

#### REFERENCES

1. Zawacki BE: The natural history of reversible burn injury. Surg Gyn Obstet 139:867-872, 1974.
2. Farber JL, Chien KR, and Mittnacht S Jr: The pathogenesis of irreversible cell injury in ischemia. Am J Pathol 102:271-281, 1981.
3. Jennings RB, Hawkins KH, Lowe JE, et al: Relation between high energy phosphate and lethal injury in myocardial ischemia in the dog. Am J Pathol 92:187-214, 1987.
4. Neely JR and Feuvray D: Metabolic products and myocardial ischemia. Am J Pathol 102:282-291, 1981.
5. Khuri SF, Kloner RA, Hillis LD, et al: Intramural pCO<sub>2</sub>: a reliable index of the severity of myocardial ischemic injury. Am J Physiol 237:H253-H259, 1979.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL	
					87 10 01	DD-DRAB(A) 636	
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCTY	6 WORK SECURITY	7 REGRADING	8 DISB'N INSTR'N	9 LEVEL OF SUM A. WORK UNIT	
NONE	A	U	U		CX		
10 NO CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a. PRIMARY	61101A	3A161101A91C	00	078			
b. CONTRIBUTING							
c. CONTRIBUTING	NONE						
11. TITLE (Precede with Security Classification Code) (U) The Effect of Interleukin-2 Administration on Mortality to Rats with Pseudomonas Burn Wound Sepsis							
12 SUBJECT AREAS							
06 05 Medicine and Medical Research 06 04 Anatomy and Physiology							
13 START DATE	14. ESTIMATED COMPLETION DATE	15 FUNDING ORGANIZATION	15 PERFORMANCE METHOD				
87 10	89 09	DA	C				
17 CONTRACT GRANT / PRIMARY RELEVANCY CERTIFIED				18. RESOURCES ESTIMATE			
a. DATE EFFECTIVE	b. APPROVED BY <i>Sam. Pruitt</i>			c. FISCAL YEARS	d. PROFESSIONAL WORK YEARS	e. FUNDS (In thousands)	
19. RESPONSIBLE DOD ORGANIZATION				20. PERFORMING ORGANIZATION			
a. NAME				a. NAME			
US Army Institute of Surgical Research				US Army Institute of Surgical Research			
b. ADDRESS (include zip code)				b. ADDRESS			
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL				c. NAME OF PRINCIPAL INVESTIGATOR			
PRUITT, B A				GRAVES, T A			
d. TELEPHONE NUMBER (include area code)				d. TELEPHONE NUMBER (include area code)			
512-221-2720				512-221-4440			
21. GENERAL USE				f. NAME OF ASSOCIATE INVESTIGATOR (if available)			
FINA				CIOFFI, W G			
MILITARY/CIVILIAN APPLICATION				g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Interleukin-2; (U) Pseudomonas; (U) Sepsis; (U) Burns; (U) Lab Animals; (U) Rats; (U) ILIR; (U) RAI							
23. (U) Following a severe thermal injury, alterations in the host immune system develop which lead to depression of the immune response. Defects in cellular and humoral systems have been reported. These defects are manifested by increased susceptibility to sepsis, impaired delayed hypersensitivity reaction, and prolongation of allograft rejection. The role of interleukin-2 administration following thermal injury in soldiers remains unclear. Therefore, the effects of exogenous interleukin-2 administration following burn wound infection will be studied in a rodent model. A literature search was conducted.							
24. (U) Two phases of this study will be performed to determine the optimal dose of interleukin-2 and the optimal postburn day for administration. During the first phase, varied doses of interleukin-2, ranging from low therapeutic levels to toxic doses, will be administered beginning on postburn day 3. Each dosing schedule will be continued 3X daily for 7 days. If an improvement in survival is seen during the first phase of the study, another phase will be performed to determine the optimum day postburn for administration of interleukin-2.							
25. (U) 8610 - 8709. This project was approved by the US Army Institute of Surgical Research Animal Care and Use Committee on 4 September 1987.							

DD FORM 1498  
83 MAR

EDITION OF MAR 68 IS OBSOLETE.

• U.S.G.P.O. 1986-491-003/50329

<b>RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY</b>				1 AGENCY ACCESSION DA309172	2 DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR&BIAR 436	
3 DATE PREV. SUMMARY 86 10 01	4 KIND OF SUMMARY H	5 SUMMARY SCTY U	6 WORK SECURITY U	7 REGRADING	8 DISSEM INSTRN CX	9 LEVEL OF SUMMARY WORK UNIT	
10 NO CODES		PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a PRIMARY		11 01A	3A161101A91C	00	079		
b CONTRIBUTING							
c CONTRIBUTING		NONE					
11 TITLE (Precede with Security Classification Code) (U) Derivative Spectroscopy Chemiluminogenic Probing of Granulocyte Redox Function in Healthy Controls and Burn Patients							
12 SUBJECT AREAS							
06 01 Biochemistry 06 05 Medicine and Medical Research							
13 START DATE 85 10		14 ESTIMATED COMPLETION DATE 87 09		15 FUNDING ORGANIZATION DA		16 PERFORMANCE METHOD C	
17 CONTRACT GRANT NUMBER DA309172				18 RELEVANCY CERTIFIED			
a DATE EFFECTIVE		b FISCAL YEARS		c PROFESSIONAL WORK YEARS		d FUNDS (In thousands)	
19 01 01		87		0.7		120	
c TYPE		88		0.0		0	
e KIND OF AWARD		f CUM. TOTAL					
19 RESPONSIBLE DOD ORGANIZATION				20 PERFORMING ORGANIZATION			
a NAME US Army Institute of Surgical Research				a NAME US Army Institute of Surgical Research			
b ADDRESS (include zip code) Fort Sam Houston San Antonio, Texas 78234-5012				b ADDRESS Fort Sam Houston San Antonio, Texas 78234-5012			
c NAME OF RESPONSIBLE INDIVIDUAL PRUITT, B A				c NAME OF PRINCIPAL INVESTIGATOR ALLEN, R C			
d TELEPHONE NUMBER (include area code) 512-221-2720				d TELEPHONE NUMBER (include area code) 512-221-3411			
21 GENERAL USE FINA				f NAME OF ASSOCIATE INVESTIGATOR (if available) JADWIN, D F			
MILITARY CIVILIAN APPLICATION M				g NAME OF ASSOCIATE INVESTIGATOR (if available) MASON, A D			
22 KEYWORDS (Precede EACH with Security Classification Code) (U) Chemiluminescence; (U) Granulocyte Function; (U) Derivative Spectroscopy; (U) Immunology; (U) Host Resistance;							
23 TECHNICAL OBJECTIVE 24 APPROACH 25 PROGRESS (Precede text of each with Security Classification Code)							
22. (Continued) (U) Burns; (U) Volunteers; (U) ILIR; (U) RAI							
23. (U) The two major objectives of this study are the development of techniques for quantifying the redox enzyme content and function of granulocyte leukocytes, and the evaluation of the sensitivity and specificity of these techniques for assessing the status of antimicrobial defense in burn patients. Chemiluminogenic probe methods for differential assessment of oxidase and peroxidase activities will be further refined and new techniques based on difference and derivative ultraviolet-visible spectroscopy will be developed for quantifying oxidase and peroxidase enzyme content. The strong relationship between granulocyte function and humoral immune status in the burn patient may also require assessment of serum complement. A literature search was conducted.							
24. (U) Ultrasensitive and differential assessment of granulocyte oxygenation activity can be achieved by measuring the luminescence resulting from oxygenation of high quantum yield substrates. New photon counting instrumentation designed for operation at physiologic temperature (37°C) will allow more rapid assessment of granulocyte function. The recent availability of diode array ultraviolet-visible spectrophotometers allows for rapid spectral analysis over a broad range. Moreover, the digital nature of the data is ideal for microprocessor-assisted derivative spectral analysis of the enzymes responsible for granulocyte redox activity. Photon counting in combination with derivative spectroscopy will							

DD FORM 1498  
83 MAR

EDITION OF MAR 68 IS OBSOLETE.

• URGPO. 1000-491-003/50329

CONTINUATION OF DD FORM 1498 FOR "DERIVATIVE SPECTROSCOPY  
CHEMILUMINIGENIC PROBING OF GRANULOCYTE REDOX FUNCTION IN  
HEALTHY CONTROLS AND BURN PATIENTS"

allow analysis of oxidase and peroxidase structure-function relationships. Such information may explain the derangement in granulocyte function responsible for increased susceptibility to infection.

25. (U) 8610 - 8709. Equipment was received during this reporting period. However, this study will be terminated effective 1 October 1987 due the primary investigator's resignation from the service.

<b>RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY</b>				1 AGENCY ACCESSION DA311491	2 DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR- (AR) 836	
3 DATE PREP SUMMARY 86 10 01	4 KIND OF SUMMARY D	5 SUMMARY SCTY U	6 WORK SECURITY U	7 REGRADING	8 DISB'N INSTR'N CX	9 LEVEL OF SUM A WORK UNIT	
10 NO. CODES		PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY		61101A	3A161101A91C	00	081		
b. CONTRIBUTING							
c. CONTRIBUTING		NONE					
11 TITLE (Precede with Security Classification Code) (U) Evaluation of in vitro Cultivated Keratinocytes as Epithelial Autografts for the Closure of Burn Wounds							
12 SUBJECT AREAS							
05 05 Medicine and Medical Research 06 13 Microbiology							
13 START DATE 86 10		14 EST. MATED COMPLETION DATE 89 09		15 FUNDING ORGANIZATION DA		16 PERFORMANCE METHOD C	
17 CONTRACT GRANT NO.				18 RELEVANCY CERTIFIED			
a. DATE EFFECTIVE		b. EXPIRATION DATE		c. FISCAL YEARS		d. PROFESSIONAL WORK YEARS	
b. CONTRACT GRANT NUMBER						e. FUNDS (in thousands)	
c. TYPE		f. AMOUNT		87		1.5	
g. KIND OF AWARD		h. COM TOTAL		88		1.5	
19 RESPONSIBLE DOD ORGANIZATION				20 PERFORMING ORGANIZATION			
a. NAME US Army Institute of Surgical Research				a. NAME US Army Institute of Surgical Research			
b. ADDRESS (include zip code) Fort Sam Houston San Antonio, Texas 78234-5012				b. ADDRESS Fort Sam Houston San Antonio, Texas 78234-5012			
c. NAME OF RESPONSIBLE INDIVIDUAL BRUITT, B A				c. NAME OF PRINCIPAL INVESTIGATOR LIVELY, J C			
d. TELEPHONE NUMBER (include area code) 512-221-2720				d. TELEPHONE NUMBER (include area code) 512-221-4440			
21 GENERAL USE FINA MILITARY CIVILIAN APPLICATION M				f. NAME OF ASSOCIATE INVESTIGATOR (if available) MC MANUS, A T			
				g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22 KEYWORDS (Precede EACH with Security Classification Code) (U) Healing; (U) Keratinocytes; (U) Cell Culture; (U) Skin; (U) Skin Graft; (U) Frozen Skin; (U) Volunteers;							
23 TECHNICAL OBJECTIVE 24 APPROACH 25 PROGRESS (Precede text of each with Security Classification Code)							
22. (Continued) (U) ILIR; (U) RAI							
23. (U) To evaluate cultured keratinocytes as grafts for epithelial closure of burn wounds. To identify technical and immunological requirements to establish frozen banks of histocompatible keratinocytes for wound coverage in burned soldiers. A literature search was conducted.							
24. (U) The possible utility of cultured keratinocytes will be established initially with cultured autologous keratinocytes. Keratinocytes will be cultured from biopsies taken early after admission of patients with large burns and limited unburned donor sites for standard partial thickness autografts. If such grafts are deemed cleanly useful, efforts will expand into investigations of allogeneic skin cultures.							
25. (U) 8610 - 8709. The preliminary arrangements are almost complete. The commencement of the clinical use of the cultivated keratinocyte grafts is expected to begin soon.							

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1. AGENCY ACCESSION DA312336	2. DATE OF SUMMARY 87 10 01	REPORT CONTROL SYMBOL DD-DR-6(1AR) 636	
3. DATE PREV SUMMARY 87 01 14	4. KIND OF SUMMARY D	5. SUMMARY SCTY U	6. WORK SECURITY U	7. REGRADING	8. DISB'N INSTR'N CX	9. LEVEL OF SUM A. WORK UNIT	
10. NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER			
a. PRIMARY	61101A	3A161101A91C	00	083			
b. CONTRIBUTING							
c. CONTRIBUTING	NONE						
11. TITLE (Precede with Security Classification Code) (U) The Effect of High Frequency Ventilation on VA/Q in Sheep with Inhalation Injury							
12. SUBJECT AREAS 06 05 Medicine and Medical Research 06 04 Anatomy and Physiology							
13. START DATE 87 01	14. ESTIMATED COMPLETION DATE 89 09	15. FUNDING ORGANIZATION DA	16. PERFORMANCE METHOD C				
17. CONTRACT GRANT NUMBER a. DATE EFFECTIVE b. CONTRACT GRANT NUMBER c. TYPE d. AMOUNT e. KIND OF AWARD f. CUM/TOTAL				18. RESOURCES ESTIMATE FISCAL YEARS a. PROFESSIONAL WORK YEARS b. FUNDS (In thousands)			
				87 0.2 3			
				88 0.2 5			
19. RESPONSIBLE DOD ORGANIZATION a. NAME US Army Institute of Surgical Research b. ADDRESS (include zip code) Fort Sam Houston San Antonio, Texas 78234-5012 c. NAME OF RESPONSIBLE INDIVIDUAL PRUITT, B A d. TELEPHONE NUMBER (include area code) 512-221-2720				20. PERFORMING ORGANIZATION a. NAME US Army Institute of Surgical Research b. ADDRESS Fort Sam Houston San Antonio, Texas 78234-5012 c. NAME OF PRINCIPAL INVESTIGATOR CIOFFI, W G d. TELEPHONE NUMBER (include area code) 512-221-4440			
21. GENERAL USE FINA MILITARY/CIVILIAN APPLICATION M				f. NAME OF ASSOCIATE INVESTIGATOR (if available) IKEUCHI, H g. NAME OF ASSOCIATE INVESTIGATOR (if available)			
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Inhalation Injury; (U) High Frequency Ventilation; (U) Ventilation-Perfusion Ratio; (U) Cardiac Output; (U) Lab							
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)							
22. (Continued) (U) Animals: (U) Sheep; (U) ILIR; (U) RAII							
23. (U) To compare volumetric diffusive ventilation with conventional ventilation in effecting changes in the pulmonary and hemodynamic parameters which are altered in an ovine inhalation injury model. A literature search was conducted.							
24. (U) Inhalation injury will be induced using the standard ovine smoke inhalation model developed at this Institute. Animals will be then be placed on conventional mechanical ventilation with a volume-limited ventilator. Ventilator settings will be altered to maintain a pH between 7.35 and 7.40 and a partial oxygen pressure between 80 and 100 mmHg. A lactated Ringer's solution will be constantly infused. Central venous pressure, pulmonary artery pressure, transpulmonary pressure, inspiratory and expiratory gas concentrations, percutaneous oxygen saturation, and partial carbon dioxide pressure will be continuously monitored. Once the ventilator settings are maximized, yielding a partial oxygen pressure between 80 and 100 mmHG and a pH between 7.35 and 7.40, the animal will be allowed to stabilize for 2 h. VA/Q distributions will then be measured utilizing the multiple inert gas elimination technique. After stabilization, the lactated Ringer's infusion will be replaced with a lactated Ringer's solution containing six inert gases. Blood and expired gas samples will be analyzed immediately by a GCMS. The animals will then be disconnected from the conventional ventilator and switched to a							

DD FORM 1498  
83 MAR

EDITION OF MAR 68 IS OBSOLETE.

USGPO 1987-491-003/50329

CONTINUATION OF DD FORM 1498 FOR "THE EFFECT OF HIGH FREQUENCY VENTILATION ON VA/Q IN SHEEP WITH INHALATION INJURY"

olumetric-diffusive ventilator. After the 2-h stabilization period, VA/Q distribution will again be measured. Data following the stabilization periods will be compared utilizing the student's t-test.

25. 8510 - 8709. (U) This project was approved by the US Army Institute of Surgical Research Animal Care and Use Committee on 14 January 1987. Six animals are to be studied, with the first animal being studied in September 1987.



RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION	2 DATE OF SUMMARY	REPORT CONTROL SYMBOL
				DA312334	87 10 01	DD-DR&B(AR) 836
3 DATE PREV SUMMARY	4 KIND OF SUMMARY	5 SUMMARY SCTY	6 WORK SECURITY	7 REGRADING	8 DISB'N INSTR'N	9 LEVEL OF SUM A WORK UNIT
87 01 14	D	U	U		CX	
10 NO. CODES	PROGRAM ELEMENT	PROJECT NUMBER	TASK AREA NUMBER	WORK UNIT NUMBER		
a. PRIMARY	61101A	3A161101A91C	00	085		
b. CONTRIBUTING						
c. CONTRIBUTING	NONE					
11 TITLE (Precede with Security Classification Code) (U) Effects of Replacement Therapy on Hemodynamic Parameters in an Ovine Model of Controlled Pure Plasma Loss						
12 SUBJECT AREAS						
06 05 Medicine and Medical Research 06 04 Anatomy and Physiology						
13 START DATE	14 EST MATED COMPLETION DATE	15 FUNDING ORGANIZATION	16 PERFORMANCE METHOD			
87 01	90 09	DA	C			
17 CONTRACT GRANT: PRIMARY RELEVANCY CERTIFIED						
a. DATE EFFECTIVE	b. FISCAL YEARS	c. PROFESSIONAL WORK YEARS		d. FUNDS (In thousands)		
87 01	87 88	0.3		25		
c. TYPE	d. AMOUNT	0.5		35		
e. KIND OF AWARD		f. CUM/TOTAL				
19. RESPONSIBLE DOD ORGANIZATION				20 PERFORMING ORGANIZATION		
a. NAME				a. NAME		
US Army Institute of Surgical Research				US Army Institute of Surgical Research		
b. ADDRESS (include zip code)				b. ADDRESS		
Fort Sam Houston San Antonio, Texas 78234-5012				Fort Sam Houston San Antonio, Texas 78234-5012		
c. NAME OF RESPONSIBLE INDIVIDUAL				c. NAME OF PRINCIPAL INVESTIGATOR		
PRUITT, B A				MASON, A D		
d. TELEPHONE NUMBER (include area code)				d. TELEPHONE NUMBER (include area code)		
512-221-2720				512-221-7832		
21. GENERAL USE				f. NAME OF ASSOCIATE INVESTIGATOR (if available)		
FINA						
MILITARY/CIVILIAN APPLICATION				g. NAME OF ASSOCIATE INVESTIGATOR (if available)		
22. KEYWORDS (Precede EACH with Security Classification Code) (U) Shock; (U) Resuscitation; (U) Hemodynamics; (U) Plasmaphoresis; (U) Fluid Replacement; (U) Albumin;						
23. TECHNICAL OBJECTIVE 24. APPROACH 25. PROGRESS (Precede text of each with Security Classification Code)						
22. (Continued) (U) Crystalloids; (U) Lab Animals; (U) Sheep; (U) ILIR; (U) RAI						
23. (U) To determine the hemodynamic consequences of controlled pure plasma loss in sheep using a method to simulate the acute burn. Subsequently, response to therapy will be assessed in burned soldiers. A literature search was conducted.						
24. (U) A plasmaphoresis filter will be used to create the model of intravascular plasma loss unique to the burn injury. This device selectively removes plasma while leaving the formed elements of blood in the vascular system.						
25. (U) 8701 - 8709. This project was approved by the US Army Institute of Surgical Research Animal Care and Use Committee on 14 January 1987. Equipment and animals have been procured and seven animals have been studied. The study is promising and will be continued.						

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

PRESENTATIONS

Pruitt BA Jr: Necrotizing soft tissue infections: new concepts in the management of surgical infections. Presented to the Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, 7 October 1986.

Pruitt BA Jr: Resuscitation and fluid management. Presented at the Buffalo Burn Symposium, Department of Surgery, State University of New York at Buffalo, Buffalo, New York, 10-11 October 1986.

Pruitt BA Jr: Diagnosis and treatment of inhalation injury and other pulmonary complications. Presented at the Buffalo Burn Symposium, Department of Surgery, State University of New York at Buffalo, Buffalo, New York, 10-11 October 1986.

Pruitt BA Jr: What's new in trauma and burns. Presented to at American College of Surgery Clinical Congress, New Orleans, Louisiana, 14-25 October 1986.

McManus WF: Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 15 October 1986.

McCoy KF: Care of the thermally injured patient. Presented to the Physical Therapy Specialist Course (91J), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 23 October 1986.

McManus WF: Thermal injury. Presented to Federal Drug Enforcement Agency pilots, Randolph Air Force Base, San Antonio, Texas, 29 October 1987.

Pruitt BA Jr: Thermal injuries - update 1986. Presented to the Association of Military Surgeons of the United States, San Antonio, Texas 3 November 1986.

McCoy KF: Physical therapy in burn care. Presented to students from Southwest Texas State University, Fort Sam Houston, San Antonio, Texas, 3 November 1986.

Cioffi WG Jr: Pulmonary and systemic vascular reactivity in thermal injury. Presented to the Association of Academic Surgery, Washington, DC, 5 November 1986.

Pruitt BA Jr: Infection and burn problems. Presented to the Physician's Assistant Course (C4A), Academy of Health

AD-A212 178

US ARMY INSTITUTE OF SURGICAL RESEARCH ANNUAL RESEARCH  
PROGRESS REPORT FOR FISCAL YEAR 1987(U) ARMY INST OF  
SURGICAL RESEARCH FORT SAM HOUSTON TX B A PRUITT


4/4

UNCLASSIFIED 01 OCT 87

F/G 6/5

NL -





Sciences, Fort Sam Houston, San Antonio, Texas, 6 November 1986.

**Summers TM:** Introduction to the hospital ministry course. Presented at Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 10 November 1986.

**McManus WF:** Resuscitation of the thermally injured patient. Presented at the Trauma Conference, William Beaumont Army Medical Center, El Paso, Texas, 13 November 1986.

**Mozingo DW:** Chemical burns. Presented at the Trauma Conference, William Beaumont Army Medical Center, El Paso, Texas, 13 November 1986.

**McManus WF:** Massive burn injury. Presented at the Ninety-Fourth Annual Meeting of the Western Surgical Association, Dearborn, Michigan, 18 November 1986.

**Kyzar DW:** Nursing administrator overview of the US Army Institute of Surgical Research. Presented to the United States Army Recruiting Service Nursing Educator Tour, Fort Sam Houston, San Antonio, Texas, 20 November 1986.

**Pruitt BA Jr:** Fluid resuscitation and wound care. Presented to the Department of Surgery, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, 21-22 November 1986.

**Luster SH:** Acute burn care: current approaches. Presented at the Occupational Therapy Symposium of the American Military Surgeons of the United States, San Antonio, Texas, 11 November 1986.

**Latona PS:** Initial management of the burn patient. Presented to the AMEDD Advanced Course at the Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 11 December 1986.

**Lively JC:** Burns. Presented to the Officers' Basic Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 13 January 1987.

**Gutierrez RT:** Closing address. Presented to the Physical Therapy Specialist Course (91J), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 22 January 1987.

**Carlson D:** Combat field feeding system - force development and experimentation. Presented to Dietetic Interns, Nutrition Care Division, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 23 January 1987.

**Pruitt BA Jr:** Early excision of burns. Presented to the 25th Anniversary Celebration Panel, Parkland Hospital Burn Center, Dallas, Texas, 26-27 January 1987.

**Cioffi WG Jr:** Inhalation injury and pneumonia. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Graves TA:** Burn wound management: topical agents, biological dressings, synthetics, and excision and grafting. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Gutierrez RT:** Overview of the US Army Medical Research and Development Command and the US Army Institute of Surgical Research. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Gutierrez RT:** Panel Discussion: Biomechanical complications. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Gutierrez RT:** Panel Discussion: Rehabilitation - occupational and physical therapy. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Jordan BS:** Functioning in an ICU environment. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Jordan BS:** Management of pain. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Jordan BS:** Review of current research at the US Army Institute of Surgical Research. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Kyzar DW:** Panel Discussion: Experiences of nonphysician medical staff in the combat zone (Vietnam) and in El Salvador. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Latona PS:** Initial care of the burn patient. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Luster SH:** Occupational therapy in burn care. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Luster SH:** Panel Discussion: Biomechanical complications. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Luster SH:** Panel Discussion: Rehabilitation - occupational and physical therapy. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Mason AD Jr:** Perspectives in clinical research. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Missavage AE:** Management of infection, sepsis, and suppurative thrombophlebitis. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Pratt SM:** Cardiovascular, gastrointestinal, and renal complications. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Pruitt BA Jr:** Pathophysiology of thermal injuries: triage and initial care. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Reilly DA:** Nutritional care. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations,

Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Robertson FM:** Fluid resuscitation, escharotomy, and fasciotomy. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Summers TM:** Psychological complications. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Zellers LA:** Air transport of burn patients. Presented at the OT/PT Conference on Management of Burns in the Theater of Operations, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 26 January-6 February 1987.

**Latona PS:** Initial management of the burn patient. Presented at Saint Rose Hospital, San Antonio, Texas, 27 January 1987.

**Pruitt BA Jr:** Treatment of the cutaneous injury. Presented at the Vesicant Workshop, Aberdeen Proving Grounds, Maryland, 3-5 February 1987.

**Pruitt BA Jr:** Recent advances in burn care. Presented to the American College of Veterinary Surgeons, San Antonio, Texas, 5 February 1987.

**Jordan BS:** Wound care and later complications. Presented to the Critical Care Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 5 February 1987.

**Latona PS:** Initial management of burns. Presented to the Critical Care Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 5 February 1987.

**Latona PS:** Initial management of the burn victim. Presented to the 328th General, Fort Sam Houston, San Antonio, Texas, 5 February 1987.

**Latona PS:** Pediatric burn patients: are they different? Presented at the 57th Air Evacuation Squadron Burn Symposium, Scott Air Force Base, Belleville, Illinois, 10 February 1987.

**Latona PS:** Wound care and later complications. Presented at the 57th Air Evacuation Squadron Burn Symposium, Scott Air Force Base, Belleville, Illinois, 10 February 1987.

**Summers TM:** Psychosocial aspects of burn care. Presented at the 57th Air Evacuation Squadron Burn Symposium, Scott Air Force Base, Belleville, Illinois, 10 February 1987.



**Miller T:** Initial management of the burn patient. Presented to the Intensive Care Course, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 12 February 1987.

**McManus WF:** Stress ulcer disease in the burned patient. Presented at the Tufts University School of Medicine New Concepts in Critical Care Symposium, Sarasota, Florida, 27 February 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented to the Physical Therapy Specialist Course (91J), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 2 March 1987.

**McManus WF:** Innovations in burn care. Presented to the Department of Medicine, Brackenridge Hospital, Austin, Texas, 12 March 1987.

**Carlson D:** Nutrition and wound healing. Presented to the Advanced Physical Therapy Course, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, 17 March 1987.

**Gutierrez RT:** Initial treatment - debridement. Presented to the Advanced Physical Therapy Course, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, 17 March 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented to the Advanced Physical Therapy Course, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, 17 March 1987.

**Gutierrez RT:** Range of motion and splinting of burns. Presented to the Advanced Physical Therapy Course, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, 17 March 1987.

**McManus WF:** Medical readiness - thermal trauma under battlefield conditions. Presented to the Advanced Physical Therapy Course, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, 17 March 1987.

**Pruitt BA Jr:** Current management of burn patients. Presented to the Department of Surgery, Morristown Memorial Hospital, Morristown, New Jersey, 25 March 1987.

**Allen RC:** Immunologic effects of burn injury. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**Cioffi WG Jr:** Inhalation injury and pulmonary complications. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**McManus AT:** Infection surveillance in burn patients. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**McManus WF:** Resuscitation of burn patients. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**Missavage AE:** Burn wound excision and closure of the burn wound. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**Pruitt BA Jr:** Epidemiology and triage of burn patients. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**Pruitt BA Jr:** Overview of techniques of burn care. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**Vaughan CM:** Neuroendocrine effects of burn injury. Presented to the Buffalo Surgical Society, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 28 March 1987.

**Latona PS:** Initial management of burns. Presented to the Critical Care Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 1 April 1987.

**Summers TM:** Psychosocial aspects of burn care. Presented to the Chaplains, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 6 April 1987.

**Pruitt BA Jr:** Surgical research and the military. Presented at the Gary P. Wratten Surgical Symposium, William Beaumont Army Medical Center, El Paso, Texas, 8 April 1987.

**Luster SH:** Occupational therapy in burn care. Presented at the Insurance Adjustors of America Annual Meeting, San Antonio, Texas, 8 April 1987.

**Pruitt BA Jr:** Fluid resuscitation in burns. Presented to the Throckmorton Surgical Society, Des Moines, Iowa, 10 April 1987.

**Pruitt BA Jr:** Current treatment of the burn wound. Presented to the Throckmorton Surgical Society, Des Moines, Iowa, 10 April 1987.

**Wallace A:** Nursing care of burn patients. Presented to the Recruiting Battalion, Santa Anna, California, 24 April 1987.

**Zelenka JP:** The role of occupational therapy in the care of burn patients. Presented to the Occupational Therapy Assistant Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 24 April 1987.

**Kyzar DW:** Overview of the US Army Institute of Surgical Research. Presented to the Recruiting Command Nurse Educator Tour, Fort Sam Houston, San Antonio, Texas, 28 April 1987.

**McManus WF:** Sulfamylon. Presented at the Nineteenth Annual Meeting of the American Burn Association's Symposium on Wound Healing, Washington, DC, 29 April 1987.

**Pruitt BA Jr:** Pathology of the burn wound. Presented at the Nineteenth Annual Meeting of the American Burn Association's Symposium on Wound Healing, Washington, DC, 29 April 1987.

**McManus AT:** Relationship of sulfonamide sensitivity to in vitro activity of silver-sulfadizine. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 30 April 1987.

**Kim SH:** Mycotic disease in burn patient autopsies. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 1 May 1987.

**McManus AT:** A comparison of quantitative microbiology and histopathology in divided burn wound biopsies. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 1 May 1987.

**Miller TM:** Air-vented mattresses within the critical burn care area: how clean are they? Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 1 May 1987.

**Pruitt BA Jr:** Panel Discussion: Ethical concerns. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 1 May 1987.

**Chu C-S:** Salvage of experimental full-thickness scalds with cooling and weak anodal direct current. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 2 May 1987.

**Shimazu TS:** Effects of PEEP on ventilation-perfusion ratios following smoke inhalation injury in a sheep model. Presented at the Nineteenth Annual Meeting of the American Burn Association, Washington, DC, 2 May 1987.

**Pruitt BA Jr:** Infection and burn problems. Presented to the C4A Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 7 May 1987.

Gutierrez RT: Physical management of burns. Presented as part of the US Army-Baylor University Program, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 8 May 1987.

Latona PS: Initial management of the burn victim. Presented as part of the US Army-Baylor University Program, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 8 May 1987.

Pruitt BA Jr: The immunologic consequences of severe injury. Presented to the Colorado Chapter of the American College of Surgeons, Denver, Colorado, 15-16 May 1987.

McManus WF: Infections in surgical patients. Presented to the Family Practice Association, McAllen, Texas, 19 May 1987.

Gutierrez RT: Physical therapy in burn care. Presented to Family Support Group Members, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, 26 May 1987.

Pruitt BA Jr: Necrotizing soft tissue infections. Presented at the Fourteenth Annual Warren H. Cole Symposium, University of Illinois College of Medicine, Chicago, Illinois, 28 May 1987.

Pruitt BA Jr: Treatment prevention of infection in the immunocompromised surgical patient. Presented at the Fourteenth Annual Warren H. Cole Symposium, University of Illinois College of Medicine, Chicago, Illinois, 28 May 1987.

Latona PS: Initial management of the burn victim. Presented at the Surviving Terrorism Symposium, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, 29 May 1987.

Pruitt BA Jr: Panel Discussion: Multisystem organ failure and intensive care therapy. Presented to the International Congress on Intraabdominal Infections, Hahmburg, Germany, 1-3 June 1987.

Gutierrez RT: Mobilization to El Salvador. Presented to the Clinical Faculties Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 3 June 1987.

Latona PS: Initial management of the burn victim. Presented at the Nursing Medical Readiness Symposium, Kessler Air Force Base, Biloxi, Mississippi, 3 June 1987.

Summers TM: Psychosocial aspects of the burn victim. Presented at the Nursing Medical Readiness Symposium, Kessler Air Force Base, Biloxi, Mississippi, 3 June 1987.

Gutierrez RT: Physical therapy management of burns. Presented to the Physical Therapy Specialist Course (91J), Academy of Health sciences, Fort Sam Houston, San Antonio, Texas, 5 June 1987.

Latona PS: Initial management of the burn victim. Presented to the 32nd Air Medical Squardon, Kelly Air Force Base, San Antonio, Texas, 7 June 1987.

Carlson D: The role of the dietitian in the critical care setting: critical knowledge for dietitians. Presented to the Nutritional Assessment Postgraduate Short Course, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 8 June 1987.

Jordan BS: Wound care and later complications. Presented to the Critical Care Nursing Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 11 June 1987.

Latona PS: Initial management of the burn patient. Presented to the Critical Care Nursing Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 11 June 1987.

Dimmick DJ: The role of the LVN in the care of the burn patient. Presented at the Madisonville State Vocational Technical School, Madisonville, Kentucky, 15 June 1987.

Gutierrez RT: Physiological response to the burn injury and care of minor burns. Presented to the Physical Therapy Specialist Advanced Course (91J), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 16 June 1987.

Gutierrez RT: Getting mobilized to El Salvador, Central America. Presented to the Physical Therapy Specialist Advanced Course (91J), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 19 June 1987.

Carlson D: Nutritional management of the burn patient. Presented to the Nutritional Assessment Postgraduate Short Course, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 19 June 1987.

Pruitt BA Jr: What's new in burns. Presented at the International Society for Burn Injuries Research Symposium, Geneva, Switzerland, 26 June 1987.

Pruitt BA Jr: Now you see it, now you don't. Presented at the International Society for Burn Injuries Research Symposium, Geneva, Switzerland, 26 June 1987.

Pruitt BA Jr: Management of patients with extensive burns. Presented to the German Army Burn Unit, Koblenz, Germany, 27 June 1987.

**Carlson D:** Panel Discussion: Use of the clinical nutrition specialist ASI. Presented to the Nutritional Assessment Postgraduate Short Course, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 26 June 1987.

**Summers TM:** Introduction to the hospital ministry. Presented to the Chaplain Candidate Hospital Ministry Course, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 6 July 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented to Family Support Group Members, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, 14 July 1987.

**Sandoval CM:** Perioperative care of the burn patient. Presented to the Operating Room Course, Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 21 July 1987.

**Pruitt BA Jr:** Current treatment of the burn wound. Presented at the Martinez Veterans Administration Medical Center, Martinez, California, 22-23 July 1987.

**Pruitt BA Jr:** Diagnosis and treatment of opportunistic infections in man. Presented at the Martinez Veterans Administration Medical Center, Martinez, California, 22-23 July 1987.

**Latona PS:** Initial management of the burn patient. Presented at Laughlin Air Force Base, Del Rio, Texas, 31 July 1987.

**Luster SH:** Upper extremity evaluation and treatment course. Presented to Occupational Therapy Officers, Fort Knox, Kentucky, 5-15 August 1987.

**Luster SH:** Predicting daily occupational staff requirements in a burn center. Presented to the Mary Lipscomb Hamrick Army Medical Specialist Corps Research Course, Xerox International Training Center, Leesburg, Virginia, 13 August 1987.

**Gutierrez RT:** Current trends in burn research and physical therapy. Presented to Physical Therapy Staff, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 18 August 1987.

**Latona PS:** Nursing care of the burn patient. Presented at the Baptist Memorial Hospital School of Nursing, San Antonio, Texas, 31 August 1987.

**Latona PS:** Nursing care of the burn patient in the emergency room. Presented to the Emergency Nursing Care Course, Fitzsimons Army Medical Center, Aurora, Colorado, 2 September 1987.

**Latona PS:** Initial management of the burn patient. Presented at the Head Nursing Meeting, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 9 September 1987.

**Keenan JR:** Initial management of the burn patient. Presented at the Preceptor Orientation, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, 10 September 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented to Blackenridge Hospital Physical Therapists, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, 15 September 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented to the Wilford Hall Medical Center Physical Therapy Officers' Advanced Course, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, 15 September 1987.

**Pruitt BA Jr:** Panel Discussion: What's new in metabolism following burn injury. Presented at the Thirty-Second World Congress of Surgery, Sydney, Australia, 23-25 September 1987.

**Pruitt BA Jr:** Treatment of patients with massive burns and predictors of outcome. Presented at the Twelfth Annual Scientific Meeting of the Australian and New Zealand Burn Association, Adelaide, Australia, 28 September 1987.

**Gutierrez RT:** Physical therapy in burn care. Presented to Family Support Group Members, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, 29 September 1987.

**Carlson D:** Nutrition in thermal injury. Presented to the Hospital Food Service Specialist Advanced Course (800-94F30), Academy of Health Sciences, Fort Sam Houston, San Antonio, Texas, 30 September 1987.

**Pruitt BA Jr:** Surgical treatment of patients with massive burns. Presented at the Royal Childrens Hospital, Melbourne, Australia, 30 September 1987.

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

PUBLICATIONS

Farrell KJ, McManus WF, Mason AD Jr, and Pruitt BA Jr: Interrelationship of cardiac index and hemoglobin concentration in a subset of hyperdynamic septic burn patients. Surg Forum 37:75-78, 1986.

Kingsley CP, Schmidt SI, and Reynolds WJ: A method for securing "piggyback" infusions (letter). Anesth Analg 65:20:209-210, 1986.

Missavage AE, McManus WF, and Pruitt BA Jr: Suppurative thrombophlebitis. In Current Therapy in Vascular Surgery. Ernst CB and Stanley JC (eds). Burlington: BC Decker, Inc, 1986.

Pruitt BA Jr: The acute burn patient. In Trauma - Emergency Surgery and Critical Care. Siegel JH (ed). New York: Churchill Livingstone, 1986, pp 1099-1132.

Pruitt BA Jr: Diagnosis and treatment of sepsis in the burn patient. In Trauma and Critical Care Surgery. Najarian JS and Delaney JP (eds). Boca Raton: Year Book Medical Publishers, Inc, 1986, pp 443-458.

Pruitt BA Jr: Individualized fluid resuscitation of the burn patient. In Trauma and Critical Care Surgery. Najarian JS and Delaney JP (eds). Boca Raton: Year Book Medical Publishers, Inc, 1986, pp 417-429.

Pruitt BA Jr and Goodwin CW Jr: Burns: including cold, chemical, and electrical injuries. In Textbook of Surgery. Scoviston DB Jr (ed). Philadelphia: WB Saunders Publishing Co, Chapter 12, 1986, pp 214-243.

Pruitt BA Jr, Goodwin CW, Vaughan GM, Aulick LH, Newman JJ, Strome DR, and Mason AD Jr: The metabolic problems of the burn patient. Acta Chir Scand (Suppl) 522:119-139, 1986.

Pruitt BA Jr and Mason AD Jr: Writing an effective abstract. In Principles and Practices of Research - Strategies for Surgical Investigators. Troidl H, Spitzer WO, McPeck B, et al (eds). New York: Springer-Verlag, Inc, 1986, pp 233-235.

Vaughan GM: Human melatonin in physiologic and diseased states: neural control of the rhythm. J Neural Transm (Suppl) 21:199-215, 1986.



Vaughan GM, Lasko J, Coggins SH, Pruitt BA Jr, and Mason AD Jr: Rhythmic melatonin response of the Syrian hamster pineal gland to norepinephrine in vitro and in vivo. J Pineal Res 3(3):235-249, 1986.

Vaughan GM, Mason AD Jr, and Reiter RJ: Serum melatonin after a single aqueous subcutaneous injection in Syrian hamsters. Neuroendocrinology 42(2):124-127, 1986.

Vaughan GM, Pruitt BA Jr, Shirani KZ, Vaughan MK, and Mason AD Jr: The thyroid axis and brain 5'-monodeiodination of thyroxine in the burned rat model of nonthyroidal illness. Neuroendocrinol Lett 8(5):221-226, 1986.

Vaughan GM and Reiter RJ: Pineal dependence of the Syrian hamster's nocturnal serum melatonin surge. J Pineal Res 3(1):9-14, 1986.

Yurt RW and Pruitt BA Jr: Burns. In Surgical Emergencies. Gardner B and Shaftan GW (eds). Philadelphia: JP Lippincott Co, 1986, pp 538-545.

McManus AT, Kim SH, McManus WF, Mason AD Jr, and Pruitt BA Jr: Comparison of quantitative microbiology and histopathology in divided burn-wound biopsy specimens. Arch Surg 122(1):74-76, January 1987.

Shirani KZ, Pruitt BA Jr, and Mason AD Jr: The influence of inhalation injury and pneumonia on burn mortality. Ann Surg 205(1):82-87, January 1987.

Burleson DG, Vaughan GK, Mason AD Jr, and Pruitt BA Jr: Flow cytometric measurement of rat lymphocyte subpopulations after burn injury and burn injury with infection. Arch Surg 122(2):216-220, February 1987.

Shippee RL, Wilson SW, and King N: Trace mineral supplementation of burn patients: a national survey. J Amer Diet Assoc 87(3):300-303, March 1987.

Pruitt BA Jr: Burn treatment for the unburned (editorial). JAMA 257(16):2207-2208, April 1987.

Vaughan GM and Reiter RJ: The Syrian hamster pineal gland responds to isoproterenol in vivo at night. Endocrinology 120(4):1682-1684, April 1987.

Culbertson GR, McManus AT, Conarro PA, McManus WF, Mason AD Jr, and Pruitt BA Jr: Clinical Trial of imipenem/cilastatin in severely burned and infected patients. Surg Gynecol Obstet 165(1):26-33, July 1987.

Shimazu T, Yukioka T, Hubbard GB, Langlinais PC, Mason AD Jr, and Pruitt BA Jr: A dose-responsive model of smoke

inhalation injury. Severity-related alteration in cardiopulmonary function. Ann Surg 206(1):89-98, July 1987.

Pruitt BA Jr: Infection: cause or effect of pathophysiologic change in burn and trauma patients. In Lipid Mediators in the Immunology of Shock. Paubert-Braquet M (ed). New York: Plenum Publishing Corporation, 1987, pp 31-42.

Pruitt BA Jr: What's new in surgery: trauma and burns. Bulletin of the American College of Surgeons 72:56-61, 1987.

Vaughan GM, Pruitt BA Jr, and Mason AD Jr: Nyctohemeral rhythm in melatonin response to isoproterenol in vitro: comparison of rats and Syrian hamsters. Comp Biochem Physiol (C) 87(1):71-74, 1987.

US ARMY INSTITUTE OF SURGICAL RESEARCH  
FORT SAM HOUSTON  
SAN ANTONIO, TEXAS 78234-5012

MOTION PICTURES

Pruitt BA Jr and McManus WF: Critical Decisions in Surgery  
#2: Management of Severe Burns. New York: Park Row  
Publishers, 1986.

# DISTRIBUTION LIST

## Number of Copies

5	Commander US Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick Frederick, Maryland 21701-5012
1	Commander Letterman Army Institute of Research Building 1110 Presidio of San Francisco, California 94129-6800
1	Director Walter Reed Army Institute of Research Building 40 Washington, DC 20307-5100
1	Commander US Army Aeromedical Research Laboratory Building 8708 Fort Rucker, Alabama 36362-5292
1	Commander US Army Institute of Dental Research Building 40 Washington, DC 20307-5300
1	Commander US Army Medical Biomedical Research and Development Laboratory Building 568 Fort Detrick Frederick, Maryland 21701-5010
1	Commander US Army Medical Research Institute of Chemical Defense Building E3100 Edgewood Avenue Aberdeen Proving Ground, Maryland 21010-5425
1	Commander US Army Medical Research Institute of Infectious Diseases Building 1425 Fort Detrick Frederick, Maryland 21701-5011

**Number of  
Copies**

1	Commander US Army Research Institute of Environmental Medicine Building 42 Natick, Massachusetts 01760-5007
1	Defense Technical Information Center ATTN: DTIC-DDA Alexandria, Virginia 22304-9990
1	Commandant Academy of Health Sciences ATTN: AHS-CDM Fort Sam Houston, Texas 78234
1	Director Biological and Medical Sciences Division Office of Naval Research 800 North Quincy Street Arlington, Virginia 22217
1	Commanding Officer Naval Medical Research and Development Command National Naval Medical Center Bethesda, Maryland 20014
1	Headquarters United States Air Force Medical Service Center ATTN: Chief, Aerospace Medical Consultant Division Building 150 (SGPA) Brooks Air Force Base, Texas 78255
1	Director of Defense Research and Engineering ATTN: Assistant Director Environmental and Life Sciences Washington, DC 20301

END

FILMED

11-89

DTIC